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AIM
The human protein PRAME (preferentially expressed antigen of mela-
noma) is frequently overexpressed in tumours. Importantly, high expression 
levels are associated to poor clinical outcome in melanoma, neuroblastoma, 
and breast cancer. However, its function and molecular mechanisms in nor-
mal and cancer cells are not yet well understood and the cellular pathways 
affected by PRAME are still elusive. Although PRAME has been indicated as a 
promising potential target for cancer therapy and anti-tumour immunization 
protocols, efforts to develop strategies to interfere with the oncogenic activi-
ty of PRAME are hindered by a lack of information about its function.
The aim of this thesis was to investigate the molecular function of 
human PRAME using cell line model systems and a powerful combination of 
proteomic and genomic techniques. We developed innovative biochemical 
approaches to dissect the protein-protein interaction network of PRAME, and 
we setup chromatin immunoprecipitation assays coupled to next-generation 
sequencing technologies to reveal binding profile of PRAME to the human 
genome in cancer cells.
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OUTLINE
Chapter 1 provides a general introduction and an overview of the knowl-
edge available on PRAME and the PRAME-like gene family. This chapter intro-
duces also the proteomic and genomic techniques developed and applied in 
this thesis.
Chapter 2 describes the setup and application of epitope-tagging affinity 
purification and mass spectrometry analysis to the identification of the pro-
tein interactors of PRAME.
In chapter 3 we extend the results of chapter 2 and characterize PRAME 
as a component of Cullin2-based ubiquitin ligases. Furthermore, we pres-
ent the first genome-wide ChIP-seq profiling of PRAME that associates this 
oncoprotein to the NFY signaling pathway.
Chapter 4 presents the results of improved protein-complex purifica-
tion protocols and analysis of the PRAME interactome to a deeper level. We 
characterize direct interactions between PRAME and the human EKC/KEOPS 
complex and we show that EKC subunits associate with PRAME binding sites 
on chromatin. 
Chapter 5 reports the development of rabbit antibodies against PRAME 
and their validation for use in several assays. We further discuss the experi-
mental strategies that can be undertaken to generate genome-wide ChIP-
seq profiles of a protein of interest, including epitope-tagging approaches. Fi-
nally, we investigated the reported function of PRAME as dominant repressor 
of  retinoic acid signaling using proliferation assays and PRAME knockdown 
systems.
Chapter 6 summarizes the results of the previous chapters and discusses 
the implications of this thesis for further research.
In the Appendix, the work performed for this thesis is presented in a 
chronological context, as a reference for similar projects in the future.
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LIST OF ABBREVIATIONS AND 
GENE SYMBOLS
Ab, antibody
ChIP, chromatin immunoprecipitation
CRL, Cullin-RING ligases
CUL2, cullin 2
EKC, Endopeptidase-like Kinase Chromatin-associated
ELOB/TCEB2, elongin B/transcription elongation factor B (SIII), polypeptide 2
ELOC/TCEB1, elongin C/transcription elongation factor B (SIII), polypeptide 1
IP, immunoprecipitation
KEOPS, kinase, putative endopeptidase and other proteins of small size
LAGE3, L antigen family, member 3
MS, mass spectrometry
NFY, nuclear transcription factor Y
OSGEP, O-sialoglycoprotein endopeptidase
PRAME, preferentially expressed antigen in melanoma
RBX1, ring-box 1
RING, really interesting new gene
TP53RK, TP53 regulating kinase
TPRKB, TP53RK binding protein
WB, western blot
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Cancer is a general term that refers to more than hundred different dis-
eases that are all characterised by uncontrolled cell proliferation. Collectively, 
cancers constitute the second leading cause of human mortality worldwide 
(WHO, 2012). Cancers are mostly classified based on the tissue of origin and 
histological analysis of tissue sections or cells, based on which diagnosis 
and prognosis are made. Some cancers are also tested for specific molecular 
markers of known prognostic value, i.e. ERalpha and HER2 for breast cancer. 
The advent of array-based techniques, and more recently high-throughout 
sequencing, to quantitatively measure the levels of messenger RNA tran-
scripts has substantially increased the power to sub-classify cancers based on 
gene expression profiles (McDermott et al, 2011). Importantly, specific gene 
expression signatures have been characterised that are predictive of progno-
sis and can therefore guide therapeutic interventions, like the Mammaprint 
70-gene profile for breast cancer (McDermott et al, 2011; van ‘t Veer et al, 
2002). 
The human oncoprotein PRAME
The human gene PRAME (preferentially expressed antigen of melanoma) 
is frequently overexpressed in tumours and constitutes a molecular marker of 
poor clinical outcome for several cancers like melanoma, neuroblastoma and 
breast cancer (Kilpinen et al, 2008; Oberthuer et al, 2004; Epping & Bernards, 
2006; Doolan et al, 2008; Haqq et al, 2005). The discovery of the PRAME 
gene was reported in 1998 by the Coulie lab (Ikeda et al, 1997). The authors 
identified PRAME as the gene encoding an antigenic peptide recognised by 
tumour-specific cytolytic T-lymphocytes isolated from a melanoma patient. 
The gene encodes a putative protein of 509 amino acids with unknown 
function. In healthy adult tissues, PRAME is expressed at high levels only in 
the testis, while low levels were detected in the adrenals, ovary, endometri-
um, and very low levels in skin, brain, breast, and kidney (Ikeda et al, 1997). 
However, PRAME is frequently overexpressed in a wide range of solid and 
haematological tumours including melanoma, head and neck carcinoma, 
ovarian cancer, breast carcinoma, lung carcinoma, renal carcinoma, neuro-
blastoma, and various acute and chronic haematological malignancies (Ikeda 
et al, 1997; Kilpinen et al, 2008). 
Based on its peculiar expression pattern, PRAME belongs to the cate-
gory of cancer-testis antigens, similarly to the MAGE, BAGE and GAGE gene 
families. The expression in healthy tissues other than testis, however, 
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differentiates PRAME from other cancer-testis antigens, whose expression is 
restricted to normal testis. Since the testis does not bear HLA molecules, it 
is invisible to the immune system and high expression of PRAME (and other 
CTA proteins) in this tissue does not trigger an immune response. It has been 
suggested that the low expression of PRAME in other normal tissues is insuf-
ficient for recognition by cytolytic T-lymphocytes, and only upon malignant 
overexpression would the immune system be able to mount an anti-PRAME 
immune response (Ikeda et al, 1997; van Baren et al, 1998).
PRAME expression in cancer
A large number of studies investigated the transcript levels of PRAME in 
cohorts of cancer patients. While normal skin and benign nevi were found 
negative, high PRAME expression was found to correlate with the stage of 
melanoma lesions (Haqq et al, 2005), and a similar trend was reported for 
neuroblastoma: 93% of primary lesions and 100% of advanced cases overex-
pressed PRAME (Oberthuer et al, 2004). On the contrary, PRAME levels were 
lower in neuroblastoma cases characterised by a good prognosis and a high 
frequency of spontaneous regression (Fischer et al, 2006). 
Importantly, significant associations were found between higher PRAME 
expression levels and poor clinical outcome (i.e. shorter overall and dis-
ease-free survival) in neuroblastoma (Oberthuer et al, 2004), as well as 
serous ovarian adenocarcinoma patients (Partheen et al, 2008). High PRAME 
mRNA levels were also found to be an independent prognostic factor of poor 
clinical outcome in breast cancer by two independent studies (Doolan et al, 
2008; Epping et al, 2008).
PRAME transcripts were detected in about 30-40% of acute and chronic 
leukaemias, and hypomethylation of the PRAME locus seems to have a role 
in this process (Roman-Gomez et al, 2007; Schenk et al, 2007). Studies on 
patients affected by BCR-ABL-positive chronic myeloid leukaemia (Ph+ CML) 
indicated that PRAME was activated in the advanced stages and blast crisis 
(Radich et al, 2006; van Baren et al, 1998). The fact that PRAME was not 
expressed in the early stages, when the BCR-ABL translocation is already 
present, prompted the authors to suggest that the BCR-ABL translocation 
is not sufficient to activate PRAME, and the later activation could be due to 
a secondary correlation with the progression of the disease. However, two 
studies reported that PRAME expression could be induced by transfection 
of BCR-ABL in cell line models (De Carvalho et al, 2011; Watari et al, 2000). 
18
Therefore, it cannot be excluded that additional (still BCR-ABL-mediated) 
signals are necessary for full activation of PRAME in CML blasts.
Although a growing body of evidence indicates that PRAME contributes 
markedly to the oncogenic phenotype of several cancers, some studies 
have shown that PRAME expression can be associated also with leukaemia 
subtypes characterised by a favourable prognosis. In particular, high PRAME 
levels were reported in patients with the genomic translocations t(8;21) and 
t(15;17), which result in the expression of the AML1-ETO and PML-RARA fusion 
proteins, respectively (van Baren et al, 1998). A larger recent study on pa-
tients carrying the PML-RARA translocation reported that high PRAME levels 
at diagnosis were associated with a better clinical outcome (Santamaría et al, 
2008).
Finally, several studies indicated that PRAME expression levels are a 
useful marker to monitor the presence of cancer cells in the body (also called 
“minimal residual disease”) in patients during and after chemotherapy 
(Steinbach et al, 2002; Santamaría et al, 2008).
Molecular studies of PRAME
There are indications that epigenetic processes are involved in the 
regulation of PRAME expression. DNA hypomethylation of two different 
regions of the PRAME locus was reported to correlate with expression in cell 
lines as well as in the progression of CML. Notably, hypomethylation induced 
by 5-aza-dC treatment resulted in PRAME upregulation in several cell lines, 
suggesting that all the factors required for PRAME expression were present 
in the cells, and that DNA methylation mediates the silencing of this locus 
(Ikeda et al, 1997; Roman-Gomez et al, 2007; Schenk et al, 2007). 
Five different transcript variants of PRAME have been described (Schenk 
et al, 2007). These variants show two different transcription start sites 
(positions +1 and +151), but they all encode the same amino acid sequence. 
Regulation of expression of the different variants has not yet been reported, 
and their functional relevance is unclear (Schenk et al, 2007). Recent analysis 
of small non-coding RNAs revealed that PRAME can be targeted by the mi-
croRNA miR-211, and downregulation of miR-211 correlates with upregulation 
of PRAME in melanoma cell lines (Sakurai et al, 2011). 
Although numerous studies reported expression patterns of PRAME in 
human malignancies, the molecular and cellular functions of PRAME are 
not yet clear. In a functional genetic screen, ectopic expression of PRAME 
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was found to repress the growth inhibitory effects of histone deacetylase 
inhibitors (HDACi) (Epping et al, 2007). HDACi induce proliferation arrest and 
apoptosis in cancer cells but not in normal healthy cells; therefore, they are 
promising compounds for use in the treatment of cancer (Kim & Bae, 2011). 
Ectopic expression of human PRAME in mouse embryonic fibroblasts (MEFs) 
prevented growth arrest and apoptosis upon treatment with the HDACi 
PXD101, while PRAME overexpression did not affect proliferation in standard 
culturing conditions (Epping et al, 2007). Luciferase reporter assays indicated 
that PRAME could repress retinoic acid signaling induced by PXD101, while 
PRAME silencing in A375 melanoma cells sensitized the cells to PXD101 treat-
ment in vitro as well as in a xenograft model (Epping et al, 2007).
The authors reported in a separate publication that PRAME interacts with 
the retinoic acid receptor alpha (RARA) and suggested that PRAME mediates 
repression of retinoic acid signaling via recruitment of the transcriptional re-
pressor EZH2 to RARA target genes (Epping et al, 2005). In particular, the au-
thors reported in vitro protein-protein interactions between PRAME and the 
ligand binding domain of RARA fused to GST, while a mammalian two-hy-
brid system detected an interaction between the ligand binding domain of 
RARA and the C-terminus of PRAME (aa. 416-509). Co-immunoprecipitation 
experiments further suggested that this interaction requires the C-terminal 
LRELL amino acid motif in PRAME and the presence of the ligand all-trans 
retinoic acid (atRA). Luciferase reporter assays indicated that expression of 
PRAME represses retinoic acid signaling and that this effect is mediated by 
protein-protein interactions with the transcriptional repressor EZH2. A ChIP 
assay suggested that PRAME associates with the RARB2 promoter, a known 
target of retinoic acid signaling. Finally, PRAME silencing in A375 melanoma 
cells was reported to restore retinoic acid signaling and inhibit retinoic acid 
induced growth arrest both in proliferation assays in vitro and in a xenograft 
model in vivo (Epping et al, 2005). Contrary to the model put forward by the 
Bernards lab, Wadelin et al. could not reproduce the interactions between 
PRAME and the ligand binding domain of RARA in GST pulldown and yeast 
two-hybrid assays (Wadelin et al, 2010). Furthermore, studies on primary 
AML and breast cancer samples indicated that PRAME expression did not as-
sociate with a down-regulation of retinoic acid signaling (Epping et al, 2008; 
Steinbach et al, 2007). 
Notably, it was reported that overexpression of SOX9 in melanoma 
cell lines lead to increased sensitivity to retinoic acid and at the same time 
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downregulation of PRAME (Passeron et al, 2009). However, the authors 
did not provide a causative link between these two findings. Therefore, 
it is still unclear whether the downregulation of PRAME plays any role in 
the increased sensitivity to retinoic acid caused by SOX9 overexpression, or 
whether it is an unlinked event.
In conclusion, a putative role for PRAME in the retinoic acid signaling 
pathway remains unclear, and additional studies are required to shed light 
on these mechanisms.
PRAME in leukaemia
The molecular functions of PRAME in leukaemia cells are also controver-
sial, since conflicting reports suggested that PRAME might induce caspase-in-
dependent cell death (Tajeddine et al, 2005), or rather promote cell survival 
repressing pro-apoptotic genes (Tanaka et al, 2011).
Tajeddine et al. reported that PRAME causes decreased proliferation 
and caspase-independent cell death in CHO-K1, HeLa and KG1 cell lines. 
Using a microarray-based approach, transfection of PRAME in leukaemia KG1 
cells was found to downregulate expression of the HSP27, CDKN1A/p21 and 
S100A4 genes, which are inhibitors of apoptosis. However, these associations 
were not reported in a microarray gene expression analysis of paediatric 
AML samples with high versus low PRAME expression (Goellner et al, 2006). 
Moreover, an independent study on paediatric AML samples by real-time PCR 
found that high levels of PRAME were not associated with down-regulation 
of HSP27, S1000A, CDKN1A/p21 or RARB (Steinbach et al, 2007).
Tajeddine et al. also reported that downregulation of PRAME by siRNA 
increased proliferation and tumorigenicity of K562 leukaemia cells in a 
xenograft nude mice model. On the contrary, Tanaka et al. showed that 
siRNA transfection in the same cell line suppressed proliferation in vitro and 
promoted apoptosis. Another study in agreement with Tajeddine et al. found 
that silencing of PRAME promoted cell proliferation of K562 cells; however, 
the same effect was obtained upon overexpression of PRAME in HL60 cells 
(Oehler et al, 2009). Moreover, PRAME silencing on K562 cells expressing 
increased numbers of RARA receptors did not show any difference in prolifer-
ation in the same assays (Oehler et al, 2009). It is possible that the functional 
relevance of PRAME differs between different cell types and cancers, and 
further analyses are required in order to understand the mechanisms and 
pathways in which PRAME is involved.
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Evolution of the PRAME gene family
PRAME is the founding member of a large family of genes with a pecu-
liar evolutionary history. In human, the PRAME gene family is comprised of 
the single PRAME gene on chromosome 22, and a cluster of 22 PRAME-like 
genes and 10 pseudogenes on chromosome 1 (Birtle et al, 2005). 
Molecular evolution analyses established that the PRAME-like gene 
cluster originated from a translocation dating shortly before the divergence 
between rodents and primates (~85-95 million years ago). In fact, synthenic 
regions of rodent and primate genomes contain PRAME-like homologues, 
while dog and chicken genomes do not (Birtle et al, 2005). After the first 
translocation event, the mouse and primate loci underwent an independent 
and very rapid expansion by “birth-and-death” processes, i.e. gene duplica-
tion and pseudogene creation. This process explains the finding that mouse 
Prame-like genes are monophyletic, similarly to the human PRAME-like 
genes. In other words, while ~80% of mouse genes have a single human 
orthologue, there is no pair of mouse and human PRAME genes with a sim-
ple 1:1 orthology. This evidently hinders the development of mouse model 
systems for the study of human PRAME genes.
Furthermore, independent duplication events have been detected in all 
branches of the primate lineage (Rhesus Macaque Genome Sequencing and 
Analysis Consortium et al, 2007). Extensive duplications occurred early in the 
primate evolution as well as in recent chimpanzee evolution, while the ma-
caque branch seems to have been less dynamic (Figure 1). The chimpanzee 
and hominin branches separated around 6-7 million years ago, and two inde-
pendent large segmental duplications occurred in the terminal human branch 
in the past 3 million years. This implies that a number of human PRAME-like 
genes do not have a 1:1 orthology even with chimpanzee PRAME genes.
Besides the extraordinarily rapid and independent expansion of PRAME 
genes in the rodent and the primate lineages, there is also evidence for copy 
number variation in the PRAME-like gene cluster among human populations 
(Birtle et al, 2005). This indicates that there have been additional recent 
duplications that are not yet fixed in the human population, nor captured in 
the human genome reference sequence. 
Evidence has also been found for positive selection of amino acid resi-
dues in PRAME (Birtle et al, 2005; Rhesus Macaque Genome Sequencing and 
Analysis Consortium et al, 2007). Homology modelling suggested that the 
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positively-selected residues identified are likely to cluster on an accessible 
surface of PRAME proteins, underscoring a potential role in binding inter-
actions. Moreover, since positive selection is a common feature of genes 
involved in immunity and reproduction, it was suggested that PRAME genes 
might have roles in these processes (Birtle et al, 2005; Wadelin et al, 2010). 
Given its peculiar characteristics, it was suggested that the PRAME gene 
family has played a key role in species evolution and that the differences 
between human and chimpanzee PRAME genes may have contributed 
to the functional divergence along the hominin lineage (Birtle et al, 
2005). 
While the evolution of the PRAME-like gene cluster has 
been studied in detail, the origin of the PRAME gene 
on chr22 is unclear. Inspection of the orthologous 
genomic regions in the mouse, rat and chimp 
genomes, did not identify PRAME ortho-
logues, and gaps in the genome 
builds have not been reported 
that could accommodate 
a missing PRAME 
gene (Birtle 
et al, 
2005).
Phylogenetic tree of 
PRAME genes in the hu-
man-chimpanzee-rhesus 
macaque lineages.
Maximum-likelihood 
phylogeny for PRAME-like 
genes in the human (H), 
chimpanzee (P), and rhesus 
macaque (M) genomes, 
showing the duplication 
history in the context of 
the species tree (adapted 
from Rhesus Macaque 
Genome Sequencing and 
Analysis Consortium et al, 
2007). 
This reconstruction reveals 
extensive duplication 
early in primate evolution 
(branch a), in recent chim-
panzee evolution (branch 
d), and, most notably, in 
recent human evolution 
(branch e). The PRAME 
gene cluster appears to 
have been much less 
dynamic on the macaque 
lineage (branch b) and in 
early hominins (the human 
and chimpanzee branch, 
branch c).
Figure 1
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PRAME-like genes and early development
Despite the extraordinary evolutionary history of PRAME genes, their 
biological and molecular function is still poorly understood. While no reports 
have been published yet on human PRAME-like genes, a number of studies 
in the mouse identified roles for this gene family in oogenesis (Dadé et al, 
2003), spermatogenesis (Wang et al, 2001) and stemness (Bortvin et al, 
2003; Cinelli et al, 2008).
A number of mouse PRAME-like genes were first identified as genes 
with specific expression in the oocyte, and therefore they were first called 
“oogenesin” (Dadé et al, 2003; Minami et al, 2003). Analysis of their predict-
ed amino acid sequence suggested that the encoded proteins belong to the 
leucine-rich repeat (LRR) superfamily and fold in a non-globular horse-shoe 
structure (Dadé et al, 2003).
Four PRAME-like genes were found to play roles in pluripotency and 
development of mouse embryos cloned by nuclear transfer (Bortvin et al, 
2003). In a study aimed at identifying genes involved in establishing or 
maintaining developmental pluripotency, the authors performed an in silico 
analysis to identify genes with an expression pattern similar to that of Oct4 
(Bortvin et al, 2003). OCT4 is a transcription factor expressed in pluripotent 
cells of the early embryo and adult germ cells that is known to play an 
essential role in the control of developmental pluripotency. Ten genes were 
found that satisfied the search criteria, among which Pramel4, Pramel5, Pra-
mel6, Pramel7. Analysis of expression of these genes established that they 
are active in pluripotent embryonic tissues (blastocyst, morula and 4-cell 
embryo), while they are not expressed in differentiated somatic tissues. Im-
portantly, analysis of their activity in mouse embryos cloned from somatic or 
embryonic stem (ES) cells revealed that successful reactivation of the full set 
of Oct4-genes correlated with successful development of the cloned embry-
os to term. The authors concluded that although the biological functions of 
these genes have yet to be elucidated, they serve as informative markers for 
pluripotent cell types and cloned embryos (Bortvin et al, 2003).
Another study fond that the MBD3 component of the nucleosome re-
modelling and histone deacetylation (NuRD) complex mediates silencing of 
Pramel6 and Pramel7 expression in mouse embryonic stem cells (Kaji et al, 
2006). These genes were found to be expressed at very low levels in wild 
type ES cells, while knockout of Mbd3 resulted in elevated transcript levels 
as well as increased H3K9 and H4 acetylation levels at their genomic loci, 
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but not at the silent Pramel5 promoter. This correlated with LIF-independent 
maintenance of pluripotency in culture and a defect in lineage commitment 
of Mbd3-/- ES cells. Although a causative role for Pramel6 and Pramel7 in 
these processes was not addressed, expression analysis suggested that Pra-
mel6 and Pramel7 contribute in deciding the fate of ES cells (Kaji et al, 2006).
An independent study confirmed that Pramel6 and Pramel7 are preva-
lently expressed in embryonic pluripotent cells, and further determined that 
whereas Pramel6 is typically expressed in all cells of the morula and blas-
tocyst, Pramel7 is expressed only in the inner part of the morula and in the 
inner cell mass of the blastocyst, similarly to Nanog, a factor known to be 
involved in pluripotency (Cinelli et al, 2008). Notably, ectopic overexpression 
of the STAT3 transcription factor resulted in overexpression of Pramel6 and 
Pramel7 and allowed the derivation of pluripotent embryonic stem cell lines 
from mouse strains that are otherwise “non permissive” to this procedure. 
Remarkably, overexpression of Pramel7 in ES cells was sufficient to sustain 
maintenance of pluripotency when cells were cultured in the absence of 
LIF, indicating an important role for this protein in maintaining ES cells in a 
pluripotent state (Cinelli et al, 2008).
Ubiquitin pathways
Modification of proteins by the addition of ubiquitin (a highly conserved 
76-amino-acid polypeptide) or ubiquitin-like proteins has emerged as a major 
mechanism by which virtually all events in cells can be regulated, includ-
ing cell cycle progression, gene transcription, DNA repair, protein turn-over, 
receptor trafficking, and apoptosis (Deshaies & Joazeiro, 2009; Budhidarmo et 
al, 2012).
Ubiquitination (also known as ubiquitylation) is best-known for targeting 
proteins for degradation by the 26S proteasome, but other functions include 
modulation of protein interactions and alteration of subcellular distribution.
Members of ubiquitin pathways play also important roles in cancer and 
a number of them have been identified as either oncogenes (i.e. MDM2) or 
tumour suppressor genes (i.e. BRCA1 and VHL), and the first pharmacological 
inhibitors of the proteasome have entered the clinic as anti-cancer drugs, and 
significant efforts are undertaken in this field of drug discovery (Joazeiro et 
al, 2006).
Attachment of ubiquitin to target proteins is performed by a cascade of 
three enzymes (E1-E2-E3) (Deshaies & Joazeiro, 2009; Metzger et al, 2012 
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and references therein). The first step is the activation of ubiquitin by one 
predominant ubiquitin-activating enzyme E1. Activated ubiquitin is then 
transferred from E1 to one of the 30-40 mammalian ubiquitin-conjugat-
ing enzymes (UBCs or E2s), and eventually to the final substrates that are 
bound specifically to one of the several hundreds different ubiquitin ligases 
(E3s). Substrates can be modified by a single ubiquitin on one or more sites 
(monoubiquitination and multi-monoubiquitination, respectively) or can be 
tagged with chains of ubiquitin (polyubiquitination). Chain formation can oc-
cur through the seven internal lysine residues on ubiquitin (K6, K11, K27, K29, 
K33, K48, and K63) or its N-terminus (M1). Ubiquitin chains are recognized 
by specialised ubiquitin-binding domains (UBDs) that form transient, nonco-
valent interactions either with ubiquitin moieties or with the linkage region 
in their chains and determine the function of the modification (Ikeda et al, 
2010). K48-linked polyubiquitin chains were originally described as the signal 
that targets substrates for proteasomal degradation, while atypical K11, K63, 
and M1-linked chains were associated to DNA repair, cell cycle progression 
and inflammation. However, recent reports have challenged the notion that 
specific chain topologies regulate specific cellular processes, and it still un-
clear how a specific type of linkage is generated and how this is translated to 
the fate of the modified protein (Ikeda et al, 2010).
The ubiquitination cascades result in the formation of a covalent bond 
between the C-terminus of ubiquitin and, most frequently, the epsilon-amino 
group of a lysine side chain in the substrate. The ubiquitination of the N-ter-
minus of proteins or other amino acids like threonine, serine, or cysteine has 
also been described. E3-mediated attachment of ubiquitin to substrates is 
highly regulated in response to cellular cues and one substrate can be also 
ubiquitinated by different ubiquitin ligases while, on the other hand, one 
ligase can target several proteins. Moreover, E3s themselves can undergo 
both self-ubiquitination and be ubiquitinated by heterologous ligases. Exam-
ples are the RING finger 1B component of the polycomb repressive com-
plex 1 (PRC1), which self-ubiquitinates to increase its activity, while MDM2 
self-ubiquitination targets itself and the p53 proto-oncogene for proteasome 
degradation (Weissman et al, 2011).
Since E3s dictate the specificity toward a variety of substrates and at the 
same time interact with an E2, they are the most structurally complex and 
diverse enzymes in the pathway (Zimmerman et al, 2010). E3 ligases can 
be classified into two main structural classes that bear either a HECT (ho-
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mologous to E6-AP carboxy terminus) domain or a RING (really interesting 
new gene) domain, although a few have a U-box, which is structurally and 
functionally similar to the RING domain (Budhidarmo et al, 2012). HECT-con-
taining E3 ligases, of which there are ~20 in humans, form an intermediate 
conjugate with the ubiquitin received from a charged E2 before transferring 
it to the target. In contrast, the more prevalent (~500) RING-containing E3 
ligases bring together an ubiquitin-charged E2 and a substrate protein and 
facilitate the transfer of ubiquitin directly from the charged E2 to the sub-
strate (Deshaies & Joazeiro, 2009).
Cullin-RING E3 ubiquitin ligases
Among the E3 RING ligases, the structurally-related multisubunit 
cullin-RING ubiquitin ligases (CRLs) are particularly significant (Petroski & 
Deshaies, 2005; Sarikas et al, 2011). This is a diverse group of E3 complexes 
characterized by containing both a cullin family protein and a RING finger 
protein (RBX1 or RBX2). The human genome encodes for six cullin proteins, 
CUL1, CUL2, CUL3, CUL4A, CUL4B, and CUL5, and two additional related pro-
teins, PARC and CUL7, which are considered atypical cullins. 
Extensive genome-wide analysis of the cullin family has suggested that 
three ancestral cullin genes, termed ‘Culα’, ‘Culβ’ and ‘Culγ’, appeared in ear-
ly eukaryotic evolution, from which the cullin genes evolved after the split 
of the unikonts (which include animals and fungi) and the bikonts (which 
include plants) (Marín, 2009). The human CUL1, CUL2, CUL5, CUL7 and PARC 
genes were derived from one common ancestral gene (Culα), and the avail-
able data indicate that the emergence of multiple Culα genes in animals has 
been accompanied by a diversification of their protein partners and complex 
subunits. The CUL3 and CUL4A/4B genes evolved from two distinct ancestors, 
the Culβ and Culγ gene, respectively (Marín, 2009). 
CRLs are the most abundant E3s as it is predicted that about 400-500 
different E3 are encoded in the human genome. Their diversity is due to the 
fact that many alternative complexes can be generated in a combinatorial 
way: multiple related substrate receptor proteins may substitute for each 
other to form similar but functionally distinct complexes. 
The roles of the cullin protein in this type of complex are quite well 
understood. Structural data indicate that cullins have an overall elongated 
crescent-shaped structure consisting of a stalk-like N-terminal domain (NTD), 
and a globular C-terminal domain (CTD) (Zimmerman et al, 2010) (Figure 
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2). The NTD binds adaptor proteins and substrate receptor subunits, which 
confers substrate specificity, while the CTD binds the RING-finger containing 
protein RBX1 or RBX2, which recruits the ubiquitin-conjugating enzyme E2. In 
this context, cullins act as backbones that facilitate ubiquitination by correctly 
positioning the RING finger protein and the substrate (Marín, 2009; Zimmer-
man et al, 2010; Petroski & Deshaies, 2005) (Figure 2).
Cullin-RING ligases can be classified in a number of main CRL classes 
based on the different adaptors, substrate receptors, and RING-finger pro-
teins used (Marín, 2009; Petroski & Deshaies, 2005): 
1. Cullin1/RBX1/SKP1/F-box-receptor CRLs (historically known as SCF 
complexes) that contain SKP1 or related proteins as adaptors and 
proteins with F-box motifs as substrate receptors; 
Figure 2
Structural model of cul-
lin-RING (CRL) ubiquitin 
ligases.
The cullin-based E3 
ubiquitin ligases position a 
substrate in close proximity 
to the RING-bound E2 ubiq-
uitin-conjugating enzyme 
(not shown), which 
catalyzes the transfer of 
ubiquitin to the substrate. 
(A) Schematic model of the 
CRL modular architecture 
(adapted from Sarikas et 
al, 2011). (B-E) Structural 
models of CRLs with the 
scaffold cullin proteins, 
RING-box proteins, adaptor 
proteins and substrate re-
ceptors (from Zimmerman 
et al, 2010).
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2. Cullin2/RBX1/ElonginBC/VHL-box-receptor and Cullin5/RBX2/Elongin-
BC/SOCS-box-receptor CRLs (BC-box CRLs), which contain two Elongin 
proteins as adaptors and BC-box containing proteins as substrate 
receptors (Petroski & Deshaies, 2005; Okumura et al, 2012; Mahrour et 
al, 2008);
3. Cullin3/RBX1/BTB-receptor CRLs, characterized by lacking additional 
adaptors and containing proteins with BTB (broad complex/tram-
track/bric-a-brac) domains as substrate receptors, directly bound to 
the cullins; 
4. Cullin4/RBX1/DDB1/WD40-proteins CRLs, which contain DDB1 as 
adaptor and proteins with WD40 domains as substrate receptors, also 
called DCAFs (DDB1–CUL4A-associated factors).
Despite sharing the identical adaptor proteins Elongin B and Elongin 
C, CUL2 and CUL5 direct the assembly of E3 ligases with distinct substrate 
receptor proteins: CUL2 with von Hippel-Lindau (VHL) or related BC-box pro-
teins, and CUL5 with suppressors of cytokine signaling (SOCS)-box proteins. 
Sequence comparison of the VHL and SOCS-box proteins revealed that they 
each include a degenerate, ~12 amino acid sequence motif with consensus 
sequence [S,T,P]Lxxx[C,S,A]xxxF (Mahrour et al, 2008; Kamura et al, 2004). 
This motif, which is referred to as the BC-box, is required for binding to the 
Elongin BC complex. Downstream of the BC-box, a Cul2- or Cul5-box is pres-
ent, which mediates the specific interaction to the corresponding cullin scaf-
fold (Mahrour et al, 2008; Kamura et al, 2004). The most studied substrate of 
EloBC-cullin ligases is the von Hippel-Lindau (VHL) protein, the product of the 
VHL tumour suppressor gene. More than half of sporadic clear cell renal carci-
nomas contain inactivating mutations of VHL, and the VHL complex has ubiq-
uitin ligase activity and targets the hypoxia-inducible factor-α (HIF-α) family 
of transcription factors (HIF-1–3α) for proteasomal degradation. At normal 
oxygen levels, proline residues within the oxygen-dependent degradation 
domain of HIF-α are hydroxylated and recognized by pVHL for polyubiquitina-
tion and proteasome-mediated degradation (Okumura et al, 2012).
The ligase activity of CRLs was found to be modulated by the covalent 
conjugation of an ubiquitin-like molecule, Nedd8 (Deshaies & Joazeiro, 2009). 
This modification, termed neddylation, activates the E3 ligase activity by 
promoting substrate polyubiquitination, likely via the induction of extensive 
conformational changes. Neddylation is a reversible modification that can 
29
be enzymatically removed by the COP9 complex, and cullins are thought to 
undergo dynamic regulation by neddylation-deneddylation cycles. Another 
level of regulation of CRLs activity is performed by the CAND1 protein (Cul-
lin-Associated and Neddylation-Dissociated-1), which inhibits the E3 ligase 
activity of CRLs by binding to both the C-terminus as well as the N-terminus 
of all cullins in their un-neddylated forms (Deshaies & Joazeiro, 2009).
The EKC/KEOPS complex
Two independent laboratories have identified an ancient and highly 
conserved multiprotein complex named KEOPS (Downey et al, 2006) or EKC 
(Kisseleva-Romanova et al, 2006), starting from genetic clues in yeast. This 
complex has orthologues from Archaea to Eukarya and so far it has been 
implicated in telomeres maintenance, transcriptional regulation, and t6A 
modification of tRNAs (Kisseleva-Romanova et al, 2006; Downey et al, 2006; 
Daugeron et al, 2011; Yacoubi et al, 2011; Srinivasan et al, 2011). Yeast EKC 
comprises four subunits which are also conserved in the human genome 
(human orthologues are indicated in brackets): Pcc1p (LAGE3, also known as 
ESO3), the ATPase Kae1p (OSGEP), the kinase Bud32p (TP53RK, also known as 
PRPK), and Cgi121p (TPRKB). In addition, yeast EKC also includes Gon7p (also 
known as Pcc2p), which appears to be fungi-specific (Kisseleva-Romanova et 
al, 2006). 
The laboratory of Domenico Libri isolated Pcc1, a protein of small size 
with no predicted functional domains in a search for suppressors of a splicing 
defect and demonstrated that its function is not related to splicing. Their 
genetic and biochemical experiments led to the description of the five-sub-
unit EKC complex. Furthermore, the authors showed that Pcc1p is required 
for efficient transcription of several yeast genes induced by pheromones or 
galactose, and that deletion of Pcc1 inhibited the recruitment of the SAGA 
and Mediator co-activators (Kisseleva-Romanova et al, 2006). 
A parallel genome-wide screen in yeast identified the cgi121 null mutant 
as a suppressor of the telomere-capping defect of cdc13-1 cells (Downey et 
al, 2006). Deletion of CGI121 or other EKC subunits resulted in short telomeres 
in an otherwise wild-type context. A detailed analysis of three-dimensional 
crystal structures of archaeal EKC subunits revealed that the complex has 
a linear topology Pcc1-Kae1-Bud32-Cgi121, and Pcc1 is an obligate dimer 
that can support dimerization of the full complex in a V shape (Figure 3). 
Dimerization of the Pcc1p and Kae1p subunits was found to be necessary for 
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cell viability (Mao et al, 2008), and an intact interaction surface between 
Kae1p and Bud32p was required for both the transcriptional and telomere 
maintenance functions (Hecker et al, 2008).
Intriguingly, the OSGEP subunit is also present in bacteria (YgjD) and eu-
karyotic genomes express an OSGEP paralogue (Qri7/OSGEPL1) that localizes 
to mitochondria (Reinders et al, 2006). Comparative genomic studies identi-
fied OSGEP as one of the very few genes present in all genomes sequenced 
so far (Galperin, 2008), suggesting an extremely conserved function. Very 
recently, several groups have reported a crucial role for the YgjD/Kae1/OSGEP 
protein family in the biosynthesis of N6-threonylcarbamoyl adenosine (t6A) 
(Daugeron et al, 2011; Yacoubi et al, 2011; Srinivasan et al, 2011): a universal 
modification at position 37 of tRNAs decoding ANN codons, which is required 
for accurate translation of messenger RNAs (Yarian et al, 2002). 
Human LAGE3 belongs to the NY-ESO gene family together with the 
closely related LAGE1 and LAGE2 (Alpen et al, 2002), and all three genes are 
clustered in the same region on chromosome X. While LAGE3 is ubiquitously 
expressed, LAGE1 and LAGE2 are cancer-testis antigens with high expression 
in healthy testis and upregulation in a number of cancer tissues, similar to 
PRAME. Notably, expression of the N-terminal domain of LAGE3 fused to 
the C-terminus of Pcc1p could partially rescue the growth defects of a Pcc1 
N-terminal mutant yeast strain, while full length LAGE3 could not substitute 
for Pcc1 (Kisseleva-Romanova et al, 2006)
Human TP53RK was first cloned by cDNA subtraction as an interleukin-2 
upregulated gene in cytotoxic T-cells, and it was shown to phosphorylate the 
human oncoprotein p53 at Serine 15 (Abe et al, 2001). Recombinant TP53RK 
Figure 3 Composite model of the archaeal EKC/KEOPS complex in dimeric form (from Mao et al, 2008).
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expressed in bacteria was found catalytically inactive, but incubation with 
COS-7 cell lysates was sufficient to activate the enzymatic activity, suggesting 
the need for activators and potentially protein interactors. The kinase Akt/
PKB was found to play a role in the activation of TP53RK through phosphor-
ylation of the Ser250 residue (Facchin et al, 2007). Underscoring a high level 
of functional homology, TP53RK could partially rescue the growth phenotype 
of Bud32 deletion in yeast, and Bud32 could interact with and phosphorylate 
human p53 in vitro (Facchin et al, 2003), although yeast does not possess a 
bone fide p53 homologue. 
Human TPRKB was first isolated by a two-hybrid screen using TP53RK as 
a bait, and was suggested to inhibit the binding of TP53RK to p53 (Miyoshi et 
al, 2003).
Although the structures of several EKC subunits have been characterised 
and phenotypes caused by mutations or depletion of EKC have been de-
scribed in yeast, the precise molecular functions and mechanisms of EKC in 
Archaea as well as Eukarya are still unclear.
Purification and identification of protein complexes 
Recent advances in genome sequencing technologies have resulted 
in hundreds of genomes being completely sequenced, and this number is 
rapidly growing (http://www.ensemblgenomes.org/). In parallel, computa-
tional algorithms have been developed that can efficiently predict and an-
notate genes, thereby generating comprehensive lists of predicted proteins 
for many species (the “proteomes”). However, such lists are not sufficient 
to understand cellular processes, which are dependent on the coordinated 
action of multiprotein complexes and dynamic signaling networks of inter-
acting proteins. Therefore, experimental approaches have been developed 
to dissect protein-protein interaction networks (the “interactomes”) in order 
to fully understand the cellular machinery (Mering et al, 2002; Gingras et al, 
2007).
A powerful technique to identify protein-protein interactors is the puri-
fication of entire protein complexes by epitope-tagging and affinity-based 
methods coupled to mass spectrometry identification. This approach has 
been successfully applied at a high-throughput scale for the dissection of the 
yeast and human interactomes (Ewing et al, 2007; Gavin et al, 2002), and 
also to the study of specific proteins of interests (Le Guezennec et al, 2006).
Epitope tags are short amino acid sequences that can be recognised by 
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specific immunoprecipitation-grade antibodies (i.e. FLAG, HA, MYC) or other 
affinity reagents (i.e. calmodulin-binding columns, streptavidin beads). The 
first step entails cloning the coding sequence of the target protein in frame 
with sequences coding for one or multiple tags in a suitable expression vec-
tor, often retroviral. Subsequently, viral particles are produced to transduce 
the target cells and polyclonal or monoclonal cultures with stable expression 
of the tagged protein are selected. The tagged protein of interest is purified 
from protein extracts together with its protein partners, which are subse-
quently identified by mass spectrometry (Figure 4). The list of interactors 
identified can be further validated by epitope-tagging of these proteins in a 
so-called “complex walking” approach. Importantly, proteins can take part 
to multiple complexes at the same time, but this cannot be inferred from a 
simple list of interactors. However, several lists of interactors generated by 
complex walking can be integrated to generate an interaction network. In 
this way, distinct complexes can be dissected and shared or specific subunits 
among these complexes can be identified.
Figure 4
Discovery of protein interactors by complex 
purification and mass spectrometry.
The main steps of biochemical protein-complex 
purifications and subsequent identification of 
the purified proteins by mass spectrometry are 
illustrated. First, a protein extract is made from 
a suitable cell system and antibodies (or other 
affinity reagents) are used to enrich for the protein 
complex of interest (in colours) and wash away un-
related proteins (grey circles). The proteins purified 
are separated by electrophoresis and subjected 
to enzymatic digestion with trypsin. The peptides 
obtained are identified by mass spectrometry, and 
data analysis generates a list of proteins specifical-
ly present in the original sample.
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Importantly, this approach allows to deduce the function of unknown or 
predicted proteins, since proteins that interact with one another or are part 
of the same complex are often involved in the same cellular processes. If an 
uncharacterised target protein interacts specifically with a protein of known 
function, such function can be generally extended to the target protein of 
interest and follow-up experiments can be designed based on this data.
Chromatin immunoprecipitation and high-throughput 
sequencing
Chromatin immunoprecipitation (ChIP) is a powerful technique to study 
protein-DNA interactions in the context of chromatin in vivo. Genome-wide 
profiling of protein-DNA interactions (ChIP-seq) together with quantitative 
measurements of transcriptomes (mRNA-seq) are increasingly used to deci-
pher the regulatory networks that underlie biological processes in health and 
disease (Park, 2009).
In a ChIP assay, proteins are covalently crosslinked to their binding sites 
on chromatin by incubation of the cells or tissues with formaldehyde (Figure 
5). Crosslinked chromatin is then extracted from the cell nuclei and fragment-
ed by sonication or enzymatic digestion into pieces of a few hundred base 
pairs. The fragmented chromatin is used as input in an immunoprecipitation 
reaction using antibodies against a target protein, i.e. a transcription factor, 
histone, or polymerase. In this way, the DNA associated to the protein of 
interest is enriched and purified. The presence of genomic DNA regions of in-
terest (binding sites) can be determined by real-time quantitative PCR assays 
using specific primers. However, this approach is inherently limited to a priori 
knowledge or hypotheses on putative binding sites for the protein studied.
The introduction of microarrays (ChIP-chip) and more recently next-gen-
eration sequencing approaches (ChIP-seq) has enabled the discovery of 
unknown binding sites and the rapid and efficient mapping of protein-DNA 
interactions at the genomic scale in the same experiment. For ChIP-seq 
experiments on the Illumina sequencing platform, the DNA obtained from 
a ChIP experiment is subject to an adaptor ligation step, which adds specif-
ic sequences to both ends of the DNA molecules. After a PCR amplification 
step, the “sequencing library” is obtained. The library is hybridized on a 
glass surface via sequences present in the adaptors, and each molecule 
is subsequently amplified by isothermal bridge amplification, generating 
clusters of about 1000 identical molecules. The clustered flowcell is then 
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installed on the sequencer (Genome Analyzer or HiSeq) and subject to a se-
quence-by-synthesis protocol, generating millions of sequence reads in one 
experiment within a few days.
The ChIP-seq technique is characterized by a number of key features: 
first of all, ChIP-seq has single-nucleotide resolution, which allows the 
precise determination of a binding site and a more accurate discovery of 
relevant sequence motifs. Very low amounts of ChIP DNA (10-50 ng) and a 
limited number of PCR amplification cycles are required. Although the PCR 
can introduce some GC-bias, the background levels of a ChIP-seq experiment 
are significantly lower than ChIP-chip, and the dynamic range is theoretically 
unlimited. Taken together, these factors result in a very high sensitivity for 
this technique, which allows the identification of binding sites with moder-
Figure 5
Real-time
qPCR
Sequencing
Crosslinking
Sonication
Chromatin isolation
De-crosslinking and 
DNA isolation
Immunoprecipitation
Figure 5
Chromatin immunoprecipitation tech-
nique (ChIP). The different steps involved 
in the ChIP technique are illustrated (see 
main text for a detailed description).
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ate enrichment that would not be detected with an array approach. This is 
not only relevant for the study of low-affinity binding sites, but also for the 
profiling of proteins that do not bind DNA directly but rather via protein-pro-
tein interactions and of proteins that establish only weak interactions with 
chromatin. The genomic coverage in ChIP-Seq is only limited by alignability 
of the sequence reads to the reference genome and not by probe design and 
cross-hybridization issues. If needed, the specificity of the alignments can be 
further increased by generating longer or paired-end reads. Moreover, ChIP-
seq data can be reanalysed at a later stage if a new genome build becomes 
available. Finally, the steady drop in the costs of Next-Generation sequenc-
ing together with recent protocols allowing barcoding and multiplexing of 
samples have made ChIP-seq experiments more cost-effective, especially for 
higher eukaryotes and large genomes. 
A critical aspect of ChIP-seq experiments is that a suitable ChIP-grade 
antibody against the protein of interest is needed. Nowadays, thousands of 
antibodies are available from many different commercial suppliers, but only 
a limited number of them works in native immunoprecipitation assays, and 
even fewer work in ChIP. Therefore, antibodies must be thoroughly tested be-
fore use in order to assess their specificity (cross-reaction with other proteins 
containing a similar epitope is a common problem) and sensitivity (signal 
vs. background in ChIP experiment). Therefore, proper negative controls are 
crucial in order to draw valid conclusions. Several different types of negative 
controls are being used in the literature, but not all of them have the same 
power. Some researchers compare the ChIP-qPCR recoveries of the antibody 
of interest with an unrelated antibody on the same genomic locus. While this 
type of negative control might establish a background level related to the 
primers used in qPCR, it does not address the specificity (i.e. cross-reactivity) 
of the antibody of interest or the background levels related to the antibody 
itself. Primers designed on genomic loci that are not bound by the protein of 
interest can better indicate background levels related to the antibody. Other 
useful controls to test the specificity of the antibody are experiments per-
formed on cells that lack the protein of interest, for instance upon knockout 
or knockdown. Similarly, ChIP assays can be performed on epitope-tagged 
proteins in a cell line expressing the tagged protein while the wild type cell 
line is used as negative control. Alternatively, serum or antibodies harvested 
before the immunization protocol against the protein of interest (preimmune 
serum) can establish if the signal detected in ChIP is an aspecific signal relat-
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ed to the animal used for the immunization, or rather a specific signal caused 
by antibodies raised in the immunization. A positive result can arguably 
represent a signal related to the protein of interest, but cross reactivity with 
proteins containing the same epitope cannot be formally excluded.
Next-generation sequencing approaches have been successfully ap-
plied also to genome-wide expression profiling (mRNA-seq) (Pepke et al, 
2009). Also in this case, the larger dynamic range, higher sensitivity and the 
digital nature of the mRNA-seq data have constituted distinct advantages 
compared to array-based approaches. The increasing use and applications 
of these sequencing technologies and the large-scale data collection should 
form the basis for truly integrative systems biology analyses. Developments 
of the computation aspects will allow researchers to combine and correlate 
hundreds or thousands of protein binding profiles, transcriptomes, and pro-
tein-protein interaction datasets, with the final goal to decipher molecular 
regulatory pathways and eventually address important biological questions.
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ABSTRACT
Preferentially expressed antigen of melanoma (PRAME) is frequently 
overexpressed in tumors and high PRAME levels correlate with poor clini-
cal outcome of several cancers. However, the molecular mechanisms and 
pathways in which PRAME acts are still unclear. In order to investigate the 
molecular function(s) of PRAME, we set out to identify its protein interac-
tors. To this end, we developed a biochemical protein-complex purification 
approach using epitope-tagged versions of PRAME and immunoprecipitation 
assays coupled to mass spectrometry analysis. In this chapter, we report the 
setup and optimization of these techniques, which led us to identify specific 
interactions between PRAME and Cullin2-based E3 ubiquitin ligases. 
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INTRODUCTION
The human protein PRAME (Preferentially expressed antigen in melano-
ma) is frequently overexpressed in cancer, and high expression levels often 
correlate with poor clinical outcome (Ikeda et al, 1997; Kilpinen et al, 2008; 
Oberthuer et al, 2004; Haqq et al, 2005). PRAME is the founding member of 
a large family of PRAME-like genes, characterized by a recent evolutionary 
history and a high degree of conservation (Birtle et al, 2005; Consortium et 
al, 2007). 
Computational analysis of the human genome identified 22 PRAME-like 
genes and 10 pseudogenes (Birtle et al, 2005). Analysis of the primary ami-
no acid sequence of PRAME revealed that it is a leucine-rich repeat protein 
(Epping et al, 2005; Birtle et al, 2005) and it was suggested that PRAME 
could fold into a horse-shoe structure (Birtle et al, 2005; Wadelin et al, 2010). 
However, defined functional motifs could not be identified and the molecular 
function(s) of PRAME and PRAME-like proteins are still unclear.
An experimental approach to gain insight into the function of an un-
known protein is to identify its protein-protein interactors, since proteins 
that interact with one another or are part of the same complex are generally 
involved in the same cellular processes (Phizicky et al, 2003). If the interac-
tors identified have a known function, this function can often be extended 
to the unknown protein and specific follow-up experiments can be designed. 
If the interactors identified are also uncharacterized proteins, inspection of 
their amino acid sequences might reveal functional domains or motifs that 
can eventually give clues to putative functions. A powerful approach to de-
termine protein interactors and entire protein complexes involves the stable 
expression of epitope-tagged versions of the protein of interest in a suitable 
cell system using retroviral delivery. Subsequently, the protein and its inter-
acting partners are biochemically purified using antibodies or affinity-based 
reagents which specifically and efficiently bind to the epitope tags, and the 
proteins are identified by mass spectrometry and database searches (Aeber-
sold & Mann, 2003; Rigaut et al, 1999).
In this chapter, we describe the application of epitope-tagging and mass 
spectrometry analysis to the unbiased identification of the protein interactors 
of PRAME. We successfully setup a single-step protein complex purification 
protocol and discovered that the human oncoprotein PRAME establishes 
interactions with Cullin2-based E3 ubiquitin ligases.
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RESULTS AND DISCUSSION
The ProtA-TEV-3xMyc epitope tag in FM6 cells
Since PRAME is overexpressed in the vast majority of human melanomas, 
we set out to identify its protein interactors applying a tap-tag (tandem affinity 
purification) approach in the human melanoma cell line FM6 (Rigaut et al, 1999). 
A modified pZOME retroviral system was used to generate FM6-pZ3XN-PRAME 
cell lines stably expressing PRAME fused to a combination of N-terminal tags: 
2xProtA-2xTEV-3xMYC (ProtA-TEV-3xMYC-PRAME; 72 kDa) (Fig. 1A). A similar tag 
with a single MYC epitope was successfully used for the characterization of pro-
teins complexes involved in transcriptional regulation (Le Guezennec et al, 2006).
The purification strategy includes a first incubation of protein extracts with 
crosslinked IgG beads for which the protein A domains have a high affinity (Fig. 
1B). After incubation, several washes are performed to discard unbound proteins, 
and recombinant TEV (Tobacco Etch Virus) protease is added to cleave the tags at 
its recognition site. This proteolytic cleavage releases the bait protein and its inter-
acting partners in solution. The last step is a MYC immunoprecipitation to further 
purify the complex.
Western blot of protein extracts from FM6-pZ3XN-PRAME cells showed a 
prominent band at the expected size, and a lower band with a significantly lower 
intensity (Fig. 1C). These extracts were used to optimize the conditions for TEV 
cleavage. The amounts of TEV required and the incubation temperature were 
tested in preliminary experiments (not shown). Western blot analysis of whole cell 
extracts after incubation with TEV showed that cleavage was most efficient after 
overnight incubation at 4°C (Fig. 1D, lanes 7 and 8).
Next, a small-scale purification experiment was performed to test the effi-
ciency of IgG binding and TEV cleavage. Figure 1E shows that after incubation of 
protein extract with IgG beads, about 50% of ProtA-TEV-3xMYC-PRAME was bound 
to IgG beads (lane 4), while about 50% was still present in the supernatant (lane 
2). When TEV protease was added to the beads and incubated overnight, however, 
almost no cleavage was detected in the eluates (lanes 6 and 9) and the intact 
protein was still bound to the beads. Independent experiments confirmed that TEV 
could efficiently cleave its recognition site in ProtA-TEV-3xMYC-PRAME from soluble 
protein extracts, but not when the tagged protein was bound to IgG beads.
A possible explanation for the inefficient cleavage is that the 27 kDa TEV pro-
tease might not be able to efficiently access its target sites when ProtA-TEV-3xMYC-
PRAME is immobilized on IgG beads. In conclusion, although this epitope tag had 
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Figure 1
TAP approach in FM6-pZ3XN-
PRAME cells.
(A) Schematic representation of 
ProtA-TEV-3xMYC-PRAME.
(B) Overview of the tandem af-
finity purification (TAP) procedure. 
The target protein is light blue, 
its protein interactors orange. 
The first purification is based on 
binding of the proteinA domains 
of the tagged protein to IgG beads. 
Most unbound proteins (in grey) 
are washed off and the target 
protein complex is released by TEV 
protease cleavage. The complex 
is further purified by a second 
purification using beads with 
Myc antibodies and elution with 
molar excess of MYC peptide (red 
square).
(C) Protein levels of PRAME in cell 
lines. Western blot analysis of 
endogenous and epitope-tagged 
PRAME. Left panel: FM6-pZ3XN-
PRAME stable cell lines and 
HEK293T cells transiently trans-
fected with pcDNA5-StrepII-2xTEV-
MYC-3xHA-PRAME (TAG-PRAME, 
69 kDa) are analyzed with MYC 
antibody. Right panel: whole cell 
extracts from the cell lines indi-
cated are probed with anti-PRAME 
affinity-purifed antibody P4 (1:1000 
dilution). Equal amounts of extracts 
were loaded for all samples, and 
this was checked by Ponceaus S 
staining of the membranes.
(D) TEV cleavage on protein 
extracts. Whole cell extracts from 
FM6-pZ3XN-PRAME cells were sub-
jected to TEV cleavage at 4°C for 
4 hours or overnight. For each re-
action, 18 μl of whole cell extracts 
were mixed with 59 μl IPP150/0,1 
buffer and 1 μl of TEV protease 
(preparation batch 14-2), or 2 μl 
of the same protease preparation 
diluted 1:1 in glycerol (TEV glyc), 
or 1 μl buffer (no TEV control). The 
effect of protease inhibitors was 
tested by incubating extracts with 
1 μl TEV and 1x protease inhibitors 
cocktail. After incubation, 14 μl 
laemli buffer 4x was added and 
the sample boiled to stop the 
reaction; 25 μl of all reactions were 
analyzed by western blot with MYC 
antibody.
(E) TEV cleavage of epitope 
tagged PRAME bound on IgG 
beads is ot efficient. IgG beads 
were incubated for 1h with PBS 
(TEV) or PBS with 1% BSA (No 
TEV, and TEV+BSA). Beads were 
subsequently washed with 
IPP150/0,1 buffer without protein 
inhibitors; 15 μl of beads were 
mixed with 100 μl IPP150/0,1 
and 50 μl of FM6-pZ3XN-
PRAME whole cell extract, and 
rocked for 2h at 4 degrees. The 
supernatant was collected, and 
the beads washed with 500 
μl of IPP150/0,1. Elution was 
performed by adding 100 μl of 
IPP150/0,1 and 2 μl of TEV pro-
tease with rocking at 4 degrees 
overnight. The supernatant (TEV 
eluate) was collected, and beads 
washed and boiled in 100 μl 
laemli buffer. 20% fractions of all 
samples were analyzed by west-
ern blot with MYC antibody.
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Figure 2
LZRS-StrepII-TEV-MYC-3xHA-PRAME 
in suspension cells.
(A) Map of the LZRS-ZeoR retroviral 
plasmid. The multi cloning site (MCS) is 
indicated in the square. The sequence 
coding for TAG-PRAME was cloned as a 
BamHI-XhoI fragment.
(B) Nucleotide and amino acid 
sequences of the StrepII-2xTEV-MYC-
3xHA tag. 
(C) Western blot analysis of single 
cell clones of HeLaS3-TAG-PRAME and 
K562-TAG-PRAME cells with HA.Y11 
antibody against the HA TAG. Arrows 
indicate the two main bands for TAG-
PRAME; asterisks indicate background 
bands. Clone numbers are indicated; 
WT, wild type cells (negative control); 
poly, polyclonal culture; ctrl, HEK293T 
cells transiently transfected with 
pcDNA5-TAG-PRAME. Equal amounts of 
whole cell extracts were loaded and 
checked by Ponceau S staining of the 
membrane (not shown).
(D) Gene expression analysis of 
PRAME by real-time RT-PCR. Left 
panel, cDNA prepared from the cell 
lines indicated was analyzed with two 
different primers for PRAME and the 
results normalized against GAPDH. 
Right panel, independent experiment 
with normalization against a pool of 
reference genes (GAPDH, ACTB, GUSB). 
HeLaS3 cells growing in suspension or 
adhesion (plate) were tested.
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been successfully applied to the purification of protein complexes (Le Guezennec et 
al, 2006), it could not be applied to the analysis of PRAME protein interactors.
The StrepII-2xTEV-MYC-3xHA epitope tag in K562 cells
We next tested a different N-terminal combinatorial tag: StrepII-2xTEV-MYC-
3xHA (further referred to as TAG) that could allow the use of several combinations 
of two-step purification strategies (Le Guezennec et al, 2006). Stable cell lines 
expressing StrepII-2xTEV-MYC-3xHA-PRAME (TAG-PRAME, 69 kDa) were generated 
using the retroviral LZRS-ZeoR vector in the human leukaemia K562 cells, which 
express PRAME at high levels, and the cervical cancer HeLaS3 cells, which express 
PRAME at very low to undetectable levels (Fig. 2A and B). 
Single cell colonies were selected and tested for expression: K562-TAG-PRAME 
clone 12 and HeLaS3-TAG-PRAME clone 3 were chosen for further experiments 
(Fig. 2C). Gene expression analysis by real-time RT-PCR indicated that TAG-PRAME 
was expressed at the same levels as endogenous PRAME in K562-TAG-PRAME 
clone 12 cells, and about 3-fold higher in HeLaS3-TAG-PRAME clone 3 cells (Fig. 2D).
Preliminary results indicated that large amounts of protein extracts would be 
needed for purifications of sufficient quantities of PRAME and associated proteins. 
We therefore set up protocols for growth and harvest of suspension cells from 
multiple 5-liter spinner flasks in parallel. For this purpose, we optimized a nuclear/
cytoplasmic protein extraction protocol for both K562 and HeLaS3 cells and we 
assessed the quality of all extractions by western blot analyses for the nuclear 
protein HDAC2 and the cytoplasmic marker α-tubulin. Representative experiments 
are presented in Figure 3A. TAG-PRAME was detected in both the cytoplasmic and 
nuclear fractions, similarly to the endogenous PRAME protein (not shown).
Notably, cytoplasmic extracts yielded on average between 3 and 4-fold more 
proteins than nuclear extracts (in mass). Therefore, for quality control of the protein 
extractions, equivalent fractions in volume - and not the same amount of micro-
grams - of nuclear and cytoplasmic extracts were analyzed by western blot. In this 
way, it is possible to directly compare the two fractions and assess the potential 
contamination of the cytoplasmic extract by nuclear proteins and vice versa.
Two-step TAG-PRAME purifications
At the time of our study, it was generally assumed that a single immuno-
precipitation (IP) step does not sufficiently enrich for the bait, because too many 
aspecific interactors are still present in the eluates. This would result in a mixture 
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of proteins with a too high complexity to allow the successful identification of bait 
and interacting proteins by mass spectrometry. Therefore, most studies used a 
tandem affinity purification protocol in order to increase the purity of the protein 
complex of interest (Rigaut et al, 1999). In line with these studies, we performed 
several small-scale pilot experiments with tandem IPs, each one with two rounds 
of peptide elution. The two eluates from the first IP were pooled and used as input 
for a second IP with a different antibody. We tested three antibodies in different 
combinations: mouse MYC produced in house from hybridoma cultures, rabbit HA 
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Figure 3
Tandem affinity purification 
approach from K562-TAG-PRAME 
cells.
(A) Western blot analysis of nuclear 
and cytoplasmic protein extracts 
from K562 cell lines. 
(B-D) Western blot analyses of pilot 
experiments for TAG-PRAME complex 
purification with a two-step IP 
approach; 3% of each sample were 
analyzed, unless indicated otherwise. 
All membranes were probed with 
mouse HA.Y11 antibody.
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from Abcam (ab9110), and the PRAME affinity-purified antibody P4. Representative 
experiments are shown in Figure 3B-D: MYC-HA, HA-MYC, and P4-MYC purifications.
In order to assess the efficiency of the protocol, equivalent fractions for all 
steps were analysed by western blot: input (nuclear extract), supernatant after in-
cubation of the extract with beads-Ab, first and second peptide eluates, and beads 
after elution. Comparison of the protein levels in input and supernatant gives infor-
mation on the efficiency of the binding of the tagged protein to the beads, while 
comparison of eluates and beads gives information on the efficiency of elution. 
Lanes 1 to 5 (Fig. 3B-D) show that TAG-PRAME could be efficiently bound and 
peptide-eluted with any of the three antibodies used in the first IP. Notably, later 
experiments revealed that peptide elution from the HA-ab9110 antibodies was 
only possible when using a specific lot of the antibody, and later lots did not allow 
peptide elution any more.
Although the first IP steps were efficient for all three antibodies, the final 
yields after the second purifications were considered too low to proceed with a 
large-scale purification (compare final eluates in lanes 7 with input levels in lanes 
1). With this low efficiency, too large amounts of protein extracts and antibodies 
would be required to obtain enough purified proteins for detection by mass spec-
trometry.
Single-step TAG-PRAME purification and mass spectrometry
Based on the previous results, we set out to experimentally test whether a 
single IP purification approach could be applied to the identification of PRAME 
protein partners. In order to reduce the background levels, we used relatively strin-
gent buffers to wash the antibody-beads after incubation with the protein extracts 
and before peptide elution. Figure 4A shows that increasing the salt concentration 
of the wash buffer from 150 to 300 mM reduced very significantly the number of 
background interactions detected by SDS-PAGE and silver stain of peptide eluates 
from a MYC IP on either K562-TAG-PRAME or K562 wild type extracts. A salt con-
centration of 500 mM NaCl did not improve the results further, and we therefore 
chose the 300 mM concentration for follow up experiments. Notably, we did not 
identify clear bands specific for the TAG-PRAME eluates, consistent with the notion 
that TAG-PRAME is present at very low abundance in such eluates as compared to 
background proteins.
Next, we performed a large-scale immunoprecipitation experiment with 
crosslinked MYC beads and 10 ml of nuclear extracts from K562-TAG-PRAME cells, 
52
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Figure 4
Single-step immunopre-
cipitations from K562 
cells.
(A) Background levels in 
single-step IP protocol are 
decreased by 300 mM 
NaCl buffer. MYC IPs were 
performed with 300 μl 
nuclear extracts from the 
cell lines indicated and 20 μl 
MYC-beads. After incubation, 
the beads were washed 
with buffers of different salt 
concentration, as indicated. 
Peptide eluates were 
resolved by SDS-PAGE and 
protein bands visualized by 
silver staining.
(B) Western blot analysis 
of large scale MYC IP from 
K562-TAG-PRAME nuclear 
extracts. The fraction of 
samples analyzed is indi-
cated. The mouse HA.Y11 
antibody was used.
(C) Silver staining of eluates 
from large scale MYC IP. 
Both first and second 
eluates from large scale 
IPs on the nuclear extracts 
indicated were resolved 
on SDS-PAGE and proteins 
visualized by silver staining. 
Molecular weights (kDa) of 
the marker are indicated on 
the left.
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corresponding to about 6 litres of culture and 6x109 cells. Immunoprecipitation 
from 4 ml of nuclear extracts of parental K562 cells (about 2,5 litre culture and 
2,5x109 cells) was performed as negative control. Western blotting of an aliquot 
of the peptide eluates confirmed the efficiency of the IP protocol (Fig. 4B). We 
resolved the eluates on SDS-PAGE and visualized the proteins by silver staining (Fig. 
4C). Several bands were identified, the most intense being present in both the 
TAG-PRAME and the negative control samples, representing background interac-
tions with beads or antibodies. However, a number of fainter bands were specifi-
cally present in the TAG-PRAME eluates and not in the negative control. The entire 
gel lanes were excised in multiple fractions and processed for mass spectrometry 
analysis.
The peptides identified were used in a MASCOT database search and the 
proteins found in the TAG-PRAME and WT eluates were compared to generate a list 
of proteins specific for the TAG-PRAME sample (Table 1). PRAME was successfully 
identified with 7 different peptides, establishing that a single IP/MS approach can 
be successfully applied to the purification of PRAME protein complexes.
Remarkably, peptides were found in the TAG-PRAME eluates that matched all 
known subunits of Cullin2 E3 ubiquitin ligases (Petroski & Deshaies, 2005): Cullin2 
(CUL2), Transcription elongation factor B polypeptide 1 (TCEB1, also called Elongin 
C), Transcription elongation factor B polypeptide 2 (TCEB2, also called Elongin B), 
and RING-box protein 1 (RBX1), suggesting a functional link between PRAME and 
this complex. These interactions were confirmed by western blot of independent 
immunoprecipitation experiments and were further characterized in other chapters 
of this thesis.
Taken together, our results show that a specific epitope tag may not always 
be useful for the purification of a protein of interest. The ProtA-2xTEV-MYC tag had 
been previously used for the purification of protein complexes (Le Guezennec et 
al, 2006), but in the case of PRAME the TEV cleavage step proved too inefficient. 
On the contrary, we successfully used the N-terminal StrepII-2xTEV-MYC-3xHA tag 
and identified PRAME interactors using a single-step purification approach with 
crosslinked MYC beads and peptide elution. We identified specific interactions 
between PRAME and all the known subunits of Cullin2-based E3 ubiquitin ligases, 
suggesting a functional link between ubiquitination pathways and the oncogenic 
properties of PRAME.
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IPI ID
Mass 
(kDa)
Description
N. 
peptides
IPI00014311 87,6 Cullin-2 13
IPI00003362 72,5 HSPA5 protein 12
IPI00300341 12,6 Transcription elongation factor B polypeptide 1 7
IPI00019282 58,7 Melanoma antigen preferentially expressed in tumors 7
IPI00013890 27,9 Isoform 1 of 14-3-3 protein sigma 6
IPI00021447 58,3 Alpha-amylase 2B precursor 6
IPI00012382 31,1 U1 small nuclear ribonucleoprotein A 5
IPI00026670 13,2 Transcription elongation factor B polypeptide 2 5
IPI00644708 43,8 TIA-1 related protein isoform 2 5
IPI00017963 13,6 Small nuclear ribonucleoprotein Sm D2 5
IPI00013881 49,5 heterogeneous nuclear ribonucleoprotein H1 5
IPI00015809 36,9 Probable O-sialoglycoprotein endopeptidase 4
IPI00294997 42,9 Nucleoside diphosphate kinase 7 4
IPI00027285 24,8 Isoform SM-B’ of Small nuclear ribonucleoprotein-associated proteins B and B’ 4
IPI00419373 39,8 Isoform 1 of Heterogeneous nuclear ribonucleoprotein A3 4
IPI00029266 10,9 Small nuclear ribonucleoprotein E 3
IPI00000874 22,3 Peroxiredoxin-1 3
IPI00005615 41,9 Nucleolysin TIAR 3
IPI00152871 65,3 Leucine-rich repeat-containing protein 15 precursor 3
IPI00219483 50,6 Isoform 2 of U1 small nuclear ribonucleoprotein 70 kDa 3
IPI00033025 51,1 Isoform 1 of Septin-7 3
IPI00179964 57,4 Isoform 1 of Polypyrimidine tract-binding protein 1 3
IPI00216402 15,5 Histone H3.1t 3
IPI00081836 13,8 Histone H2A type 1-H 3
IPI00013885 27,9 Caspase-14 precursor 3
IPI00006662 21,5 Apolipoprotein D precursor 3
IPI00013296 17,6 40S ribosomal protein S18 3
IPI00013396 17,6 U1 small nuclear ribonucleoprotein C 2
IPI00302850 13,3 Small nuclear ribonucleoprotein Sm D1 2
IPI00016572 8,5 Small nuclear ribonucleoprotein G 2
IPI00010740 76,2 Isoform Long of Splicing factor, proline- and glutamine-rich 2
IPI00291398 43,3 Isoform Long of Nucleolysin TIA-1 isoform p40 2
IPI00171611 15,3 Histone H3.2 2
IPI00152785 13,8 Histone H2B type 1-O 2
IPI00217466 22,2 Histone H1.3 2
IPI00003881 46,0 heterogeneous nuclear ribonucleoprotein F 2
IPI00002966 95,1 Heat shock 70 kDa protein 4 2
IPI00020487 14,2 Extracellular glycoprotein lacritin precursor 2
IPI00013031 22,5 Dual specificity protein phosphatase 14 2
IPI00062206 35,5 DDX39 protein 2
IPI00742905 147,9 ATP-dependent RNA helicase A 2
IPI00217030 29,7 40S ribosomal protein S4, X isoform 2
IPI00003949 17,2 Ubiquitin-conjugating enzyme E2 N 1
IPI00003386 12,7 RING-box protein 1 1
IPI00032314 14,9 L antigen family member 3 1
Table 1
PRAME putative protein interactors from the first large scale MYC IP. The tables lists all proteins identified 
with at least 2 peptides and a selection of proteins identified with only 1 peptide.
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MATERIALS AND METHODS
Cell culture and plasmids 
HEK293T and FM6 cells were cultured 
in DMEM, K562 and HeLaS3 in RPMI medi-
um (Gibco, Invitrogen) at 37°C in 5% CO2. 
Both media were supplemented with 5% 
Glutamax, 10% fetal bovine serum, 100 U/
ml of penicillin, 100 µg/ml of streptomycin 
(Gibco, Invitrogen). Stable cell lines were 
generated by retroviral transduction, as 
described (Costessi et al, 2011). Genera-
tion of plasmids pcDNA5-TAG-PRAME and 
LZRS(Zeo)-TAG-PRAME, and preparation of 
nuclear/cytoplasmic extracts are described 
elsewhere (Costessi et al, 2011).
Antibodies and western blot
Mouse monoclonal MYC (9E11) were 
produced in-house from hybridoma 
cultures; the PRAME antibody P4 was gen-
erated by peptide immunization of rabbits 
and affinity-purification. The following 
commercial antibodies were used: rabbit 
HA (Abcam ab9110), mouse monoclonal 
HA.Y11 (Covance MMS-101P; 1:3000 dilution 
for WB), alpha-tubulin (Santa Cruz B-7, sc-
5286; 1:2000 dilution for WB), HDAC2 (Bio-
mol SA-402; 1:3000-1:5000). Proteins were 
separated on conventional 10% SDS-PAGE 
gels and western blots were visualized by 
ECL (GE Healthcare) or Odyssey (LiCor). All 
antibodies were diluted in PBS/T with 5% 
skimmed milk for western blot analyses.
Tandem affinity purifications of StrepII-
2xTEV-MYC-3xHA-PRAME
Pilot purifications with two tandem IP 
steps were performed on nuclear extracts 
of K562-TAG-PRAME cl.12 cells. For the first 
IP reaction, 300 µl nuclear extract were 
mixed with 700 µl IPP150/0,5 buffer (300 
mM NaCl, 10 mM Tris-HCl pH 8, 0,5 mM 
EDTA, 0,5% NP-40) supplemented with 
protease and phosphatase inhibitors (1 mM 
PMSF, 1 mM Na
3
VO
4
, 1 mM NaF, 1x Protease 
Inhibitor Cocktail, Roche), and either 50 µl 
of PRAME P4 antibody, 9 µl HA antibody 
(Abcam ab9110) or 100 µl of crosslinked 
MYC-beads. After either 2 hours or over-
night incubation, 100 µl of ProtG beads 
(Sigma) were added to P4 and HA IPs and 
incubated for 2 hours. Subsequently, the 
reactions were spun down and supernatant 
(containing unbound proteins) collected. 
The beads were washed 3 times with 
IPP150/0,5, and subjected to 2 round of 
peptide elution with 500 µl elution buffer 
(IPP150/0,5 with inhibitors and 100 µg/ml 
peptide) for 30 minutes in a thermoshaker 
at 28°C and 1000 rpm. After elution, the 
beads (containing bound proteins that were 
not eluted) were boiled in 250 µl laemli 
buffer. The two eluates from the first IP 
were pooled and used as input to the sec-
ond IP, using half the amount of antibody 
and beads: either 50 µl MYC-beads, 4,5 µl 
HA antibody, or 25 µl P4 antibody. Incuba-
tion and elutions were performed as in the 
first IP step with 100 µl of elution buffer.
Large scale single-step MYC immunopre-
cipitation
Large scale IP was performed by mix-
ing 10 ml nuclear extracts from K562-TAG-
PRAME cells (from about 6 liter cultures) 
with 50 µl crosslinked MYC-beads, and 4 
ml nuclear extracts from K562 wild type 
cells with 15 µl MYC-beads. After overnight 
incubation at 4°C in rotation, the beads 
were spun down and washed 3 times with 
5 ml IPP300/0,5, and once with IPP150/0,5. 
Two consecutive peptide elutions were 
performed with either 100 µl (TAG-PRAME) 
or 30 µl (wild type) elution buffer, as 
described above.
Silver staining
The peptide eluates were resolved 
by SDS-PAGE and the proteins were fixed 
by incubating the gel in fixation solution 
(40:10:50 v/v/v ethanol: acetic acid: water) 
for 20-30 minutes at room temperature 
and gentle rocking. The gel was wash 
twice with washing solution (30% v/v 
ethanol in water) on a shaking platform for 
20 minutes, rinsed twice with water, and 
incubated with water for 20 minutes on a 
shaking platform. 
The gel was incubated in sensitizing 
solution (0,02% sodium thiosulfate) for 1-2 
minutes, rinsed 3 times with water, and 
incubated for 30 minutes in chilled 0,1% 
AgNO
3
 solution at 4°C. The gel was quickly 
rinsed twice with water and incubated in 
developing solution (0,05% formaldehyde 
in 2% sodium carbonate). When a sufficient 
degree of staining was obtained the reac-
tion was stopped with 5% acetic acid. The 
gel was washed several times in 1% acetic 
acid and stored in water.
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Preparation of samples for mass spec-
trometry
The lanes from the SDS-PAGE gel 
corresponding to the first eluates were 
excised with a clean scalpel, chopped into 
small pieces and transferred into 1,5 ml 
tubes. The gel particles were equilibrated 
for 5 minutes with 100 µl ABC (50 mM am-
monium bicarbonate) and centrifuged to 
discard the liquid. Then, 100 µl acetronitrile 
was added and incubated for 5 minutes 
to shrink the gel particles. The ABC and 
acetonitrile steps were repeated twice, or 
until the particles turned white. The gel 
pieces were swelled in 100 µl reduction 
buffer (10mM dithiothreitol in 50mM 
NH
4
HCO
3
) and incubated for 20 minutes at 
56°C to reduce the protein. All liquid was 
discarded and the gel pieces were shrunk 
in 100 µl acetonitrile. The acetonitrile was 
replaced by 100 µl alkylation buffer (55 
mM iodoacetamide in 50 mM NH
4
HCO
3
) 
and incubated for 20 minutes at room tem-
perature in the dark. The gel particles were 
washed with 100 µl ABC (50mM Ammoni-
um Bi Carbonate) for 5 minutes and ABC 
was replaced by 100µl acetonitrile; these 
steps were repeated twice. Gel pieces were 
rehydrated at room temperature in diges-
tion buffer (50 mM NH
4
HCO
3
) containing 
12,5 ng/µl trypsin (Promega). After 30 
minutes, 10-50 µl ABC was added to cover 
the gel pieces and samples were incubated 
overnight at 37°C. Peptides were extracted 
from the gel matrix by adding 100 µl of 2% 
TFA (trifluoroacetic acid) for 10 minutes at 
room temperature; gel particles were spun 
down and the supernatant recovered. The 
peptide extraction was repeated a second 
time. Then, 100 µl acetonitrile was added 
for 5-10 minutes at room temperature to 
shrink the gel pieces, 100 µl 2% TFA was 
added for 5-10 minutes and supernatant 
was recovered after centrifugation. All 
samples were concentrated in a vacuum 
centrifuge (Savant) to a maximum of 200 
µl, which was transferred to a stagetip. 
The peptides were eluted in 2-4 µl buffer 
B (80% acetonitrile, 1% TFA) and diluted 
10 times in buffer A (3% acetonitrile, 0,5% 
acetic acid, 1% TFA). Mass spectrometry 
analysis was performed as previously 
described (Olsen et al, 2004).
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ABSTRACT
The human tumor antigen PRAME (Preferentially expressed antigen 
of melanoma) is frequently overexpressed in tumors. High PRAME levels 
correlate with poor clinical outcome of several cancers, but the mechanisms 
by which PRAME could be involved in tumorigenesis remain largely elusive. 
We applied protein-complex purification strategies and identified PRAME as 
a substrate recognition subunit of a Cullin2-based E3 ubiquitin ligase. PRAME 
can be recruited to DNA in vitro, and genome-wide chromatin immunopre-
cipitation experiments revealed that PRAME is specifically enriched at tran-
scriptionally active promoters that are also bound by NF-Y and at enhancers. 
Our results are consistent with a role for the PRAME ubiquitin ligase complex 
in NF-Y-mediated transcriptional regulation.
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INTRODUCTION
PRAME is the founding member of a large family of PRAME genes (Birtle et 
al, 2005). PRAME genes have been implicated in oogenesis (Dadé et al, 2003), 
spermatogenesis (Wang et al, 2001) and stemness (Bortvin et al, 2003; Cinelli 
et al, 2008), but their function is poorly understood. Human PRAME was initially 
identified as the protein triggering an autologous anti-tumor immune response in 
a melanoma patient (Ikeda et al, 1997). Since then, many reports have shown that 
PRAME is not expressed in most normal adult tissues, while it is overexpressed 
in a wide variety of solid and hematological malignancies (Kilpinen et al, 2008). 
Although not prognostic for all cancers (Steinbach et al, 2002; Tajeddine et al, 
2005; van Baren et al, 1998), high PRAME expression has been found to correlate 
with the stage of melanoma lesions (Haqq et al, 2005) and with shorter overall 
survival of neuroblastoma (Oberthuer et al, 2004) and serous ovarian adeno-
carcinoma patients (Partheen et al, 2008). High PRAME mRNA levels were also 
shown to be an independent prognostic factor of poor clinical outcome in breast 
cancer (Doolan et al, 2007; Epping et al, 2008). In addition, PRAME is significantly 
activated in BCR-ABL-positive chronic myeloid leukemia (Ph+ CML) patients at the 
onset of advanced phase and blast crisis (Radich et al, 2006), and hypomethylation 
of the PRAME locus seems to play a role in this process (Roman-Gomez et al, 2007; 
Schenk et al, 2007). A growing body of evidence indicates that PRAME contrib-
utes markedly to the oncogenic phenotype of several cancers. PRAME has been 
recently implicated in retinoic acid signaling and polycomb-mediated transcription-
al repression in melanoma cells (Epping et al, 2005); however, these mechanisms 
do not seem to play a role in breast cancer (Epping et al, 2008) and acute myeloid 
leukemia (Steinbach et al, 2007). While evidence that expression of PRAME is 
restricted mainly to tumor cells has designated it as a promising therapeutic target, 
efforts to develop strategies to interfere with the oncogenic activity of PRAME are 
hindered by a lack of information about its function(s) (Paydas, 2008). 
In this study, we combined biochemical and genomics approaches to identify 
PRAME as a subunit of Cullin2-based E3 ubiquitin ligases. In addition, we show that 
PRAME is recruited in cells to epigenetically and transcriptionally active promoter 
regions bound by NFY, a transcription factor that is essential for early embryonic 
development (Bhattacharya et al, 2003) and has been implicated in the mainte-
nance of the high proliferative capacity of ES cells (Grskovic et al, 2007) as well as 
in the inhibition of differentiation (Gurtner et al, 2003).
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RESULTS
PRAME associates with Cullin2-based E3 ubiquitin ligases
To investigate the molecular function of human PRAME, we used a 
proteomic approach to identify PRAME-interacting proteins. To this end, we 
stably expressed epitope-tagged versions of PRAME suitable for protein 
purifications in two cellular backgrounds: human K562 leukemia cells, which 
endogenously express detectable levels of PRAME, and human embryonic 
kidney HEK293 cells, which lack detectable endogenous PRAME (Fig. 1A). 
When analyzed by size exclusion chromatography, both endogenous and 
epitope-tagged PRAME from K562 cells showed a broad elution profile, with 
a substantial fraction of the protein eluting earlier than expected of free 
PRAME, which has a predicted molecular mass of 58 kDa (Fig. 1B). This obser-
vation suggests that PRAME may be part of one or more protein complexes. 
We purified PRAME-associated proteins from K562-TAG-PRAME or 
HEK293-HA-PRAME cells by anti-epitope immunoaffinity chromatography and 
analyzed them by mass spectrometry. As shown in Tables 1 and 2, eluates 
from K562-TAG-PRAME and HEK293-HA-PRAME included a collection of pro-
teins not found in control samples. Among the most highly represented were 
Cullin family member 2 (Cul2), Elongins B (TCEB2) and C (TCEB1), and RING 
finger protein Rbx1, all of which are subunits of the large family of multisub-
unit, Cullin-based, ubiquitin ligases. In these ubiquitin ligases, the Elongin BC 
dimer acts as an adaptor that links an Elongin BC-box containing substrate 
recognition subunit, or BC-box protein, to heterodimeric modules composed 
of either Cullin 2 and Rbx1, or Cullin 5 and Rbx2 (Kamura et al, 2004; Kamura 
et al, 1998; Lonergan et al, 1998). The RING finger domains of the related 
Rbx1 and Rbx2 proteins in turn recruit and activate an E2 ubiquitin conjugat-
ing enzyme for ubiquitination of substrates (Kamura et al, 1999; Petroski & 
Deshaies, 2005).
The interaction of TAG-PRAME with ubiquitin ligase subunits was con-
firmed by western blotting of TAG-eluates. As shown in Figure 1C, these 
fractions contained PRAME, Elongins B and C, and two forms of Cul2 that 
most likely correspond to unmodified and a more slowly migrating Neddylat-
ed-Cul2, a hallmark of active ubiquitin ligases. Supporting the physiological 
relevance of these interactions, endogenous PRAME, Cul2, Elongin B, and 
Elongin C were all detected in anti-PRAME immunoprecipitates from nuclear 
extracts of parental K562 cells (Fig. 1D). Notably, while PRAME was clearly 
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Figure 1
PRAME assembles with Cullin2 
ubiquitin ligases. 
(A) Ectopic expression of tagged 
versions of PRAME suitable for 
purifications. Whole-cell extracts of 
K562 cells or HA-immunoprecipi-
tates from 293 cells were analyzed 
by western blot with anti-PRAME 
antibodies. K562 cells expressing 
StrepII-MYC-3xHA-PRAME (TAG-
PRAME) at near-endogenous levels 
were selected, and 293 Flp-In cells 
stably expressing HA-PRAME were 
generated using the Invitrogen Flp-In 
system.
(B) Superose 6 gel filtration analysis 
of nuclear extracts from K562-TAG-
PRAME and K562 wild type cells. 
Western blot was performed with an-
ti-HA or affinity-purified anti-PRAME 
antibodies. Both TAG-PRAME and 
endogenous PRAME partially elute in 
high-molecular weight fractions. The 
numbers represent eluates fractions. 
A less prominent and faster migrating 
band for TAG-PRAME was detected, 
that most likely corresponds to a 
C-terminal truncation.
(C) TAG-PRAME co-immunoprecipi-
tates Cullin2-EloBC complex. Nuclear 
extracts from K562 wild type and 
K562-TAG-PRAME cells were subject-
ed to anti-TAG immunoprecipitation 
and western blotting as indicated; 
0.8% of input and 33% of IP were 
loaded. A more slowly migrating 
form of Cullin2 was enriched after 
IP; this band is consistent with being 
post-translationally neddylated 
Cullin2. Asterisks indicate antibody 
heavy chains.
(D) Endogenous PRAME interacts with 
Cullin2-EloBC complex. Nuclear ex-
tracts from K562 wild type cells were 
subjected to immunoprecipitations 
with anti-PRAME or pre-immune sera 
and western blotting as indicated; 
1% of input, 1% of supernatant and 
20% of IP were loaded. PRAME was 
detected using a light-chain specific 
secondary antibody. PRAME was 
readily depleted from the extract 
after incubation with the specific an-
tibodies (compare lanes 1, 2 and 4). 
Asterisks indicate protein A that dis-
sociated from the beads after elution; 
the open arrow indicates PRAME; s/n, 
supernatant; IP, immunoprecipitates.
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depleted from the extract after incubation with the specific antibodies (Fig. 
1D, compare lanes 1, 2, and 4), Cul2, Elongin B, and Elongin C were not, con-
sistent with their function as components of the many Cullin-based ubiquitin 
ligases present in cells (Kamura et al, 1998; Mahrour et al, 2008). 
PRAME is a BC-box protein
Although we identified all of the other subunits of Cul2-based ubiquitin 
ligases as PRAME-interacting proteins, we did not detect any of the previ-
ously identified BC-box proteins in our fractions. BC-box proteins are charac-
terized by a sequence motif of about 10 amino acids, called the BC-box, that 
binds to Elongin C. In addition, a downstream Cullin-box specifies binding to 
either Cul2 or Cul5 (Kamura et al, 2004; Mahrour et al, 2008). Multiple se-
Protein name Protein ID
TAG-PRAME 
(emPAI)
TAG-PRAME 
(pept.)
Control 
(pept.)
Elongin C IPI00300341.5 4.6 6 1
Elongin B IPI00026670.3 4.2 5 0
Rbx1 IPI00003386.3 0.8 1 0
PRAME IPI00019282.1 0.7 6 0
CUL2 IPI00014311.4 0.7 12 0
Pept., number of peptides.
PRAME  
WT
PRAME  
BC-box mutant 
PRAME  
Cul2-box mutant 
Control 
Protein Gen Bank
Pept. SpC
Cov. 
(%)
NSAF
Pept. SpC
Cov. 
(%)
NSAF
Pept. SpC
Cov. 
(%)
NSAF
Pept.
name acc. no. x1000 x1000 x1000
PRAME NP_996839 11 255 24.9 22 11 275 23 29.5 15 267 27.1 17.3 0
Elongin B NP_009039 9 235 48.3 87.6 2 3 21.2 1.4 4 26 31.4 7.3 1
Elongin C NP_005639 6 160 50.9 62.8 0 0 0 0 4 13 38.4 3.8 0
CUL2 NP_003582 14 455 18.4 26.9 0 0 0 0 0 0 0 0 0
NEDD8 NP_006147 2 9 17.3 4.9 0 0 0 0 0 0 0 0 0
Pept., number of peptides; SpC., spectral counts; Cov., sequence coverage; NSAF, Normalized Spectral Abundance Factor.
 
Table 1
Table 2
PRAME-associated ubiquitin ligase subunits identified by Mass Spectrometry of purified complexes from K562 cells.
PRAME-associated ubiquitin ligase subunits identified by mass spectrometry of purified complexes from HEK 
293 cells expressing epitope-tagged wild type or mutant PRAME proteins. 
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PRAME is a BC-box substrate re-
ceptor for Cullin2-EloBC ligases.
(A) Multiple sequence alignment 
of known Elongin BC-associating 
proteins with PRAME. 
Sequences were aligned using the 
blosum62mt2 alignment matrix with 
the AlignX program of the Vector NTI 
software package. Color coding is 
based on the AlignX default similar-
ity table. Identical amino acids are 
highlighted in yellow, very similar 
ones in blue, and similar amino acids 
are shown in green. The canonical 
BC-box and Cul2-box sequences are 
indicated below the alignment.
(B) PRAME has a functional BC-box. 
SF21 cells were co-infected with the 
baculoviruses as indicated. Total cell 
lysates and anti-FLAG immunopre-
cipitates were analyzed by western 
blotting. IP, immunoprecipitation; 
mBC, BC-box mutant.
(C) BC-box defective PRAME lacks in-
teraction with endogenous Cul2-Elo-
BC ligases. Immunoblot analysis of 
12CA5 HA immunoprecipitates from 
nuclear extracts of K562 cells stably 
expressing TAG-PRAME wild type or 
TAG-PRAME BC-box mutant (PRAME 
mBC). Asterisks indicate antibody 
heavy chains.
(D) The Cul2-PRAME ligase has 
in vitro ubiquitination activity. 
Epitope-tagged subassemblies of the 
PRAME Cul2-based ubiquitin ligase 
complex were purified from insect 
cells and used in an in vitro ubiquitin 
assay (as described in Methods). The 
results were analyzed by western 
blot using rabbit anti-Flag and mouse 
anti-ubiquitin antibodies. 
(E) Model summarizing Cul2-EloBC-
PRAME interactions.
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quence alignments of PRAME with several known BC-box proteins identified 
putative BC- and Cul2-boxes near the PRAME N-terminus (Fig. 2A), raising the 
possibility that PRAME might function as a substrate recognition subunit of a 
Cul2-based ubiquitin ligase.
To assess the functionality of the predicted motifs, we introduced point 
mutations in key residues of the putative BC-box (L26P/A30F) or the puta-
tive Cul2-box (L48A/P49A). We observed that the BC-box mutation greatly 
reduced the binding of PRAME to Elongin C and Cul2 in baculovirus-infect-
ed insect cells (Fig. 2B). We next generated K562 and HEK293 cells stably 
expressing epitope-tagged PRAME carrying the BC-box or Cul2-box mutations 
and performed immunoprecipitations from nuclear extracts. In these cells, 
both mutations disrupted the interaction of PRAME with endogenous Cullin2 
complex components (Fig. 2C and Table 2), demonstrating the functionality 
of the motifs.
In order to test the biochemical activity of the Cullin2-PRAME complex, we 
performed in vitro ubiquitination assays using purified recombinant proteins. 
As shown in Fig. 2D, we observed significant synthesis of poly-ubiquitin chains 
only when all the subunits were combined in the presence of ATP, confirming 
that the Cullin2-PRAME complex is a catalytically active ubiquitin ligase. 
Taken together, these results indicate that PRAME’s BC- and Cul2-boxes 
are essential for the assembly of a PRAME-containing Elongin BC ubiquitin 
ligase, and they identify PRAME as a BC-box substrate recognition subunit of 
a Cul2-based ubiquitin ligase (Fig. 2E).
PRAME associates with chromatin
Cell fractionation and cesium chloride gradient purification of cross-
linked chromatin from K562 cells showed that PRAME associates with chro-
matin (data not shown). In addition, we observe that PRAME can be recruited 
to DNA in vitro. Consistent with the absence of recognizable DNA binding 
domains in PRAME and other PRAME complex subunits, purified PRAME 
complexes did not bind directly to DNA immobilized on agarose beads. When 
incubated with bead-bound DNA in the presence of nuclear extract, how-
ever, PRAME complexes were retained on the DNA beads, suggesting that 
activity(s) in the extract are needed to bridge PRAME’s interaction with DNA 
(Suppl. Fig. 1A). 
To investigate the chromatin-binding profile of PRAME, we performed 
ChIP assays followed by deep sequencing (ChIP-seq) using anti-PRAME 
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Figure 3
Genome-wide profiling of PRAME 
association with chromatin.
(A) Overview of PRAME binding sites. UCSC 
genome browser views of ChIP-seq profiles 
generated with preimmune (negative con-
trol) and PRAME antibodies in K562 cells. 
Specific PRAME peaks are detected at the 
promoters of the DNM2, EIF2AK3, TOP2A, 
and MYST2 genes.
(B) Genomic distribution of PRAME binding 
sites (left) compared to the distribution 
of genomic DNA (right). The majority of 
sites (43%) are located within ±1kb from a 
transcription start site.
(C) Promoter binding of PRAME occurs at 
the TSS. Frequency plot of the distances of 
PRAME binding sites from TSS shows that 
83% of PRAME promoter sites are located 
between -400 bp and +100 bp, with a peak 
at -87bp.
(D) Motif analysis identifies a CCAAT motif 
under PRAME promoter peaks. Top, logo 
of the Jaspar motif matching the most en-
riched sequence identified by GimmeMo-
tifs. Bottom, the positional preference plot 
represents the frequency of the locations 
of the CCAAT motifs with respect to the 
summits of PRAME promoter summits, and 
indicate that the CCAAT motif is enriched at 
the center of PRAME binding regions.
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antibodies or pre-immune serum as control for the specificity of the signals 
obtained. Overlapping sequence tags were joined and displayed as tag-den-
sity profiles in the UCSC genome browser. Strikingly, inspection of the profiles 
revealed that the promoter regions of many protein-coding genes had spe-
cific enrichment for PRAME, as exemplified by the screenshots in Figure 3A. 
Validation experiments by ChIP-qPCR confirmed the high quality of the se-
quencing data (Suppl. Fig. 1B). Furthermore, ChIP-seq with stably expressed, 
epitope-tagged PRAME resulted in very similar if not identical patterns of 
PRAME enrichment (data not shown). To substantiate our finding, we used 
the MACS algorithm (Zhang et al, 2008) at a false discovery rate of 10-6 and 
identified a total of 14132 PRAME binding sites. Location analysis showed 
that 43% of the PRAME sites are closer than 1 kb upstream or downstream of 
a transcription start site (TSS) (Fig. 3B). Importantly, promoters were 9-fold 
enriched as compared to the background distribution of genomic DNA. 
Recently, Heintzman et al. identified enhancer elements in K562 cells 
based on ChIP-on-chip histone modification signatures and binding of the en-
hancer-associated acetyltransferase p300 (Heintzman et al, 2009). Most en-
hancers were cell type specific, and they were enriched in genomic domains 
containing genes specifically expressed in K562 cells. When we compared the 
binding profile of PRAME to the predicted enhancers we found a significant 
overlap between promoter-distal PRAME binding sites and enhancer regions: 
44% of the distal PRAME sites overlapped predicted enhancers, whereas only 
4.1% of random genomic sites did (11-fold enrichment). Moreover, similarly to 
the annotated enhancers, the distal PRAME sites were not randomly distrib-
uted in the genome, but clustered in the vicinity of PRAME-bound promoters 
(Suppl. Fig. 1C), suggesting possible promoter-enhancer interactions.
PRAME associates with NF-Y promoters
We next analyzed all PRAME binding sites falling within 1 kb of promoters. 
When we plotted their distance to the closest TSS, we found that 83% of promot-
er-proximal sites bound by PRAME are concentrated in a narrow window between 
-400 bp and +100 bp from TSS, peaking around -87 bp relative to the TSS. 
Promoters are characterized by the presence of transcription factor bind-
ing sites that critically contribute to the regulation of gene expression. Since 
neither PRAME, nor other PRAME complex subunits contain recognizable 
DNA-binding domains, we reasoned that other transcription factor(s) might 
mediate the recruitment of PRAME to these regions. We therefore performed 
69
de novo motif discovery with GimmeMotifs (van Heeringen & Veenstra, 2010) 
using the DNA sequences underlying the promoter regions bound by PRAME. 
This analysis identified a CCAAT sequence as the top-scoring motif, which 
stood out with highly significant p-values (p<10-20) and the highest enrichment 
and MNCP scores as compared to a pool of random promoters (Fig. 3D and 
Suppl. Fig. 2). The CCAAT sequence can be bound by the Nuclear Transcription 
Factor Y (NFY), a heterotrimeric transcription factor ubiquitously expressed in 
cycling cells (Maity & de Crombrugghe, 1998). The NFYA subunit harbors the 
DNA-binding domain that recognizes the CCAAT sequence, while NFYB and 
NFYC are characterized by histone-like folds (Maity & de Crombrugghe, 1998). 
Similar de novo motif analysis performed on the distal PRAME binding sites 
identified two significant motifs: a GATA/Evi1 motif, and a Fos motif.
ChIP-seq experiments with antibodies against the NFYA and NFYB 
subunits revealed that PRAME sites at promoters are indeed bound by NFY 
in vivo. Screenshots of the sequencing data show clear enrichment of NFY at 
the representative PRAME sites DNM2 and EIF2AK3, as well as PRAME enrich-
ment at the classical NFY promoters TOP2A and CDC25C (Fig. 4A). Consecutive 
ChIP experiments (ChIP-re-ChIP) using crosslinked NFYA antibodies detected 
PRAME and NFY concomitantly on the same regions, indicating that these 
proteins are simultaneously localized at the same promoter regions (Fig. 4B). 
Using the MACS algorithm we identified a total of 28844 regions that 
were bound by NFYA and/or NFYB. The distance distributions of both NFYA 
and NFYB binding sites from TSSs showed a distinct peak around -78/-84 bp 
very similar to PRAME (Fig. 4C). We next counted the number of sequence 
tags within NFY-binding sites and performed a regression curve analysis 
(Suppl. Fig. 3). The binding of NFYA and NFYB were very closely correlated at 
the vast majority of the sites, as expected for stoichiometric binding and in 
agreement with in vitro experiments showing that all subunits are required 
for efficient DNA binding (Sinha et al, 1995). 
Globally, 71% of all PRAME binding sites overlapped NFY regions. Impor-
tantly, virtually all PRAME-bound promoters were also bound by NFY, corrob-
orating and extending the relevance of the CCAAT motif (Fig. 4D). In contrast, 
a sizeable number of NFY promoters did not contain PRAME peaks (Fig. 4D). 
We performed functional annotation of the associated genes and found that 
NFY-only genes as well as NFY genes with PRAME enrichment are associated 
with metabolic and cancer-related pathways. Furthermore, NFY-only genes 
are specifically enriched for immunological processes and intercellular junc-
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Fig  4
PRAME associates with 
NFY-b und promoters ge-
nome-wide.
(A) Overview of NFY binding to 
PRAME loci. UCSC genome brows-
er views show clear binding of 
PRAME, NFYA, and NFYB at the 
promoters of the DNM2, EIF2AK3, 
TOP2A, and MYST2 genes.
(B) Sequential ChIP (ChIP-re-ChIP) 
experiments show co-occupancy 
of PRAME and NFY. The first ChIP 
was performed with covalently 
crosslinked NFYA-beads, followed 
by either anti-PRAME serum 
(NFYA-PRAME) or preimmune 
serum as negative control 
(NFYA-preimmune).
(C) Promoter binding of NFY 
and PRAME occurs at the TSS. 
Frequency plot as in Fig. 3C 
shows very similar distributions 
of distances from TSS for NFY and 
PRAME.
(D) PRAME associates with 
a subset of NFY-promoters 
genome-wide. Venn diagram of 
the overlap between NFY-bound 
(green) and PRAME-bound 
(blue) promoters shows that 
PRAME promoters overlap almost 
completely with NFY promoters. 
On the contrary, a minority of 
NFY promoters are not bound 
by PRAME. An example is the 
TSPAN15 gene (right).
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tions, while NFY genes with PRAME binding are significantly associated with 
numerous transcription-related pathways and cell cycle regulation (Supple-
mentary Table 1).
PRAME is specifically recruited to transcriptionally active NFY 
promoters
Post-translational modifications of the histone proteins, like lysine methyl-
ations and acetylations, are implicated in the regulation of gene transcription. 
Therefore, we used histone marks to assess the transcriptional status of PRAME 
loci. For this purpose we processed ChIP-seq datasets generated by the ENCODE 
project for K562 cells (see methods), and we quantitated the signals at all 
NFY promoters. We found that the active histone marks H3K9ac and H3K4me3 
showed a strong correlation with the binding of PRAME (Fig. 5A). In contrast, 
NFY-only promoters had near-background levels of these marks.
To investigate the transcriptional status of the associated genes, we 
quantitated the occupancy in gene bodies of RNA Polymerase II and of the 
histone marks H3K36me3, which has been linked to transcriptional elonga-
tion (Krogan et al, 2003), and H3K27me3, which has been linked to repres-
sion (Barski et al, 2007). As shown in Figure 5B, NFY genes without PRAME 
binding displayed low levels of PolII and H3K36me3, and high levels of the 
repressive H3K27me3 mark. In contrast, PRAME-bound genes had significant-
ly higher occupancy of both PolII and H3K36me3 (Fig. 5B and D, and Suppl. 
Fig. 4), suggesting that PRAME is associated specifically with transcriptionally 
active genes. To substantiate these findings, we analyzed gene expression 
levels by RNA-seq in our K562 cells. In agreement with the ChIP-seq data, we 
detected few, if any, transcripts from NFY-only genes, while PRAME-bound 
NFY genes were expressed at high levels (Fig. 5C). 
We next tested if components of the Cullin2 complex are present togeth-
er with PRAME on chromatin. In the absence of ChIP-grade antibodies, we 
established stable K562 cell lines expressing Elongin C tagged with a double 
TY1 epitope (TTE-EloC), for which a ChIP-grade antibody was validated in our 
lab. ChIP-qPCR experiments showed specific binding of EloC at all the PRAME 
promoters tested (Fig. 5E). As a control, we performed similar experiments 
with TTE-PRAME.
Taken together, our data supports a model in which a Cul2/EloBC/PRAME 
complex is specifically bound to the subset of epigenetically and transcrip-
tionally active NFY promoters and nearby enhancer regions. 
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Figure 5
PRAME discriminates between 
active and inactive NFY loci.
(A) PRAME binding positively cor-
relates with H3K9ac and H3K4me3 
modifications at NFY promoters. 
Left, heat map representing median 
tag densities (tags/kb) of H3K9ac 
and H3K4me3 at promoter-associat-
ed NFY binding sites without (“No 
PRAME”) or with (“PRAME”) PRAME 
binding. Higher levels of both 
histone marks are found if PRAME 
is present. Right, UCSC genome 
browser views of two representative 
genes: TSPAN15 and PHB.
(B) PRAME binding of NFY promoters 
correlates with high H3K36me3 and 
RNA PolII, and with low H3K27me3 
in the gene body. Box plots show 
the tag density (tags/kb) over the 
bodies of the genes associated with 
NFY promoters without or with 
PRAME binding.
(C) PRAME binding correlates with 
high levels of gene expression. 
Box plot of Normalized Expression 
values computed from RNA-seq ex-
periments show that PRAME-bound 
NFY genes are expressed at higher 
levels than those without PRAME.
(D) Genome browser view of the 
genome-wide data combined. Two 
neighboring tail-to-tail NFY genes 
are shown: SPRYD4 is bound by 
PRAME and is active, while GLS2 
is not bound by PRAME and is in a 
repressed state.
(E) Model summarizing the ge-
nome-wide data.
NFY
K9ac
K4me3
K36me3K36me3
PRAME
K27me3
K27me3
NFY
0.00
0.05
0.10
0.15
0.20
0.25
0.30
alb
um
in
CE
AC
AM
3
GR
IA1
RB
BP
5
PR
AM
E
NU
P2
14_
1
NU
P2
14_
2
RIP
K5
PD
E4
DIP
_1
PD
E4
DIP
_2 MY
C
EIF
2A
K
CB
LL1
FB
XO
31
DN
M2
_1
DN
M2
_2
ME
D1
5
%
 in
pu
t K562 wt
K562-TTE
K562-TTE-PRAME
K562-TTE-ELOC
Scale 10 kb
SPRYD4
GLS2
PRAME
55 -
1 _
NFYA
80 -
1 _
NFYB
70 -
1 _
H3K4me3
100 -
1 _
H3K9ac
220 -
1 _
H3K36me3
20 -
1 _
Pol2
40 -
1 _
H3K27me3
15 -
1 _
RNA
25 -
1 _
0.
0
0.
2
0.
4
0.
6
All 
gen
es
No
 PR
AM
E
PR
AM
E
Ge
ne
 e
xp
re
ss
ion
 (N
E)
RNA
0
5
10
15
No
 PR
AM
E
PR
AM
E
H3K27me3
0
10
20
30
No
 PR
AM
E
PR
AM
E
RNAPolII
0
15
30
45
No
 PR
AM
E
PR
AM
E
Ta
g 
de
ns
ity
 (T
ag
s/1
kb
)
H3K36me3
Scale 5 kb
PHB
PRAME
60 -
1 _
NFYA
450 -
1 _
NFYB
450 -
1 _
H3K4me3
100 -
1 _
H3K9ac
100 -
1 _
Scale 10 kb
TSPAN15
PRAME
60 -
1 _
NFYA
130 -
1 _
NFYB
130 -
1 _
H3K4me3
100 -
1 _
H3K9ac
100 -
1 _
No
 P
RA
M
E
PR
AM
E
H3K4me3
H3K9ac
0 100 200 300
Tag sity
A
B
D
E
F
C
Figure 5
73
DISCUSSION
Our proteomic data reveals that the human oncoprotein PRAME is a 
BC-box substrate recognition subunit of a Cul2-based E3 ubiquitin ligase, 
suggesting a functional link between ubiquitination and the oncogenic prop-
erties of PRAME. Notably, the Von Hippel-Lindau tumor suppressor protein 
is one of the best-characterized BC-box proteins, and its tumor suppressor 
activity is due in part to its role as the substrate recognition subunit of a 
Cul2-based ubiquitin ligase (Kaelin, 2007). Intriguingly, all the annotated 
PRAME-like proteins display a complete conservation of the BC-box and Cul2-
box at their N-terminus (Suppl. Fig. 5), suggesting that all members of the 
large PRAME protein family might function as substrate recognition subunits 
of Cul2-based ubiquitin ligases, possibly displaying different degrees of speci-
ficity and/or redundancy in substrate selection. 
To date, ubiquitination has been demonstrated to play important roles 
in gene regulation, affecting several different steps in the transcriptional 
process (Collins & Tansey, 2006; Conaway et al, 2002). Many activators are 
subject to ubiquitin-mediated degradation at a rate that parallels their trans-
activation abilities (Salghetti et al, 2001). Histones, transcription factors, and 
RNA polymerase II (RNAPII) are targets of ubiquitination, and ubiquitination 
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events are required for the initiation-competent RNAPII complex to exchange 
factors and become competent for cotranscriptional mRNA processing (Mu-
ratani et al, 2005). A recent study indicated that the stability of NFYA can be 
modulated by ubiquitination and degradation via the proteasome, and that 
degradation-resistant NFYA mutants increased cell proliferation (Manni et al, 
2008). Interestingly, some of the lysine residues in NFYA that are target of 
ubiquitination could also be acetylated by p300, suggesting a regulatory com-
petition between these post-translational modifications (Manni et al, 2008).
Our genome-wide analyses reveal that PRAME is strongly enriched at 
NFY promoters, and binding of PRAME predicts a permissive epigenetic land-
scape and transcriptional activity at these regions. Moreover, we found that 
PRAME is also significantly enriched at adjacent enhancer regions, suggesting 
that it could participate in promoter-enhancer interactions. Recently, Ceribelli 
et al. reported a ChIP-on-chip analysis of NFYB in HeLa cells with 2.2% cover-
age of the human genome. Similar to our K562 data, the majority of the NFY-
bound promoters identified in HeLa cells were transcriptionally active and 
carried H3K9-14ac and/or H3K4me3 marks, while about 27% of NFY-bound 
promoters were devoid of these active marks and mostly silent. Further 
experiments implicated NFY not only in the expression of active genes, but 
also in the repression of silent ones, revealing an unexpected dual nature of 
the NFY complex (Ceribelli et al, 2008). The basis of this dual functionality, 
however, is still unclear, and genome-wide data suggest that the activity and 
inactivity of NFY promoters is determined by additional factors and mecha-
nisms that are yet to be identified. 
PRAME is the first factor reported to discriminate between active and in-
active NFY loci. Our genome-wide analyses, summarized in Figure 5F, reveal 
that PRAME is specifically recruited to NFY loci associated with the promoters 
of genes that are highly transcribed and that have high levels of H3K9ac and 
H3K4me3 at their promoters and high H3K36me3 but low H3K27me3 levels 
in their gene bodies. This data suggest a role for PRAME in transcriptional 
regulation, and possibly in the switch between activity and inactivity of NFY 
loci. It is tempting to speculate that PRAME might mediate ubiquitination, 
and possibly degradation, of one or more of the factors that are involved in 
the regulation of NFY promoters. Despite evidence that PRAME and NFYA can 
co-occupy the same genetic loci (Fig. 4B), we have not been able to detect 
stable and direct interactions between PRAME and NFY subunits by coimmu-
noprecipitation following their expression in transfected mammalian cells or 
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in baculovirus-infected insect cells (data not shown). We have also observed 
that PRAME can be recruited in vitro to a DNA fragment containing the 
NFY-dependent HSPA5 promoter by a mechanism that depends on activity(s) 
present in a nuclear extract.  It seems likely that PRAME-NFY interactions, if 
they exist, occur only on DNA and depend on additional, yet to be identified 
factors, since (i) purified NFY is not sufficient to recruit PRAME to HSPA5 pro-
moter DNA, and (ii) supplementing nuclear extract with exogenously added 
NFY does not further enhance PRAME recruitment (Suppl. Figure 1A). 
Interactions have been reported between NFY and the histone acetyl-
transferases GCN5 and PCAF (Currie, 1998), and single-gene studies showed 
that NFY can activate at least some of its target genes in cooperation with 
the acetyltransferase p300, which is able to acetylate histone tails as well 
as NFY subunits (Caretti et al, 2003; Gurtner et al, 2008; Li et al, 1998; Salsi 
et al, 2003). While these acetyltransferases constitute potential targets of 
PRAME, other unknown factors could also take part to these mechanisms. 
Notably, p300 is not only recruited to promoters, but it is also a hallmark of 
enhancer elements. Heintzman and coworkers used p300 ChIP-on-chip bind-
ing profiles to identify an enhancer-specific chromatin signature, which was 
successfully used to predict enhancer elements in several cell lines, including 
K562 (Heintzman et al, 2007). Significantly, we found that about half of the 
promoter-distal PRAME sites are localized at predicted enhancers, suggesting 
that PRAME might be implicated in promoter-enhancer crosstalk.
In an effort to gain insight into PRAME’s potential role in transcription 
regulation, we knocked down PRAME with retroviral shRNA vectors and 
measured the mRNA levels of several target genes. Despite a 70% decrease 
of PRAME transcripts, we did not observe reproducible changes in the tran-
script levels of the target genes tested (data not shown). This is perhaps not 
surprising given that PRAME is a member of a large family of closely related 
proteins that could have overlapping or redundant functions in cultured cells. 
Further, the fact that the PRAME gene family underwent an extraordinary 
expansion specifically in the rodents and primates (Birtle et al, 2005; Consor-
tium et al, 2007) suggests that they are more likely to fine-tune transcrip-
tional regulatory processes rather than to be essential for transcription. Re-
grettably, the lack of a one-to-one orthology between the human and mouse 
PRAME genes (Birtle et al, 2005) has thus far precluded the development of 
suitable knock-out mouse models for studying PRAME function.
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Notably, it is becoming clear that many proteins associate with the 
promoter regions of genes, but their depletion does not seem to cause 
significant or widespread transcriptional defects. For example, the yeast Set1 
histone methyl transferase is widely associated with active promoters, but 
deletion of the Set1 gene causes expression changes of 1.5-fold or more in 
only about twenty genes (Miller et al, 2001). Similarly, the Jmjd3 histone 
demethylase was recently shown to associate with the promoters of LPS-in-
duced genes, but the expression of most of them was unaffected by knock-
out of Jmjd3 (De Santa et al, 2009). These observations are consistent with 
the model that some factors are not strictly required for the bulk of transcrip-
tion, but instead have ancillary or regulatory functions that become apparent 
only in very specific conditions or subpopulations of cells. 
While numerous reports established a role for PRAME in human cancers, 
several studies indicated that PRAME-like genes have roles in the early stag-
es of spermatogenesis (Wang et al, 2001) and oogenesis (Dadé et al, 2003), 
as well as in embryonic development and embryonic stem cells (Bortvin et 
al, 2003). Recently, overexpression of Pramel7 in E14 embryonic stem cells 
was reported to maintain a pluripotent state in the absence of the anti-dif-
ferentiation factor LIF (Cinelli et al, 2008). These findings are consistent with 
the notion that stem cells and neoplastic tissues share many properties, and 
several oncogenic pathways were recently found to also regulate self-renew-
al mechanisms in stem cells (Reya et al, 2001). Interestingly, recent studies 
suggest important roles for NFY in stem cell biology. Knock-out mice demon-
strated that NFYA is essential for early mouse development (Bhattacharya et 
al, 2003), and NFYA was found to promote the self-renewal of hematopoietic 
stem cells (Zhu et al, 2005). Moreover, a systematic analysis of cis-regulato-
ry elements identified the CCAAT box and NFY as crucial regulators of both 
mouse and human stem cells-specific genes, and NFY was involved in the 
maintenance of the proliferative capacity of ES cells (Grskovic et al, 2007).
Taken together, our data unambiguously shows that the PRAME oncop-
rotein is part of a Cullin2-based ubiquitin ligase complex and that PRAME 
localizes to active NFY promoters, paving the road for understanding the 
functions of PRAME in normal cells and in human malignancies. Future ex-
periments will address the role of the PRAME ubiquitin ligase at TSSs, its role 
in transcription of NFY-regulated genes, and its contribution to the oncogenic 
properties of PRAME.
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MATERIALS AND METHODS
Cell culture and stable cell lines 
HEK293 cells were cultured in DMEM 
and K562 in RPMI medium (Gibco, Invitro-
gen) at 37°C in 5% CO2. Both media were 
supplemented with 5% Glutamax, 10% 
fetal bovine serum, 100 U/ml of penicillin, 
100 µg/ml of streptomycin (Gibco, Invitro-
gen). Stable HEK293-HA-PRAME cells were 
generated using pcDNA5/FRT/HA-PRAME 
and the Flp-in system (Invitrogen). K562 
stable cell lines were generated with retro-
viral constructs according to the following 
5-days protocol. On the first day, HEK293T 
cells at 50-60% confluence in a 6-cm dish 
were transfected using Lipofectamine2000 
(Invitrogen) and 1,8 µg of MD-MLV, 300 ng 
VSV-G, 3.6 µg retroviral construct, 100 ng 
pGFP. After 24 h (day 2), the virus-contain-
ing supernatant was harvested, centrifuged 
for 10 min at 3000 rpm and used for a first 
round of transduction of 106 K562 cells 
in the presence of 8 µg/ml of Polybrene 
(Sigma) for 24 h. A second round of trans-
duction was performed on day 3, and on 
day 4 the target cells were transferred to 
fresh RPMI and selection was started on 
day 5 with either 6-10 µg/ml of puromycin 
(Sigma) or 1-2 mg/ml Zeocin (Invitrogen).
Antibodies and western blot
PRAME antisera and affinity-purified 
antibodies were generated by immuniz-
ing rabbits with the previously described 
peptide FPEPEAAQPMTKKRKVDG (Epping et 
al, 2005) (V27 serum). Mouse monoclonal 
HA-12CA5 and Myc-9E11 were produced in-
house from hybridoma cultures. Commer-
cial antibodies used were: mouse mono-
clonal FLAG-M2 (Sigma), c-Myc monoclonal 
(Roche Applied Science), rabbit HA (Bethyl 
Laboratories, or Abcam ab9110), mouse 
monoclonal HA.11 (Covance MMS-101P), 
rabbit Cul2 (Zymed Laboratories 51-1890, 
mouse ElonginC (BD Transduction Labora-
tories 610760), goat ElonginB (Santa Cruz 
P-16, sc-23407), alpha-tubulin (Santa Cruz 
B-7, sc-5286), HDAC2 (Biomol SA-402).
Proteins were separated by conven-
tional SDS-PAGE or NuPAGE 4-12% Bis-Tris 
gels (Invitrogen) run with MES buffer. 
Western blots were visualized by ECL (GE 
Healthcare) or Odyssey (LiCor).
Plasmids and cloning 
Full-length human PRAME was 
PCR-amplified and cloned into NotI and 
XhoI sites of pcDNA5/FRT/TO/StrepII-2xTEV-
Myc-3xHA (Le Guezennec et al, 2006) to 
generate pcDNA5-TAG-PRAME. A Bam-
HI-XhoI fragment encoding TAG-PRAME 
was further subcloned into LZRS(Zeo) 
to generate the retroviral expression 
vector LZRS(Zeo)-TAG-PRAME. Full-length 
human PRAME (ATCC) was subcloned with 
N-terminal HA epitope tags into pcDNA5/
FRT (Invitrogen). Mutagenesis to generate 
PRAME mutants was performed using the 
QuikChange II XL site-directed mutagenesis 
kit (Stratagene) according to the manufac-
turer’s instructions. To create the pTTE ret-
roviral vector for ChIP, the ProtA-2xTEV-Myc 
cassette of the pZXN plasmid (Le Guezen-
nec et al, 2006) was removed by digestion 
with BamHI and SalI. The resulting back-
bone was ligated to overlapping synthetic 
oligos with BamHI and XhoI overhangs, 
encoding two consecutive TY1 epitopes, a 
single ERalpha epitope and an extended 
MCS. PRAME was cloned using the EcoRI 
site to generate pTTE-PRAME plasmid; EloC 
was cloned using BglII and XhoI to gener-
ate pTTE-EloC plasmid. All constructs were 
checked by sequencing.
Gel filtration analysis
Size exclusion chromatography was 
performed with a Superose 6 column on a 
SMART system (Amersham Pharmacia Bio-
tech) with buffer containing 300 mM NaCl, 
10% glycerol, 20 mM TRIS, 0,2 mM EDTA, 1 
mM DTT and 1 mM PMSF. 50 µl nuclear ex-
tract were separated in 100 µl fractions and 
analyzed by SDS–PAGE and western blot.
Purification of protein complexes from 
K562 cells
K562 cells were grown in spinner 
flasks and harvested at a confluence of 
about 106 cells/ml. For each protein ex-
traction, about 1010 cells were centrifuged 
for 15 minutes at 1600 rpm and washed 
with PBS. Cell pellets were resuspended 
in 2,5 volumes of hypotonic buffer T1 (10 
mM Hepes pH 7,9, 10 mM KCl, 0,1 mM 
MgCl
2
, 0,1 mM EDTA pH 8, 1 mM DTT, 10% 
glycerol) supplemented with phosphatase 
and protease inhibitors (1 mM NaVO
4
, 1 mM 
NaF, 1 mM PMSF, Protease inhibitor cocktail 
(Roche)). After 15 minutes of incubation 
on ice, the cell membranes were disrupted 
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with 20 strokes of Pestle A, or until 80-90% 
of the cells were stained by trypan blue. 
After centrifugation for 20 minutes at 3000 
rpm at 4ºC, the supernatant was harvested 
and regarded as the cytoplasmic frac-
tion. The pellet containing the nuclei was 
resuspended in 1 volume of T2 buffer (20 
mM Hepes pH 7,9, 420 mM NaCl, 1,5 mM 
MgCl
2
, 0,1 mM EDTA pH 8, 1 mM DTT, 10% 
glycerol) supplemented with inhibitors, and 
incubated in rotation for 1 hour at 4ºC to 
extract the nuclear proteins. The suspen-
sion was cleared by ultracentrifugation for 
30 minutes at 100000 g at 4ºC (Sorvall RC 
M150 GX). The supernatant was the nuclear 
fraction. The quality of the cytoplasmic/
nuclear extractions was determined by 
western blot of alpha tubulin (cytoplasmic 
marker) and HDAC2 (nuclear marker).
About 5-10 ml (60-120 mg) of nuclear 
extracts were incubated overnight at 4°C 
with anti-Myc (9E11) antibodies covalently 
crosslinked to protA-sepharose CL-4B (GE 
Healthcare) (see below). The following 
day, beads were washed three times with 
10 ml buffer IPP300/0,5 (300 mM NaCl, 10 
mM Tris-HCl pH 8, 0,5 mM EDTA and 0,5% 
NP-40), and the protein complexes were 
eluted with 20 µg/ml of Myc peptide in a 
thermoshaker for 30 minutes at 28°C.
Crosslinking of antibody to beads
ProtA-sepharose CL-4B (GE Healthcare) 
or protG-sepharose (Sigma) beads were 
incubated with antibody in PBS at room 
temperature for 1-2 h, then washed once 
with 10 volumes of sodium borate solution 
(0,2 M, pH 9). Chemical cross-linking of the 
antibodies to the beads was performed 
resuspending the beads in a sodium 
borate solution containing 5.2 mg/ml DMP 
(dimethyl-pimelimidate, Sigma) and incu-
bating for 30 minutes at room temperature 
with gentle rotation. The beads were 
washed once in 10 volumes ethanolamine 
(0,2 M, pH 8), incubated with ethanolamine 
for 2 h at room temperature, washed twice 
with glycine (0,1 M, pH 3) to remove un-
crosslinked antibodies, and eventually with 
PBS to neutralize the pH.
Mass Spectrometry and emPAI calcula-
tion for K562 complexes
The eluates of large scale immunopre-
cipitations from K562 cells were concen-
trated by speedvac and run shortly (~1 cm) 
on SDS-PAGE gels to remove detergents 
and the excess of peptide. The gel lane was 
then fixed, cut in small pieces, reduced and 
alkylated. Proteins were digested overnight 
with trypsin (Promega) and eluted from the 
gel with trifluoroacetic acid. Peptides were 
sequenced using a nano-high-pressure liq-
uid chromatography Agilent 1100 nanoflow 
system connected online to a 7-Tesla linear 
quadrupole ion trap-Fourier transform 
(FT) mass spectrometer (Thermo Electron, 
Bremen, Germany) essentially as described 
(Olsen et al, 2004). Proteins were identified 
using the Mascot search algorithm (Matrix 
Science) with IPI human database v3.37, 
which contains 69 164 unique entries. First 
ranked peptides (Mascot peptide scores 
≥20) were parsed from Mascot database 
search html files with MSQuant (http://
www.msquant.sourceforge.net) to gener-
ate unique first ranked peptide lists that 
were further filtered for absolute calibrated 
mass error <5 and peptide delta score >5. 
To remove redundancy at the protein level 
and to uniquely assign peptides to one IPI 
Db entry, the peptides were remapped to 
the IPI human Db using the program Pro-
tein Coverage Summarizer (http://ncrr.pnl.
gov/software/) as described (Lasonder et 
al, 2008). To determine the protein abun-
dance, we computed the exponentially 
modified Protein Abundance Index (emPAI) 
values for our data (Ishihama et al, 2005; 
Lasonder et al, 2008); emPAI values for all 
proteins were calculated as 10PAI–1 (PAI = 
observed peptides/observable peptides). 
The number of observable peptides was 
calculated by in silico tryptic digestion of 
the IPI human Db v3.37 using the program 
Protein Digestion Simulator (http://ncrr.
pnl.gov/software/).
Purification of protein complexes from 
293 cells and MudPIT analysis
To prepare protein samples for mass 
spectrometry, 293-HA-PRAME and control 
wild type cells were grown to 70–80% 
confluence in 10–20 roller bottles then 
washed, lysed and subjected to anti-HA 
agarose immunoaffinity chromatogra-
phy as described (Mahrour et al, 2008). 
TCA-precipitated proteins were urea-dena-
tured, reduced, alkylated and digested with 
endoproteinase Lys-C (Roche) followed 
by modified trypsin (Roche) as described 
(Florens & Washburn, 2006; Washburn et 
al, 2001). Peptide mixtures were loaded 
onto 100 µm fused silica microcapillary 
columns packed with 5-µm C
18
 reverse 
phase (Aqua, Phenomenex), strong cation 
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exchange particles (Partisphere SCX, 
Whatman), and reverse phase. Loaded 
microcapillary columns were placed in-line 
with a Quaternary Agilent 1100 series HPLC 
pump and a LTQ ion trap mass spectrome-
ter equipped with a nano-LC electrospray 
ionization source (ThermoFinnigan). Fully 
automated 10-step MudPIT runs were 
carried out on the electrosprayed peptides, 
as described (Florens & Washburn, 2006). 
Tandem mass (MS/MS) spectra were inter-
preted using SEQUEST against a database 
of 61 430 sequences, consisting of 37742 
human proteins (downloaded from NCBI on 
2008-03-04), 177 usual contaminants (such 
as human keratins, IgGs, and proteolytic 
enzymes), and to estimate false discovery 
rates, 30716 randomized amino acid se-
quences derived from each non-redundant 
protein entry. Peptide/spectrum matches 
were sorted and selected using DTASelect 
with the following criteria set: spectra/
peptide matches were only retained if they 
had a DeltCn of at least 0,08, and minimum 
XCorr of 1,8 for singly-, 2,0 for doubly-, and 
3,0 for triply-charged spectra. In addition, 
peptides had to be fully-tryptic and at least 
7 amino acids long. Combining all runs, 
proteins had to be detected by at least 2 
such peptides, or 1 peptide with 2 indepen-
dent spectra. Under these criteria the final 
false discovery rate at the peptide level is 
0,151 ± 0,009. Peptide hits from multiple 
runs were compared using CONTRAST. To 
estimate relative protein levels, we took 
advantage of evidence that Normalized 
Spectral Abundance Factors (NSAFs) vary 
with the relative abundance of proteins in 
a sample. NSAFs were calculated for each 
detected protein, using the formula:
€ 
NSAF( )k =
SpC /Length( )k
SpC /Length( )i
i=1
N
∑
where SpC = spectral count, L = protein 
length in amino acids, and i = all proteins 
detected in the MudPIT runs, as described 
(Florens et al, 2006; Paoletti et al, 2006).
Expression of recombinant proteins in 
Sf21 insect cells 
cDNAs encoding wild type or mutant 
PRAME, Cul2, Elongins B and C were 
subcloned into pBAcPAK8 and recombinant 
baculoviruses were generated. SF21 cells 
were cultured at 27°C in SF-900 medium 
supplemented with 10% fetal bovine 
serum. SF21 cells were co-infected with 
the recombinant baculoviruses indicated in 
the figures. 50 hours after infection, cells 
were collected, lysed, and processed as 
described (Mahrour et al, 2008).
In vitro ubiquitination assays
The PRAME-Elongin BC complex and 
the His-T7-Xpress-Cullin2/Myc-RBX1 com-
plex were obtained by co-infecting Sf21 
cells with baculoviruses encoding for each 
individual protein and purifying through 
Flag tag or nickel-agarose chromatography, 
respectively. Different combinations of 
these complexes were then incubated for 
1 h at 37°C with ~50 nM Uba1, ~0,2 µM 
UbcH5a, and 0,25 mg/ml ubiquitin, in 20 µl 
reactions containing 50 mM Tris-HCl, pH 7,6, 
50 mM NaCl, 5 mM MgCl
2
, 0.5 mM EDTA (pH 
7,9), 5% glycerol, 2 mM ATP, 0.5 mM dith-
iothreitol, 0.3 units/ml pyrophosphatase, 
60 mM creatine phosphate, and 0,3 mg/
ml creatine phosphokinase. N-terminally 
(His)6-tagged mouse E1 was expressed in 
Sf21 insect cells and purified by nickel-aga-
rose chromatography as described. Human 
UbcH5a with an N-terminal 6-histidine tag 
and a C-terminal Flag tag were expressed 
in E. coli strain BL21(DE3) and purified by 
nickel agarose. 
ChIP and qPCR
Chromatin harvests, ChIPs, and qPCR 
analyses were performed as previously de-
scribed (Denissov et al, 2007) with the follow-
ing minor adjustments. Cells were crosslinked 
for 15 min in 1% formaldehyde, they were 
resuspended in ChIP incubation buffer at a 
concentration of 16 millions/ml and sonicated 
using a Bioruptor sonicator (Diagenode) for 
15 min with settings: high power, 30 s ON, 
30 s OFF. For every ChIP reaction, 200 µl of 
sonicated chromatin were used. The immuno-
precipitated chromatin was eluted with 200 µl 
of elution buffer at room temperature for 20 
minutes and DNA was purified with QIAquick 
PCR purification kit (QIAGEN). For ChIP-seq, 
DNA eluted from 5-7 ChIP reactions was 
pooled and the DNA concentration was mea-
sured with a Qubit fluorometer and Quant-iT 
dsDNA HS Assay (Invitrogen). 
The following antibodies were used 
for ChIP: preimmune serum (preV27, “no 
antibody” control) and PRAME antiserum 
(V27); NFYA (Santa Cruz H-209, sc-10779); 
NFYB (pAb-007-100) and BB2 (against TY1 
epitope) were from Diagenode.
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For sequential ChIP experiments 
(ChIP-re-ChIP), in order to avoid antibody 
carry-over, the first ChIP was performed 
with antibody covalently crosslinked to 
ProteinA/G-Sepharose beads (Santa Cruz) 
with DMS as described above. Immunopre-
cipitated chromatin was then eluted in a 
smaller volume and further processed as a 
normal ChIP with PRAME immune serum or 
the preimmune serum as negative control. 
Real-time qPCR was performed using the 
SYBR Green mix (Biorad) with the MyIQ 
thermocycler (Bio-Rad). Specific primers for 
qPCR (Biolegio) were designed as previous-
ly described (Denissov et al, 2007) and are 
listed in Supplementary Table 2. Primers 
amplifying exon 12 of albumin were used 
as negative control.
RNA-seq library preparation and data 
analysis
Total RNA was extracted from K562 
cells with the RNeasy kit and on-column 
DNase treatment (Qiagen). 100 µg of total 
RNA were subjected to two rounds of 
poly(A) selection using the Oligotex mRNA 
Mini Kit (Qiagen) and the concentration of 
poly(A)+ RNA was measured with a Qubit 
fluorometer (Invitrogen). 200 ng of purified 
poly(A)+ RNA were diluted in 160 µl 
RNAse-free water and fragmented by addi-
tion of 40 µl 5x fragmentation buffer (200 
mM Tris acetate pH 8,2, 500 mM potassium 
acetate and 150 mM magnesium acetate) 
and incubation at 94°C for 120 seconds. 
After purification with RNeasy Minelute Kit 
(Qiagen), the quality of fragmented RNA 
was analyzed on an Experion (Bio-Rad). 
Double stranded cDNA was synthesized 
from the fragmented RNA with Superscrip-
tIII (Invitrogen) using random hexamers, 
and then used for Illumina sample prep-
ping and sequencing (see below).
A total of 7 246 489 RNA-seq reads 
were uniquely mapped to hg18 and used 
for bioinformatical analysis. Normalized 
gene expression values (NE) for RefSeq 
genes were computed with Genomatix 
Region Miner tools.
Illumina high-throughput sequencing
A starting amount of 10-20 ng of 
ChIP DNA or double stranded cDNA was 
used for sample prepping according to 
standard protocols. Briefly, end repair was 
performed with T4 DNA ligase, Klenow DNA 
polymerase and T4 PNK; a 3’ protruding 
adenosine was added using Klenow DNA 
polymerase, and T-overhang adaptors 
were ligated. DNA molecules with a size 
of 270-300 bp were selected from gel, pu-
rified and amplified with 14 cycles of PCR. 
Quality controls were performed by qPCR 
of DNA before and after sample prepping, 
and by analysis of the PCR products with 
an Experion (Bio-Rad). Cluster generation 
and sequencing-by-synthesis (35bp) were 
performed using the Illumina Genome An-
alyzer II according to standard protocols (Il-
lumina). The image files were processed to 
extract DNA sequence data, and sequences 
were mapped to the human hg18 reference 
genome using the eland program allowing 
at most one base mismatch. Sequence 
reads were filtered based on quality 
controls and sequences that could not be 
mapped uniquely on the reference genome 
were discarded. For visualization purposes, 
ChIP-seq reads were directionally extended 
to the length of the fragments used for 
sequencing and the number of overlapping 
sequence reads was determined for each 
base pair in the genome, averaged over 
a 10 bp window, and visualized in the 
University of California Santa Cruz genome 
browser (http://genome.ucsc.edu). ChIP-
seq and RNA-seq data are published in the 
GEO database (GSE26439), and in the pub-
lished history “PRAME” in Galaxy (http://
main.g2.bx.psu.edu/).
ChIP-seq analysis and peak detection
Bioinformatical analysis was per-
formed using a combination of in-house 
developed scripts, a Genomatix Genome 
Analyzer server (www.genomatix.de), and 
Galaxy tools (http://main.g2.bx.psu.edu/). 
ChIP-seq experiments generated the 
following number of uniquely-mapped 
reads: 5,5 millions for PRAME, 5,6 millions 
for preimmune (control), 8,9 millions for 
NFYA, and 8,8 millions for NFYB. In order 
to compensate for the small difference in 
sequencing depth between the PRAME and 
preimmune datasets, the number of tags of 
preimmune ChIP-seq was equalized to the 
number of tags of PRAME ChIP-seq by uni-
form removal of tags as described (Nielsen 
et al, 2008). PRAME binding sites (peaks) 
were subsequently identified with the 
MACS peak calling algorithm (Zhang et al, 
2008) using the two-sample method with 
a p-value (e) of 10-6, which compared the 
PRAME profile to the preimmune (control) 
profile. NFYA and NFYB binding sites were 
determined with MACS using the standard 
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method with extended lambda (10 kb, 50 
kb, 100 kb) and p-value (e) of 10-6. MACS 
identified a total of 141 32 PRAME peaks, 
25 151 NFYA peaks, and 16350 NFYB peaks. 
NFYA and NFYB peaks were combined in 
a total of 28 844 NFY binding sites that 
were tested for tag density. The number 
of sequence reads were counted in 500bp 
regions centered on the summits of the 
28844 NFY binding sites (with the summit 
being the site of highest enrichment as 
determined by MACS), and the data were 
visualized in dot plots using R.
Location analysis and motif discovery
To analyze the genomic distribution 
of the binding sites identified, we first 
determined the fraction of peak summits 
localized within a 2 kb window centered 
around the TSS of primary transcripts (TSS 
± 1 kb) using the Genomatix Genome 
Inspector. The genomic distribution of the 
binding sites located outside promoter re-
gions (“distal sites”) relative to genes was 
analyzed with PinkThing (http://pinkthing.
cmbi.ru.nl/). The background distribution 
of genomic DNA was determined applying 
the same approach to pools of random 
genomic sites (n > 33 000).
The distances of promoter-associated 
binding sites from TSSs were computed 
with the Genomatix Genome Inspector 
tool, and plots were generated with R.
The localization of PRAME at enhancer 
elements was determined by overlaps 
between PRAME peaks summits and en-
hancer regions recently predicted for K562 
cells (Heintzman et al, 2009). The genomic 
coordinates of the published enhancer 
regions were converted from hg17 to hg18 
with the Galaxy Lift-over function, resulting 
in 24 545 enhancers.
De novo motif discovery was per-
formed using the GimmeMotifs pipeline 
(van Heeringen & Veenstra, 2010), which 
incorporates a number of widely-used 
motif analysis tools, including MDmodule, 
MEME, Weeder, MotifSampler, BioProspec-
tor. Based on the distribution of PRAME 
binding sites, we performed motif searches 
on the DNA sequences underlying PRAME 
summits located within -400 bp and +100 
bp of a primary TSS (n=4981). A CCAAT mo-
tif scored the highest values of enrichment 
and MNCP scores, as compared to pools 
of background sequences with the same 
genomic distribution.
ENCODE datasets
We retrieved and analyzed public-
ly-available ChIP-seq datasets of H3K9ac, 
H3K4me3, H3K36me3, H3K27me3, and 
RNA-PolII generated from K562 cells by 
the “ENCODE Chromatin Group at Broad 
Institute and Massachusetts General Hos-
pital” (http://hgdownload.cse.ucsc.edu/
goldenPath/hg18/encodeDCC/wgEncode-
BroadChipSeq/).
Starting from 27 903 RefSeq genes 
with a RNA-seq expression value, we iden-
tified 7 214 genes longer than 1 kb with a 
NFY peak summit in the proximal promoter 
region. Next, we quantified the signals of 
PRAME in a 500 bp window under the NFY 
binding site, H3K9ac and H3K4me3 in a 3 
kb window, H3K36me3 and H3K27 in the 
gene body, and RNA-PolII in the gene body 
excluding the first 500 bp.
Immobilized template assay method
A 5’-biotinylated DNA fragment of 
~670 bp containing nucleotides -280 to 
+150 (relative to the annotated TSS) of 
the human HSPA5 promoter downstream 
of ~240 of DNA derived from the pGEM-T 
Easy Vector (Promega) was immobilized 
on streptavidin-coupled magnetic beads 
(Dynabeads M-280 Streptavidin, Invitrogen) 
following the manufacturer’s instructions. 
This DNA fragment contains 3 ER stress el-
ements (ERSE), each of which includes con-
tains binding sites for NFY and ATF6. Reac-
tions containing different combinations of 
Hela nuclear extract, Flag-PRAME complex 
(~50ng), and NFY (~100ng) were incubated 
with ~200ng of immobilized DNA for 30 
minutes at 30ºC in buffer containing 50mM 
NaCl, 40mM Hepes-NaOH pH 7.9, 15% 
Glycerol, 2mM MgCl
2
, 0.15mM EDTA, 1mM 
DTT, 0.02% NP-40, and 0.1mg/ml BSA. The 
magnetic beads were washed three times 
in the same buffer without BSA. Bound 
proteins were eluted by boiling the beads 
in 1X SDS loading buffer and analyzed by 
western blotting. NFY was purified by anti- 
Flag immunoaffinity chromatography from 
Sf21 cells coinfected with baculoviruses 
encoding Flag- NFYA, Myc-NFYB, and HA-
NFYC. Flag-PRAME and PRAME-associated 
proteins (including Elongins B and C, Cul2, 
and Rbx1) were purified using anti-Flag 
agarose from nuclear extracts from 293-FRT 
cells stably expressing Flag-PRAME. NE, 
HeLa nuclear extract.
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SUPPLEMENTARY INFORMATION
Supplementary figure 1
PRAME inding to DNA, ChIP-
seq validation and analysis.
(A) PRAME binds a DNA fragment 
containing the NFY-dependent 
HSPA5 promoter by a mecha-
nism that depends on activity(s) 
present in Hela nuclear extract. 
A DNA fragment containing the 
HSPA5 promoter was immobi-
lized on Streptavidin-coupled 
magnetic beads and incubated 
with various combinations of 
Flag-PRAME complex, HeLa 
nuclear extract and recombinant 
NFY expressed in and purified 
from insect cells coinfected with 
baculovirus vectors encoding 
Flag- NFYA, Myc-NFYB and HA-
NFYC. After washing, bound pro-
teins were eluted and analyzed 
by western blotting.
(B) Validation of PRAME binding 
sites by ChIP-qPCR. ChIP assays 
were performed with preimmune 
serum or anti-PRAME serum in 
K562 cells. The qPCR primers 
used targeted regions in the 
proximal promoters of the genes 
indicated, with the exception 
of albumin (exon 12). Albumin, 
CEACAM3 and GRIA1 are used 
as negative controls. For some 
genes, two independent primer 
pairs were used.
(C) Distal PRAME binding sites 
are clustered in the vicinity of 
promoter-associated PRAME 
binding sites. The box plots clear-
ly show that the PRAME binding 
sites outside promoters (n=8095) 
are not randomly distributed 
in the genome, but are instead 
significantly clustered close to 
promoter-associated PRAME 
binding sites (median distance: 
73 kb vs. 346 kb for random 
sites), similarly to annotated 
enhancer regions.
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NFY ChIP-seq data analysis.
(A) Correlation between NFYA 
and NFYB binding detected by 
ChIP-seq. NFYA and NFYB tag 
densities were determined in 500 
bp regions centered around the 
summits of NFYA and/or NFYB 
binding sites (n=28844). The data 
is displayed after sorting on NFYA 
(left) or NFYB (right) tag densi-
ties. The plots show that NFYA 
and NFYB signals are very well 
correlated for the majority of the 
binding sites. A subpopulation of 
binding sites shows high signals 
for NFYA, but low for NFYB 
(~5-10% of the sites, depending 
on the threshold applied), which 
might reflect dynamic in vivo 
binding of NFY subunits in the 
context of chromatin. PRAME 
binding sites didn’t show a bias 
towards or against these regions.
(B) Genomic distribution of NFY 
binding sites.
(C) NFYA, NFYB, and PRAME bind-
ing occur at the same site, and 
not generally within promoters. 
Each NFYA promoter summit 
is centred on the zero, and the 
distances to NFYB (green) or 
PRAME (blue) summits plotted as 
frequency density.
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Supplementary figure 4
UCSC genome browser views of all genome-wide datasets combined.
Overviews of the active NFY loci TOP2A and STAT2, and of the inactive NFY loci TSPAN15 and SLC4A8.
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- - - - - - - - - - - - - - - - MS L QA P - RR L L E L AGQS L L GDQA L A I S I L DE L PRE L F P P L F V E A
- - - - - - - - - - - - - - - - MS L QA P - RR L L E L AGQS L L GDQA L A I S I L DE L PRE L F P P L F V E A
- - - - - - - - - - - - - - - - MS I R I P P - R L L E L AGX S L L RDQA L A V S T L E E L P T E L F P P L FME A
- - - - - - - - - - - - - - - - MS I QA P P - R L L E L AGQS L L RD K P L A I S A L E E L PRE L Y L P L F L E A
- - - - - - - - - - - - - - - - MS L QT P S - R L L E L AGQS LMRKQF L T I F T L D X L PRE V S P LMFME A
- - - - - - - - - - - - - - - - MS L QS P S - R L L E L AGQS L L RNQF L T I F I L DE L PRE V F P LMFME A
- - - - - - - - - - - - - - - - MS L QT P S - R L L E L AGQS L L RNQF L T I F T L DE L PRE V S P - L FME A
- - - - - - - - - - - - - - - - MS L QA P S - R L L E L AGQS L L RNQF L T I F T L DE L PRE V F P LMFME A
- - - - - - - - - - - - - - - - MS L QA P S - R L L E L AGQS L L RNQF L T I F T L DE L PRE V F P LMFME A
BC-box Cul2-box
Supplementary Figure 5
Supplementary Table 1
NFY and PRAME E Adj.P NFY-only E Adj.P
Spliceosome 9.7 2.3E-18 Metabolic pathways 3.0 1.7E-11
Ribosome 10.2 6.5E-14 Pathways in cancer 3.8 6.6E-06
Metabolic pathways 2.5 2.1E-09 Wnt signaling pathway 5.0 1.0E-04
Huntington's disease 4.8 9.3E-08 Hedgehog signaling pathway 8.2 2.0E-04
Aminoacyl-tRNA biosynthesis 10.4 6.5E-07 Basal cell carcinoma 7.3 1.2E-03
Terpenoid backbone biosynthesis 17.0 1.3E-05 Melanogenesis 5.1 1.6E-03
Endocytosis 3.9 3.8E-05 Axon guidance 4.5 1.6E-03
Oxidative phosphorylation 4.1 2.0E-04 Glycerolipid metabolism 7.7 1.6E-03
Proteasome 7.1 2.0E-04 Antigen processing and presentation 5.2 2.8E-03
Oocyte meiosis 4.5 2.0E-04 Arginine and proline metabolism 6.4 3.8E-03
Progesterone-mediated oocyte maturation 5.0 4.0E-04 Adherens junction 5.2 4.6E-03
Cell cycle 4.0 5.0E-04 Cell adhesion molecules (CAMs) 3.9 6.3E-03
Nucleotide excision repair 6.8 6.0E-04 MAPK signaling pathway 2.8 8.8E-03
MAPK signaling pathway 2.7 1.3E-03 PPAR signaling pathway 5.0 1.2E-02
Alzheimer's disease 3.3 1.3E-03 Fc gamma R-mediated phagocytosis 4.2 1.2E-02
Mismatch repair 9.3 1.3E-03 Glycerophospholipid metabolism 4.9 1.2E-02
DNA replication 7.1 1.3E-03 Asthma 7.7 1.3E-02
Parkinson's disease 3.5 1.9E-03 Alanine, aspartate and glutamate metabolism 7.4 1.4E-02
Homologous recombination 7.6 2.4E-03 Citrate cycle (TCA cycle) 7.2 1.4E-02
RNA degradation 5.1 2.7E-03 Endometrial cancer 5.5 1.4E-02
Acute myeloid leukemia 5.0 2.7E-03 Vibrio cholerae infection 5.1 1.6E-02
Ubiquitin mediated proteolysis 3.1 8.3E-03 Insulin signaling pathway 3.4 1.6E-02
Valine, leucine and isoleucine biosynthesis 11.6 9.4E-03 Fructose and mannose metabolism 6.8 1.6E-02
Vibrio cholerae infection 4.6 9.5E-03 Renin-angiotensin system 10.2 1.6E-02
Fc gamma R-mediated phagocytosis 3.5 9.6E-03 Arachidonic acid metabolism 5.0 1.7E-02
Selenoamino acid metabolism 6.6 1.3E-02 Allograft rejection 6.1 2.1E-02
Purine metabolism 2.8 1.3E-02 Leukocyte transendothelial migration 3.4 2.1E-02
NOD-like receptor signaling pathway 4.1 1.3E-02 Regulation of actin cytoskeleton 2.7 2.1E-02
RNA polymerase 5.9 1.7E-02 Prostate cancer 3.9 2.1E-02
ErbB signaling pathway 3.4 1.7E-02 Gap junction 3.8 2.1E-02
Glyoxylate and dicarboxylate metabolism 8.5 1.8E-02 Graft-versus-host disease 5.5 2.5E-02
Prostate cancer 3.4 1.8E-02
Pathways in cancer 2.1 1.9E-02
p53 signaling pathway 3.7 1.9E-02
Long-term depression 3.7 2.0E-02
Steroid biosynthesis 7.5 2.2E-02
mTOR signaling pathway 4.1 2.3E-02
Vitamin B6 metabolism 14.2 2.3E-02
Pyrimidine metabolism 3.0 2.5E-02
2.5E-02
Functional analysis of NFY genes.
E., enrichment; adj. P, adjusted P-value.
Epithelial cell signaling in Helicobacter pylori 
infection 4.2
Complete conservation of the BC-box and Cul2-
box in the PRAME-like protein family.
All human PRAME-like proteins share a conserved 
BC-box and Cul2-box at their N-terminus. The amino 
acid sequence of human PRAME was aligned with 
ClustalX to the previously published multiple align-
ment of the human PRAME-like proteins encoded 
on human chromosome 1 [Birtle et al. 2005]. The 
alignment was edited with CLC Sequence Viewer to 
indicate dissimilar residues in grey, and to identical 
in yellow the identical residues within the BC- and 
Cul2-boxes.
Supplementary figure 5
Supplementary table 1 Functional analysis of NFY genes. E., enrichment; adj. P, adjusted P-value.
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Supplementary Table 2
ChIP-qPCR primers
alb_F Albumin (negative ctrl) TGAAACATACGTTCCCAAAGAGTTT
alb_R Albumin (negative ctrl) CTCTCCTTCTCAGAAAGTGGCATAT
#72_F CEACAM3 (negative ctrl) TCTCTGTGACCTCCTTGCTG
#72_R CEACAM3 (negative ctrl) GGTCCCTGAACCTGGTGTTA
#6_F RBBP5 GCCCAAATATATGCCTGACC
#6_R RBBP5 TTCCCGGAGCAAATAATCTT
#14_F NUP214_1 CAAGCTTGACGTCACCAAAG
#14_R NUP214_1 AGCAAACTTCCTCCCCTCAG
#15_F NUP214_2 GCCACGCCACTACTCAGC
#15_R NUP214_2 CGTCAAGCTTGGTCAGAGGA
#16_F PRAME GGGGAGCTGTACCCTGAAG
#16_R PRAME CTGGGAGGAAGTGGGTTTT
#23_F RIPK5 AAGGATCGCTGGAGGACAC
#23_R RIPK5 TTCTCCAGCCTTGAGGTTTT
#24_F PDE4DIP_1 GACTCTGCTGTCACCCTCCT
#24_R PDE4DIP_1 TCTTGGGGGTCAGTCTCTCT
#25_F PDE4DIP_2 AAGTGGTGTAACCCGACTCC
#25_R PDE4DIP_2 TCTCTCTTTTCCGAGAAGCTG
#46_F MYC AGGGATCGCGCTGAGTATAA
#46_R MYC CTGCCTCTCGCTGGAATTA
#47_F EIF2AK CGCTAACTGCCTCTTGATTG
#47_R EIF2AK GCACTTGCCTCCCACTCT
#48_F CBLL1 TGAAGCACATGAGGAGAAGC
#48_R CBLL1 GGGACTCAGGCATAGTTC
#49_F FBXO31 AGAAAGTGGTGATGCCGAGT
#49_R FBXO31 CAGCGCGTCAGTCTCATAAT
#92_F CCBN2 CCGGCTGTTGTGACAATCAAA
#92_R CCBN2 CAAATACCGCGTCGCTTGC
ChIP-qPCR primersSupplementary table 2
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ABSTRACT
The human tumour antigen PRAME (preferentially expressed antigen in 
melanoma) is frequently overexpressed during oncogenesis, and high PRAME 
levels are associated with poor clinical outcome in a variety of cancers. 
However, the molecular pathways in which PRAME is implicated are not 
well understood. We recently characterized PRAME as a BC-box subunit of a 
Cullin2-based E3 ubiquitin ligase. In this study, we mined the PRAME inter-
actome to a deeper level and identified specific interactions with OSGEP and 
LAGE3, which are human orthologues of the ancient EKC/KEOPS complex. 
By characterizing biochemically the human EKC complex and its interactions 
with PRAME, we show that PRAME recruits a Cul2 ubiquitin ligase to EKC. 
Moreover, EKC subunits associate with PRAME target sites on chromatin. Our 
data reveal a novel link between the oncoprotein PRAME and the conserved 
EKC complex and support a role for both complexes in the same pathways.
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INTRODUCTION
The human oncoprotein PRAME (preferentially expressed antigen in mela-
noma) was first identified and cloned as the antigen responsible for an anti-tu-
mour immune response in a melanoma patient (Ikeda et al, 1997). Follow-up 
experiments revealed that PRAME is expressed at low levels in few normal 
adult tissues like adrenals, ovaries, and endometrium, and at high levels only 
in the testis (Ikeda et al, 1997; Kilpinen et al, 2008). However, overexpression 
of PRAME is frequently found in a wide variety of human cancers, including 
acute and chronic haematological tumours, synovial sarcoma, lung, breast, 
and renal carcinoma (Allander et al, 2002; Ikeda et al, 1997). Importantly, 
high PRAME levels were found to correlate with advanced stages of disease in 
melanoma (Haqq et al, 2005), neuroblastoma (Oberthuer et al, 2004), serous 
ovarian adenocarcinoma (Partheen et al, 2008), and chronic myeloid leukae-
mia (Radich et al, 2006), and to constitute an independent prognostic factor of 
poor clinical outcome in breast cancer (Doolan et al, 2008; Epping et al, 2008). 
In contrast, high levels of PRAME were found to correlate with good prognosis 
in leukaemia cases carrying the t(15;17) PML-RAR translocation (acute promye-
locitic leukaemia) (Santamaría et al, 2008).
Although these findings suggested a role for PRAME in human malignan-
cies, the detailed molecular mechanisms and pathways involved are not yet 
clear. PRAME was reported to repress retinoic acid signaling in melanoma cell 
lines (Epping et al, 2005), but this was not confirmed for breast cancer or leu-
kaemia cases (Steinbach et al, 2007; Epping et al, 2008). Conflicting reports 
on leukaemia cells suggested that PRAME might induce caspase-independent 
cell death (Tajeddine et al, 2005), or repress apoptosis-related genes to pro-
mote cell survival (Tanaka et al, 2011). 
Recently, through biochemical characterization of PRAME-containing 
protein complexes, we established that this oncoprotein is a component 
of Cullin2-based E3 ubiquitin ligases and belongs to the family of BC-box 
proteins, associating PRAME to a clear biochemical activity and pathway 
(Costessi et al, 2011). PRAME establishes direct interactions with other ligase 
subunits through conserved N-terminal motifs: a BC-box (aa. 25-34) mediates 
interactions with the ElonginB-ElonginC heterodimer, and a downstream 
Cul2-box (aa. 48-56) mediates interactions with the Cullin2 scaffold protein. 
Genome-wide chromatin immunoprecipitation experiments further revealed 
that Cul2-PRAME ubiquitin ligases specifically associate with active promot-
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ers regulated by the transcription factor NFY and with proximal enhancers 
(Costessi et al, 2011).
Two independent laboratories have identified an ancient and highly 
conserved multiprotein complex named KEOPS (Downey et al, 2006) or EKC 
(Kisseleva-Romanova et al, 2006), which has orthologues from Archaea to 
Eukarya and has been implicated in telomeres maintenance, transcriptional 
regulation, and t6A modification of tRNAs. Yeast EKC comprises four subunits 
which are also conserved in the human genome (human orthologues are 
indicated in brackets): Pcc1p (LAGE3, also known as ESO3), the ATPase Kae1p 
(OSGEP), the kinase Bud32p (TP53RK, also known as PRPK), and Cgi121p 
(TPRKB). In addition, yeast EKC also includes Gon7p (also known as Pcc2p), 
which appears to be fungi-specific (Kisseleva-Romanova et al, 2006). 
Intriguingly, the OSGEP subunit is also present in bacteria (YgjD) and 
eukaryotic genomes express an OSGEP paralogue (Qri7/OSGEPL1) that localizes 
to mitochondria (Reinders et al, 2006). Comparative genomic studies identified 
OSGEP as one of the very few genes present in all genomes sequenced so far 
(Galperin, 2008), suggesting an extremely conserved function. Very recently, 
several research groups have reported a crucial role for the YgjD/Kae1/OSGEP 
protein family in the biosynthesis of N6-threonylcarbamoyl adenosine (t6A) 
(Daugeron et al, 2011; Yacoubi et al, 2011; Srinivasan et al, 2011): a universal 
modification at position 37 of tRNAs decoding ANN codons, which is required 
for accurate translation of messenger RNAs (Yarian et al, 2002). 
Human LAGE3 belongs to the NY-ESO gene family together with the closely 
related LAGE1 and LAGE2 (Alpen et al, 2002), and all three genes are clustered 
in the same region on chromosome X. While LAGE3 is ubiquitously expressed, 
LAGE1 and LAGE2 are cancer-testis antigens with high expression in healthy testis 
and upregulation in a number of cancer tissues, similarly to PRAME.
The aim of the present study was to mine the protein-protein inter-
actome of the PRAME oncoprotein to a deeper level by protein complex 
purification and mass spectrometry. Our experiments revealed that PRAME 
specifically interacts with the EKC complex in human cells and that it recruits 
Cul2-based E3 ubiquitin ligases to EKC. We further show that EKC subunits 
co-localize with PRAME at the promoter regions of transcriptionally active 
human genes, supporting a common functional role for these complexes on 
chromatin. Overall, our findings provide novel and important insights in the 
molecular pathways in which the oncoprotein PRAME is active.
99
RESULTS
PRAME interacts with the EKC/KEOPS complex
We have recently applied biochemical purification strategies and char-
acterized PRAME as a component of Cullin2 E3 ubiquitin ligases (Costessi et 
al, 2011). Here, we improved the immunoaffinity purification protocols and 
mined the PRAME interactome to a deeper level (see materials and meth-
ods). We isolated epitope-tagged PRAME (StrepII-Myc-3xHA-PRAME, referred 
to as TAG-PRAME) from K562 cells, which express high levels of endogenous 
PRAME, and from HeLaS3 cells, which express endogenous PRAME at very 
low to undetectable levels. As expected, mass spectrometry analysis of HA 
immunoprecipitates detected Cullin2 ligase components with the highest 
emPAI: Cullin2, Elongin B, Elongin C, and Rbx1 (Table 1). Notably, western 
blot analysis showed that Cullin2 and Elongin C were expressed to similar 
levels in nuclear extracts from the two cell lines (not shown).
Furthermore, a number of additional proteins were specifically detected 
in eluates of K562-TAG-PRAME and HeLaS3-TAG-PRAME cells, but not in the 
control parental cell lines. These included OSGEP (O-sialoglycoprotein endo-
peptidase) and LAGE3 (L antigen family member 3), which are the human 
orthologues of the Kae1 and Pcc1 subunits of the recently described EKC 
complex (Table 1). OSGEP and LAGE3 were present with a similar abundance 
in TAG-PRAME eluates from both K562 and HeLaS3 cell lines, consistent with 
similar expression levels. However, in these eluates we did not identify pep-
tides matching TP53RK or TPRKB, which are the predicted human orthologues 
of the EKC subunits Bud32 and Cgi121, respectively. 
Other potential interactors identified in PRAME eluates were BAG2 and 
UBL4A (Table 1). BAG2 (BAG family molecular chaperone regulator 2) is a nu-
cleotide exchange factor for the chaperone protein Hsp70 that contributes to 
the processing of misfolded proteins (Xu et al, 2008). Similarly, UBL4A (Ubiq-
uitin-like protein 4A) is part of a chaperone protein complex that promotes 
correct membrane targeting of tail-anchored proteins (Wang et al, 2011; 
Mariappan et al, 2010). Peptides for both BAG2 and UBL4A were identified in 
all anti-HA eluates from K562-TAG-PRAME cells, but were not detected in the 
anti-MYC eluates. Additional experiments are therefore needed to establish 
whether these proteins are real interactors of PRAME or rather false posi-
tives. For the purpose of this study, we further concentrated on EKC subunits.
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The specificity of the interactions between PRAME and EKC subunits was 
confirmed by transient transfections in HEK293T cells and coimmunoprecipi-
tation experiments of TAG-PRAME with OSGEP and LAGE3 fused to a TTE (TY1-
TY1-ER) epitope tag (Fig. 1A). We also used a baculovirus expression system 
to co-express FLAG-PRAME with different combinations of the four human 
EKC subunits in Sf21 insect cells. Consistent with the transient transfection 
experiments, we observed that PRAME could bind to OSGEP and LAGE3 inde-
pendent of TP53RK and TPRKB. Interestingly, although both OSGEP and LAGE3 
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Figure 1
PRAME interacts with 
OSGEP and LAGE3.
(A) Coimmunoprecipitation 
assays verify the interac-
tion of PRAME with the EKC 
subunits OSGEP and LAGE3. 
Constructs expressing the 
indicated proteins were 
transiently transfected 
in 293T cells. Anti-TAG 
immunoprecipitations were 
performed with rabbit 
HA antibody (Abcam). 
TAG-PRAME was detected 
with monoclonal anti-HA 
(Covance) and TTE-tagged 
proteins with monoclonal 
BB2 (Diagenode) which 
recognizes the TY1 tag. 
The lower panel shows 
a scheme of the tagged 
proteins used (tags and 
coding sequences are not 
on scale).
(B-C) PRAME directly 
interacts with EKC complex 
through OSGEP and LAGE3. 
SF21 cells were co-infected 
with baculoviruses express-
ing the indicated proteins. 
Anti-FLAG immunoprecip-
itations were performed, 
and total cell lysates and 
eluates were analyzed by 
western blotting. Panels 
showing anti-HA immuno-
blots are from the same 
exposure of the same blot, 
as are the panels showing 
anti-cMyc immunoblots. 
Asterisks indicate light 
chains of the antibodies 
used in the immunoprecip-
itation.
102
P
ro
te
in
 ID
P
ro
te
in
 d
es
cr
ip
ti
on
K562 LAGE3
K562 OSGEP
K562 TP53RK
K562 TPRKB
HeLa LAGE3
K562 ctrl 1
K562 ctrl 2
K562 ctrl 3
HeLa ctrl
K562 LAGE3 
emPAI
K562 OSGEP 
emPAI
K562 TP53RK 
emPAI
K562 TPRKB 
emPAI
HeLa LAGE3 
emPAI
IP
I0
00
32
31
4.
2
LA
G
E3
 L
 a
nt
ig
en
 f
am
ily
 m
em
be
r 
3
6
8
8
6
7
0
0
0
0
4.
62
9.
00
9.
00
4.
62
6.
50
IP
I0
00
15
80
9.
1
O
SG
EP
 P
ro
ba
bl
e 
O
-s
ia
lo
gl
yc
op
ro
te
in
 e
n
do
pe
pt
id
as
e
12
17
17
12
21
0
1
0
0
3.
28
6.
85
6.
85
3.
28
11
.7
4
IP
I0
02
90
30
5.
3
TP
53
R
K
 T
P
53
-r
eg
ul
at
in
g 
ki
n
as
e
8
10
15
9
7
0
0
0
0
2.
73
4.
18
10
.7
9
3.
39
2.
16
IP
I0
03
01
43
2.
3
TP
R
K
B
 Is
of
or
m
 1
 o
f 
TP
53
R
K-
bi
n
di
n
g 
pr
ot
ei
n
5
11
15
8
6
0
0
0
0
2.
16
11
.5
9
30
.6
2
5.
31
2.
98
IP
I0
00
26
67
0.
3
TC
EB
2 
Tr
an
sc
ri
pt
io
n
 e
lo
n
ga
ti
on
 f
ac
to
r 
B
 p
ol
yp
ep
ti
de
 2
3
8
1
2
2
1
0
4
3
1.
68
12
.9
0
0.
39
0.
93
0.
93
IP
I0
00
14
31
1.
4
CU
L2
 C
ul
lin
-2
21
0
1
2
0
2
0
8
0
1.
49
0.
00
0.
04
0.
09
0.
00
IP
I0
00
19
28
2.
1
P
R
A
M
E 
M
el
an
om
a 
an
ti
ge
n
 p
re
fe
re
nt
ia
lly
 e
xp
re
ss
ed
 in
 t
um
or
s
6
18
3
0
0
0
0
0
0
0.
74
4.
25
0.
32
0.
00
0.
00
IP
I0
06
46
16
7.
2
C1
4o
rf
14
2 
hy
po
th
et
ic
al
 p
ro
te
in
 L
O
C8
45
20
1
2
1
0
3
0
0
0
0
0.
59
1.
51
0.
59
0.
00
2.
98
IP
I0
00
07
79
7.
3
FA
BP
5;
FA
BP
5L
7 
Fa
tt
y 
ac
id
-b
in
di
ng
 p
ro
te
in
, e
pi
de
rm
al
2
0
0
1
0
0
0
2
0
0.
59
0.
00
0.
00
0.
26
0.
00
IP
I0
00
05
65
8.
3
U
BL
4A
 U
bi
qu
iti
n-
lik
e 
pr
ot
ei
n 
4A
2
8
6
3
5
2
0
2
2
0.
47
3.
64
2.
16
0.
78
1.
61
IP
I0
00
19
91
2.
3
H
SD
17
B4
 P
er
ox
is
om
al
 m
ul
tif
un
ct
io
na
l e
nz
ym
e 
ty
pe
 2
7
0
10
3
0
2
0
0
0
0.
44
0.
00
0.
69
0.
17
0.
00
IP
I0
03
95
86
5.
4
RB
BP
7 
H
is
to
ne
-b
in
di
ng
 p
ro
te
in
 R
BB
P7
3
6
1
2
8
2
2
3
0
0.
44
1.
07
0.
13
0.
27
1.
64
IP
I0
03
04
90
3.
4
SP
RR
1B
 C
or
ni
fin
-B
1
0
0
0
0
0
0
0
0
0.
39
0.
00
0.
00
0.
00
0.
00
IP
I0
07
42
94
3.
1
N
U
P4
3 
N
uc
le
op
or
in
 N
up
43
2
0
0
0
1
0
0
0
0
0.
36
0.
00
0.
00
0.
00
0.
17
IP
I0
03
00
34
1.
5
TC
EB
1 
Tr
an
sc
ri
pt
io
n
 e
lo
n
ga
ti
on
 f
ac
to
r 
B
 p
ol
yp
ep
ti
de
 1
1
6
3
1
0
1
0
2
1
0.
33
4.
62
1.
37
0.
33
0.
00
IP
I0
02
93
43
4.
2
SR
P1
4 
Si
gn
al
 r
ec
og
ni
tio
n 
pa
rt
ic
le
 1
4 
kD
a 
pr
ot
ei
n
1
2
3
0
1
0
0
2
0
0.
33
0.
78
1.
37
0.
00
0.
33
IP
I0
04
46
35
4.
1
- 
CD
N
A
 F
LJ
41
80
5 
fis
, c
lo
ne
 N
O
VA
R2
00
09
62
1
0
0
0
0
0
0
0
0
0.
33
0.
00
0.
00
0.
00
0.
00
IP
I0
00
20
02
5.
3
SH
3P
XD
2B
 C
D
N
A
 F
LJ
20
83
1 
fis
, c
lo
ne
 A
D
KA
03
08
0
1
0
0
0
0
0
0
0
0
0.
23
0.
00
0.
00
0.
00
0.
00
IP
I0
00
27
62
6.
3
CC
T6
A
 T
-c
om
pl
ex
 p
ro
te
in
 1
 s
ub
un
it 
ze
ta
3
24
11
8
8
0
1
0
3
0.
22
3.
85
1.
06
0.
69
0.
69
IP
I0
08
69
11
8.
2
- 
A
nt
i-
(E
D
-B
) 
sc
FV
 (
Fr
ag
m
en
t)
1
0
1
1
0
1
1
1
0
0.
21
0.
00
0.
21
0.
21
0.
00
IP
I0
03
86
76
5.
2
PD
E4
D
 Is
of
or
m
 7
 o
f 
cA
M
P-
sp
ec
ifi
c 
3’
,5
’-
cy
cl
ic
 p
ho
sp
ho
di
es
te
ra
se
 4
D
1
0
0
1
0
0
0
1
0
0.
21
0.
00
0.
00
0.
21
0.
00
IP
I0
00
07
42
3.
1
A
N
P3
2B
 Is
of
or
m
 1
 o
f 
A
ci
di
c 
le
uc
in
e-
ric
h 
nu
cl
ea
r 
ph
os
ph
op
ro
te
in
 3
2 
fa
m
ily
 m
em
be
r 
B
1
0
6
2
0
0
0
4
0
0.
19
0.
00
1.
89
0.
43
0.
00
Ta
bl
e 
2
H
u
m
an
 E
K
C-
in
te
ra
ct
in
g 
p
ro
te
in
s 
id
e
n
ti
fi
e
d 
b
y 
M
as
s 
Sp
e
ct
ro
m
et
ry
 o
f 
p
u
ri
fi
e
d 
co
m
p
le
xe
s 
fr
o
m
 n
u
cl
ea
r 
e
xt
ra
ct
s 
of
 K
5
62
 a
n
d 
H
e
La
S3
 c
el
ls
. P
ro
te
in
s 
in
te
ra
ct
in
g 
w
ith
 e
ac
h 
of
 h
um
an
 E
KC
 s
ub
un
it
s 
w
er
e 
id
en
tifi
ed
 b
y 
an
ti-
H
A
 im
m
un
op
re
ci
pi
ta
tio
ns
 a
nd
 m
as
s 
sp
ec
tr
om
et
ry
 o
n 
th
e 
ce
ll 
lin
es
 in
di
ca
te
d.
 C
om
po
ne
nt
s 
of
 C
ul
lin
2 
lig
as
es
 a
nd
 E
KC
 c
om
pl
ex
 a
re
 in
di
ca
te
d 
in
 b
ol
d.
 
103
could bind PRAME independent of the other (Fig. 1B, lanes 3 and 6), LAGE3 
appears to enhance the PRAME-OSGEP interaction, since substantially more OS-
GEP bound to PRAME when LAGE3 was also expressed (Fig 1B, compare lanes 
1, 4, and 5 to lane 6, and Fig. 1C, compare lane 4 to lanes 5 and 6). Finally, we 
observed small amounts of TP53RK and TPRKB copurifying with FLAG-PRAME 
dependent on both OSGEP and LAGE3 (Fig. 1B, lanes 1, 3, and 6).
Taken together, our results identified stable interactions between PRAME 
and human orthologues of the EKC/KEOPS complex.
EKC purifications from K562 cells
We next studied the expression patterns of EKC, Cullin2 ligase subunits and 
PRAME in normal and cancer cells by querying the GeneSapiens gene expression 
database (Kilpinen et al, 2008). This database contains mRNA expression data 
of most human genes across almost 10000 array experiments from 175 healthy 
and pathological tissues. Consistent with the literature, we found that PRAME is 
expressed only in very few normal adult tissues while it is upregulated in several 
cancers (Suppl. Fig. S1). On the contrary, LAGE3, OSGEP, TP53RK, TPRKB, and CUL2 
seem to be expressed in most if not all tissues (Suppl. Figures S1-S4).
To explore further the protein-protein interactions between PRAME and 
EKC, we generated K562 cell lines stably expressing epitope-tagged versions 
of each of the four human predicted human EKC subunits and performed pro-
tein complex purifications. As shown in Table 2, each EKC subunit co-purified 
with the other three subunits of the complex, indicating that a complete EKC 
complex is present in human cells. 
Furthermore, TAG-OSGEP and TAG-LAGE3 (but not TAG-TP53RK or TAG-
TPRKB) copurified with significant amounts of endogenous PRAME, consis-
tent with TAG-PRAME purifications. Remarkably, TAG-OSGEP and TAG-LAGE3 
associated also with Cullin2 ligase components (Table 2). The few peptides 
for Cul2-PRAME components identified in TAG-TP53RK and TAG-TPRKB eluates 
were not supported by western blot of the same samples (not shown).
Interestingly, peptides matching the putative protein C14orf142 were 
specifically identified in eluates from OSGEP, LAGE3 and TP53RK (Table 2). 
Similarly to LAGE3 and TPRKB, C14orf142 is predicted to be a small protein 
without clear structural domains. It is tempting to speculate that this protein 
might constitute a novel EKC interactor in human cells.
Although we did not identify peptides matching Cul2 by mass spectrom-
etry of TAG-OSGEP eluates, we did detect small amounts of Cul2 by western 
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blotting of the same samples (Fig. 2, lane 6). Intriguingly, the level of Cul2 
detected in TAG-OSGEP eluates was substantially lower than in TAG-PRAME 
eluates (Fig. 2, lanes 4 and 6), while Elongins B and C were present in similar 
amounts in all purifications. These findings might indicate that OSGEP estab-
lishes less stable interactions with Cullin2 as compared to PRAME. Consistent 
with the mass spectrometry results, TAG-PRAME did not copurify with TPRKB 
(Fig. 2, lane 4), while a clear band was detected in TAG-OSGEP eluates.
Our proteomic experiments show for the first time that a complete EKC 
complex is present in human cells, and that the OSGEP and LAGE3 subunits are 
present in a complex together with PRAME and Cullin2 ligase components. 
Topology of the human EKC complex
In order to study the topology of the interactions within the human EKC 
complex, we expressed pairs of EKC subunits in the baculovirus system and 
performed immunoprecipitations (Fig. 3). As shown in figure 3, we observed 
reciprocal coimmunoprecipitation of HA-LAGE3 and c-Myc-OSGEP and of HA-
TPRKB and c-Myc TP53RK, respectively. In addition, c-Myc TP53RK copurified 
with HA-OSGEP upon anti-c-Myc immunopurification, although this interaction 
was not detected in the reciprocoal experiment, raising the possibility that 
the c-Myc epitope was occluded and/or that binding of the antibody to the 
epitope disrupts the interaction. Taken together, these experiments estab-
lished that human EKC has the linear configuration LAGE3-OSGEP-TP53RK-
TPRKB, consistent with the three-dimensional structures of archael EKC 
orthologues that were recently reported (Mao et al, 2008). 
Input TAG IP
TAG-
PRAME
TAG-
OSGEP
WTTAG-
PRAME
TAG-
OSGEP
WT
TAG-PRAME
TAG-OSGEP
EloB
EloC
1 2 3 4 5 6
TPRKB
Cul2/NEDD8-Cul2
PRAME
TAG-PRAME
* *
Figure 2
Figure 2
OSGEP interacts with PRAME and Cul2 
ubiquitin complex components.
OSGEP interacts with PRAME and Cul2-Elo-
BC ligases. Immunoblot analysis of TAG-
PRAME and TAG-OSGEP protein complexes 
purified from K562 cells to verify the mass 
spectrometry data. Mock purification was 
performed on wild type cells. 0.8% of input 
and 33% of IP were separated on NuPage 
4-12% gels. Tagged proteins were detected 
with mouse HA antibody (Covance, top 
panel); endogenous PRAME and TAG-
PRAME were detected in the second panel 
with affinity-purified PRAME antibody after 
staining for Cul2; the other proteins were 
detected as indicated. Asterisks indicate 
protein A that dissociated from the beads 
after elution.
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Interestingly, Mao et al. reported that archael Pcc1, the orthologue of 
human LAGE3, forms highly interdigitated homodimers and hypothesized 
that dimerization of Pcc1 might support dimerization of the full EKC complex. 
Moreover, the crystal structures indicated that one moiety of Pcc1 could bind 
only one moiety of Kae1. We tested the dimerization properties of human 
EKC using combinations of different epitope tags in transient transfection 
experiments. As shown in figure 4A, FLAG-OSGEP coimmunoprecipitated 
TTE-OSGEP when LAGE3 was cotransfected (lane 4), establishing that multiple 
OSGEP moieties are present in the same biochemical complex. Important-
ly, the concomitant expression of PRAME did not affect these dimerization 
properties (Fig. 4A, compare lanes 4 and 5). Taking into consideration the 
structural information available for archaeal EKC, our data suggest the forma-
tion of a tetrameric LAGE3-OSGEP assembly (Fig. 4A).
In the same experiments, we noticed that OSGEP levels were significant-
ly lower in the absence of LAGE3 (Fig. 4A, compare lanes 2 and 4), suggest-
ing that the stability of OSGEP could be critically dependent on interactions 
with other proteins. To address this hypothesis, we transfected FLAG-OSGEP 
together with each of the other EKC subunits or PRAME. Fig. 4B shows that 
LAGE3, TP53RK and PRAME could all enhance the stability of OSGEP. TPRKB 
did not alter OSGEP levels, consistent with the absence of a direct interaction 
between these two proteins. Interestingly, LAGE3 exerted the highest positive 
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Figure 3
Organization of human 
EKC complex. 
SF21 cells were co-infected 
with baculoviruses express-
ing the indicated proteins. 
Anti-FLAG immunoprecip-
itations were performed, 
and total cell lysates and 
eluates were analyzed by 
western blotting. Interac-
tions detected are sum-
marized in the diagram on 
the right. Panels showing 
anti-HA immunoblots are 
from the same exposure of 
the same blot, as are the 
panels showing anti-cMyc 
immunoblots. Asterisk 
indicates light chains of 
the antibodies used in the 
immunoprecipitation.
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Figure 4
OSGEP protein levels are 
modulated by protein-protein 
interactions.
(A) Multiple OSGEP moieties are 
present in the same complex. 
Constructs expressing the indi-
cated proteins were transiently 
transfected in 293T cells. Total 
cell lysates and FLAG eluates 
were analyzed by western blot-
ting. A plasmid expressing GFP 
was cotransfected to control for 
the transfection efficiency.
(B) OSGEP levels are affected by 
protein-protein interactions. 293T 
cells were transfected with con-
structs expressing FLAG-OSGEP 
and the proteins indicated. The 
bar graph shows FLAG-OSGEP 
levels quantified by immunoblot 
with the Odyssey system (values 
are the average of two
independent experiments). A 
plasmid expressing GFP was 
cotransfected to control for the 
transfection efficiency.
(C) and (D) LAGE3-OSGEP
interface mutants decrease 
OSGEP protein levels. Transient 
transfections in 293T cells with 
the mutant constructs indicated 
and immunoblot by Odyssey of 
total cell lysates. Graphs report 
intensities of FLAG-OSGEP quanti-
fied with Odyssey (A.U., arbitrary 
units).
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effect, which correlates with the possibility to form tetrameric LAGE3-OSGEP 
complexes, while TP53RK can bind only one moiety of OSGEP. The finding that 
PRAME had a relatively modest effect on OSGEP levels might reflect a less sta-
ble interaction between OSGEP and PRAME, than between OSGEP and TP53RK.
We investigated further the effect of LAGE3 on the protein levels of 
OSGEP in transient transfection experiments with mutant constructs. Based 
on the crystallographic structures of archael EKC (Mao et al, 2008), we intro-
duced point mutations in aminoacid residues predicted to be involved in the 
protein-protein interactions between OSGEP and LAGE3: R94A in OSGEP, and 
L129R or T133R in LAGE3. Additionally, we generated OSGEP mutant P35A/
P36A (referred to as PPAA) and LAGE3 mutants K95A and K109A, which are 
not predicted to contribute to the OSGEP-LAGE3 interaction. As shown in 
figure 4C, the OSGEP mutant R94A showed lower steady-state levels, which 
could not be enhanced by co-expression of wild-type LAGE3, while OSGEP 
PPAA behaved like the wild type. Similarly, levels of wild-type OSGEP were 
not enhanced upon co-expression of either T133R or L129R LAGE3 mutants, 
while the LAGE3 lysine mutants behaved the same as wild type LAGE3.
Taken together, our data suggests (i) that the human EKC complex is 
organized in the same way as its archaeal counterpart, (ii) that dimerization 
of LAGE3 can mediate formation of higher order structures containing at least 
two molecules of OSGEP, (iii) that formation of these higher order structures 
is independent of PRAME, and (iv) that the protein levels of OSGEP can be 
significantly modulated by protein-protein interactions.
PRAME bridges Cullin2 ligases to the EKC complex
We next studied the role of the Cullin2 complex in the association of 
PRAME with EKC. Transient transfection experiments showed that the interac-
tion of PRAME with OSGEP and LAGE3 does not require an intact BC-box, since 
a BC-box defective PRAME (PRAME M2) coimmunoprecipitated OSGEP and 
LAGE3 as efficiently as wild type PRAME (Fig. 5A). 
Next, we purified TAG-LAGE3 protein complexes from HeLaS3 cells, which 
express very low to undetectable levels of endogenous PRAME. As expected, 
all EKC subunits copurified with TAG-LAGE3, while no peptides were identified 
for PRAME (Table 2). Importantly, components of Cullin2 ligases did not co-
purify with LAGE3 in these cells. The abundance of EKC subunits was similar 
in the eluates from K562-TAG-LAGE3 and HeLaS3-TAG-LAGE3 cells, consistent 
with similar protein levels in the two cell lines.
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These results, together with the finding that TAG-OSGEP and TAG-LAGE3 
associate with endogenous PRAME and Cullin2 ligase components in K562 
cells, suggested that PRAME could be involved in recruiting a Cullin2 ligase to 
the EKC complex.
To test this hypothesis, we knocked down endogenous PRAME with 
stable transfection of retroviral constructs in K562-TAG-OSGEP and K562-
TAG-LAGE3 cell lines and performed immunoprecipitations. Figure 5B clearly 
shows that downregulation of PRAME significantly reduced the interaction 
between each EKC subunit and Cul2, EloB and EloC, establishing that PRAME 
is required for these interactions. As expected, the interaction of TAG-OSGEP 
and TAG-LAGE3 with TPRKB was not affected by PRAME knockdown. Notably, 
we found that the level of Cul2 detected in TAG-OSGEP eluates was substan-
tially lower than in TAG-LAGE3 eluates (Fig. 5B, lanes 1 and 4), despite similar 
amounts of EloB and EloC. These results are similar to the previous compari-
son between TAG-OSGEP and TAG-PRAME eluates (Fig. 2, lanes 4 and 6).
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Figure 5
PRAME recruits Cul2-Elo-
BC ligases to EKC.
(A) PRAME does not require 
an intact BC-box to interact 
with EKC components. 
Coimmunoprecipitation 
assays as in Fig.1A with wild 
type and BC-box mutant M2 
PRAME.
(B) PRAME bridges Cullin2 
ligases to EKC complex. 
Immunoblot analysis as in 
Fig. 2 of TAG-OSGEP or TAG-
LAGE3 immunoprecipitates 
with or without knock down 
of endogenous PRAME. 
Asterisk indicates heavy 
chains of the antibodies 
used in the immunoprecip-
itation.
(C) Models of the protein 
complexes architecture.
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Taken together, our data reveal that PRAME can bridge Cullin2 ligases to 
the EKC complex (Fig. 5C).
Cul2-PRAME ligases and EKC subunits co-localize to active 
promoters
The yeast orthologues of OSGEP (Kae1p) and LAGE3 (Pcc1p) have been 
reported to associate with the promoters and transcribed regions of sever-
al genes in a transcription-dependent manner (Kisseleva-Romanova et al, 
2006). Genome-wide chromatin immunoprecipitation experiments revealed 
that PRAME and Cullin2 complex components are specifically enriched at 
transcriptionally active promoters that are also bound by the transcription 
factor NFY, and at nearby enhancers (Costessi et al, 2011).
In the absence of validated ChIP-grade antibodies against EKC subunits, 
we generated K562 cell lines stably expressing the proteins of interest fused 
to the TTE epitope tag (TY1-TY1-ER), which can be efficiently and specifically 
used in ChIP-qPCR experiments (Costessi et al, 2011). To determine whether 
human OSGEP and LAGE3 are present on chromatin, we performed ChIP assays 
with the BB2 antibody (which recognizes the TY1 tag) and tested a panel of 
PRAME-bound promoters. The results in figure 6 clearly show that all PRAME-
bound promoters tested are efficiently recovered in both K562-TTE-OSGEP and 
K562-TTE-LAGE3 cells, but not in parental K562 cells or control K562-TTE cells. 
Our genomic experiments extend the biochemical interactions to the 
chromatin environment, establishing that PRAME and EKC subunits associate 
with the same promoter regions.
OSGEP and LAGE3 are present 
at PRAME-bound promoters 
on chromatin. 
ChIP-qPCR experiments using 
BB2 antibody were performed on 
K562 cells lines stably expressing 
TTE-OSGEP or TTE-LAGE3. As 
control for specificity, ChIPs were 
performed on the parental cells 
(wt) and on cells transduced with 
the vector expressing the tag 
only (K562-TTE) using a panel 
of primer sets for PRAME biding 
sites. Values are expressed as 
mean recoveries ± standard de-
viation from three independent 
experiments.
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DISCUSSION
We recently reported the first purifications of PRAME-containing protein 
complexes by epitope-tagged immunoprecipitations and mass spectrome-
try, which revealed that PRAME is a BC-box substrate receptor component of 
Cullin2-based E3 ubiquitin ligases (Costessi et al, 2011). In the present study, 
we identified novel interactions of Cul2-PRAME ligases with the human EKC/
KEOPS complex, we discovered that PRAME recruits ligase components to 
EKC, and we showed that these proteins associate with the same promoter 
regions, strongly suggesting a functional link between these complexes in 
the same pathway.
 EKC is an ancient and extremely conserved complex with orthologues 
in Archaea and Eukarya. It has been implicated in telomere maintenance, 
transcriptional regulation, and t6A modification of tRNAs in yeast (Kissele-
va-Romanova et al, 2006; Downey et al, 2006; Daugeron et al, 2011; Yacoubi 
et al, 2011; Srinivasan et al, 2011). Our interaction data support a linear 
architecture LAGE3-OSGEP-TP53RK-TPRKB for the human EKC complex and di-
merization around the LAGE3 subunit, with two OSGEP moieties per complex. 
Our results are fully consistent with recently reported crystal structures of 
archaeal EKC proteins (Mao et al, 2008). 
Consistent with the notion that all subunits contribute to the activity of 
the complex, yeast EKC was reported to constitute a stable entity. Downey 
et al. reported that deletion of either Bud32p, Cgi121p, or Gon7p resulted in 
shorter telomeres. An independent study found that Pcc1p was required for 
efficient transcription of several yeast genes induced by pheromones or ga-
lactose, and that deletion of Pcc1 inhibited the recruitment of the SAGA and 
Mediator co-activators (Kisseleva-Romanova et al, 2006). Dimerization of the 
Pcc1p and Kae1p subunits was found to be necessary for cell viability (Mao et 
al, 2008), and an intact interaction surface between Kae1p and Bud32p was 
required for both the transcriptional and telomere maintenance functions 
(Hecker et al, 2008). Most recently, the yeast EKC complex was shown to be 
essential for a universal chemical modification of tRNAs, called threonyl car-
bamoyl adenosine (t6A) (Srinivasan et al, 2011; Yacoubi et al, 2011; Daugeron 
et al, 2011). This modification occurs at position 37 of tRNAs decoding ANN 
codons, including the first ATG of all protein-coding mRNAs, and is required 
for efficient translation (Yarian et al, 2002). The t6A modification activity was 
dependent on Pcc1p, the ATPase activity of Kae1p, and the kinase activity of 
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Bud32p, but not on Cgi121p (Srinivasan et al, 2011).
In our experiments, all human EKC orthologues co-purified together and 
with similar abundance both in K562 and HeLaS3 cells, demonstrating for the 
first time that a complete and stable EKC complex is present in human cells. 
However, we consistently found that PRAME complexes contained primari-
ly OSGEP and LAGE3, and very low or undetectable levels of the other two 
subunits TP53RK and TPRKB. This might reflect a PRAME-mediated disruption 
of an otherwise stable EKC complex, or a preferential binding of PRAME to an 
already existing (and possibly dynamic) EKC submodule that was not previ-
ously detected in yeast. It is tempting to speculate that PRAME could medi-
ate ubiquitination of EKC components via recruitment of the Cul2 E3 ligase 
complex. In an attempt to test this hypothesis, we performed ubiquitination 
assays upon transient transfections in HEK293 cells in presence or absence of 
the proteasome inhibitor MG132, and in vitro assays with purified proteins. 
As expected for BC-box proteins, we detected polyubiquitin chains associated 
with PRAME itself. However, the high background signals in these assays did 
not allow us to detect a putative ubiquitination of EKC subunits. Hence, our 
assays could not rule out that EKC might be ubiquitination targets of Cul2-
PRAME, and more efforts are needed to test this hypothesis experimentally.
Interestingly, dynamic regulation of EKC components has been reported: 
the kinase activity of Bud32p was repressed by association with Kae1p (Heck-
er et al, 2008), but promoted by binding to Cgi121p (Mao et al, 2008). More-
over, we found that the protein levels of OSGEP can be significantly modulat-
ed by association with other proteins (Fig. 4), with LAGE3 exerting the most 
pronounced positive effect, followed by TP53RK and PRAME. Interestingly, 
the effect of LAGE3 correlates with the formation of tetrameric complexes in 
which an LAGE3 dimer binds two OSGEP moieties (Fig. 4A), which are likely 
not in direct contact with each other (Mao et al, 2008).
The results of our transient transfection experiments and those obtained 
using the baculovirus system suggested (i) that PRAME is able to interact 
independently with LAGE3 and OSGEP and (ii) that LAGE3 enhances the asso-
ciation of OSGEP with PRAME. Considering the dimerization properties of the 
LAGE3-OSGEP submodule, we therefore considered the possibility that mul-
tiple PRAME moieties might be present in the same protein complex. In this 
case, both epitope-tagged PRAME and endogenous PRAME should be present 
in the same protein complex in K562-TAG-PRAME cells, since the expression 
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level of the two proteins were similar. Contrary to this hypothesis, however, 
TAG-PRAME did not co-immunoprecipitate endogenous PRAME in our experi-
ments (see Fig. 2 lane 4). Although we cannot formally exclude the possibil-
ity that TAG-PRAME might compete with the endogenous protein, our data 
are most consistent with the idea that there is only one PRAME molecule 
per complex. Notably, our data suggest that the interaction between PRAME 
and LAGE3-OSGEP is very stable, since it was efficiently detected in all assays 
and despite the long incubations times in our protein-complex purification 
protocols. However, we cannot exclude that high levels of PRAME might be 
required for the interactions to take place in cells. Taking into account the 
published crystal structures of archaeal EKC, we propose the models depicted 
in Figure 5C for the architecture of the human EKC complex and the relation-
ship between EKC and Cul2-PRAME ligases. Further experiments are needed 
to confirm the stoichiometry of PRAME-EKC complexes, and to characterize 
the interaction surfaces involved.
Besides the functional experiments in yeast, no information is available 
yet about EKC functions in other organisms. At present, only studies focusing 
on single subunits of the human complex have been reported. LAGE3 ap-
pears to be ubiquitously expressed, while the two closely related LAGE1 and 
LAGE2 are cancer-testis antigens with high expression confined to healthy 
testis and cancer tissues (Alpen et al, 2002). Interestingly, expression of the 
N-terminal domain of LAGE3 fused to the C-terminus of Pcc1p could partially 
rescue the growth defects of a Pcc1 N-terminal mutant yeast strain, while 
full length LAGE3 could not substitute for Pcc1 (Kisseleva-Romanova et al, 
2006). The OSGEP gene was found expressed in all somatic tissues tested and 
it lies in a head-to-head orientation with the tightly regulated APEX gene, 
which encodes a multifunctional DNA repair enzyme (Ikeda et al, 2002). 
Analyses of their bidirectional promoter identified a CCAAT box crucial for 
OSGEP transcription. Futhermore, OSGEP could partially rescue the growth 
defects of the yeast kae1D mutant (Kisseleva-Romanova et al, 2006), under-
lining degrees of functional conservation. Human TP53RK was first cloned by 
cDNA subtraction as an interleukin-2 upregulated gene in cytotoxic T-cells, 
transcripts were detected in a number of normal tissues and cancer cell lines, 
and it was shown to phosphorylate the human oncoprotein p53 at Serine 
15 (Abe et al, 2001). Recombinant TP53RK expressed in bacteria was found 
catalytically inactive, but incubation with COS-7 cell lysates was sufficient to 
activate the enzymatic activity, suggesting the need for activators and po-
113
tentially protein interactors. The kinase Akt/PKB was found to play a role in 
the activation of TP53RK through phosphorylation of the Ser250 residue (Fac-
chin et al, 2007). Underscoring a high level of functional homology, TP53RK 
could partially rescue the growth phenotype of Bud32 deletion in yeast, and 
Bud32 could interact with and phosphorylate human p53 in vitro (Facchin 
et al, 2003), although yeast does not possess a bona fide p53 homologue. 
Human TPRKB was first isolated by a two-hybrid screen using TP53RK as a 
bait, and was suggested to inhibit the binding of TP53RK to p53 (Miyoshi et 
al, 2003). Expression of TP53RK was detected in the  high-PRAME expressing 
cell line K562 as well as in the low-PRAME expressing cell line KG1 (Miyoshi 
et al, 2003). Gene expression data obtained from the GeneSapiens database 
further suggests that EKC subunits are expressed in most if not all human 
tissues (Suppl. Figures S2-S4).
Considering the extreme conservation of EKC components during evo-
lution, it can be expected that at least some of the functions and pathways 
already identified for this complex in yeast could be valid for human cells as 
well. However, it cannot be excluded that human EKC acquired additional, yet 
to be identified functions during evolution. The absence of efficient knock-
down or knock-out models have so far hindered advanced functional analysis 
of EKC in higher eukaryotes. Future studies will have to address these issues, 
and in particular to understand the connections between apparently different 
functions ascribed to this complex, like phosphorylation of the p53 onco-
gene, chemical modification of tRNAs, and physical association with promot-
er regions. 
Kae1p and Pcc1p have been found to associate with active chromatin 
and to regulate expression of some of the yeast promoters to which they are 
recruited (Kisseleva-Romanova et al, 2006). A pcc1-4 mutation prevented 
activation of GAL1 by impairing recruitment of the SAGA histone acetyltrans-
ferase and mediator without affecting recruitment of the activator Gal4p. In 
contrast, while Pcc1p was recruited to the constitutively active PMA1 and the 
heat-shock inducible HSP104 genes in a transcription-dependent manner, 
transcription of these genes was not affected in the pcc1-4 mutant.
Our ChIP assays revealed that LAGE3 and OSGEP are also present on 
chromatin and, in particular, that they colocalize with PRAME at many of 
its target sites, consistent with our protein-protein interaction data. Since 
neither PRAME nor EKC proteins possess known DNA-binding domains, it is 
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not clear whether they can bind DNA directly. Genome-wide ChIP-seq exper-
iments have recently revealed that PRAME associates with transcriptionally 
active NFY-regulated promoters and nearby enhancers (Costessi et al, 2011). 
Therefore, the transcription factor NFY might play a direct or indirect role in 
the targeting of a Cul2-PRAME-EKC complex to chromatin. It is also not clear 
whether there is a hierarchy in the association of PRAME and EKC proteins 
with chromatin. In order to address this point, we established stable cell lines 
with downregulation of endogenous PRAME using the published retroviral 
pRetroSuper system in either K562 wild type or K562-TTE-LAGE3 cells and 
we performed ChIP experiments. Unfortunately, despite a 70% downregu-
lation of PRAME mRNA levels, our preliminary results did not support a solid 
conclusion on the hierarchy of binding to chromatin for PRAME and EKC. 
More experiments, and likely in a different cell and knockdown system, are 
required to address this point.
Importantly, EKC proteins have an ancient evolutionary origin and seem 
to be ubiquitously expressed in adult tissues, while PRAME appeared more 
recently in evolution, and its expression seems to be tightly confined to 
particular developmental stages and tissues and to be particularly dereg-
ulated in oncogenesis. These characteristics are consistent with a model 
in which EKC can associate with chromatin independently of PRAME. Only 
when PRAME is expressed would a Cul2-PRAME ubiquitin ligase be recruit-
ed to chromatin by virtue of specific protein-protein interactions between 
LAGE3-OSGEP and PRAME. 
In an attempt to study the putative function of EKC subunits on target 
gene transcription, we established K562 cells with stable downregulation 
of OSGEP or LAGE3 using pRetroSuper vectors and performed genome-wide 
mRNA-seq analyses. Despite a 50-80% knockdown efficiency for OSGEP and 
LAGE3, we did not detect genes with significant expression changes when 
compared to a GFP knockdown control. Our inconclusive data could of course 
be the result of inefficient downregulation of the target genes. Although the 
K562 cell line was successfully used to dissect the protein-protein interac-
tion network, we cannot exclude that this cell line might not be suitable for 
the study of the finer putative chromatin functions and signaling of EKC and 
PRAME.
The development of ChIP-grade antibodies against EKC components will 
be a crucial step to address important questions as to whether PRAME target 
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sites are a subset of EKC sites (or viceversa), and to address the functional 
relationships between EKC, Cul2-PRAME ligases and NFY on transcriptional 
regulation of target genes, and potentially other pathways like the recently 
described modification of tRNAs.
Taken together, our data reveal a novel link between the human on-
coprotein PRAME and the ancient EKC complex. Our data clearly show that 
PRAME can recruit Cullin2 ubiquitin ligases to EKC, and that these complexes 
associate with the same genomic regions, supporting a functional link in the 
same pathways. Our results add a new twist to both PRAME and EKC biology 
and provide an important contribution to understanding the molecular mech-
anisms in which these proteins are active, both in healthy and cancer cells.
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MATERIALS AND METHODS
Cell culture and stable cell lines 
HEK293T cells were cultured in DMEM 
and K562 and HeLaS3 in RPMI medium 
(Gibco, Invitrogen) at 37°C in 5% CO2; cell 
lines were obtained from ATCC. Both media 
were supplemented with 5% Glutamax, 
10% fetal bovine serum, 100 U/ml of pen-
icillin, 100 µg/ml of streptomycin (Gibco, 
Invitrogen). K562 and HeLaS3 stable cell 
lines were generated with retroviral con-
structs as described (Costessi et al, 2011). 
Transient transfections were performed 
with Lipofectamine2000 (Invitrogen).
Antibodies and western blot
Mouse monoclonal HA-12CA5 and 
Myc-9E11 were produced in-house from 
hybridoma cultures, PRAME antibodies 
were previously described (Costessi et al, 
2011). Commercial antibodies used were: 
mouse monoclonal FLAG-M2 (Sigma), c-Myc 
monoclonal (Roche Applied Science), rabbit 
HA (Bethyl Laboratories), mouse mono-
clonal HA.11 (Covance MMS-101P), rabbit 
Cul2 (Zymed Laboratories 51-1890), mouse 
ElonginC (BD Transduction Laboratories 
610760), goat ElonginB (Santa Cruz P-16, 
sc-23407), mouse TPRKB (Abcam ab68245), 
mouse BB2 against TY1 tag (Diagenode), 
GFP (Santa Cruz). Proteins were separat-
ed by conventional SDS-PAGE or NuPAGE 
4-12% Bis-Tris gels (Invitrogen) run with 
MES buffer. Western blots were visualized 
by ECL (GE Healthcare) or Odyssey (LiCor) 
for quantification.
Plasmids and cloning 
A modified version of the retroviral 
vector LZRS(Zeo) with an improved MCS 
was made by ligation of a synthetic oligo to 
generate LZRSn(Zeo). The sequence coding 
for the StrepII-TEV-MYC-3xHA tag was 
excised with BamHI and NotI from pcDNA5-
TAG-PRAME and subcloned in LZRSn(Zeo) to 
generate LZRSn-TAG, where the EcoRI site is 
in the same frame as in the pTTE retroviral 
vector (Costessi et al, 2011).
The TTE cassette was subcloned from 
pTTE (Costessi et al, 2011) to pcDNA3.1(+) 
using BamHI and XhoI sites to generate 
pcDNA-TTE for transient transfections. 
Full-length human OSGEP was am-
plified by PCR from cDNA prepared from 
K562 cells to generate a NotI-EcoRI-OS-
GEP-SalI fragment, which was cloned into 
pFLAG-CMV2 (pFLAG-OSGEP). OSGEP was 
subsequently subcloned as an EcoRI-SalI 
fragment into the EcoRI and XhoI sites of 
pTTE and pcDNA-TTE, to generate pTTE-OS-
GEP and pcDNA-TTE-OSGEP, respectively. 
OSGEP was cloned as a NotI-SalI fragment 
downstream the TAG in LZRSn(Zeo), gener-
ating LZRSn-TAG-OSGEP. 
LAGE3 CDS was obtained from Invitro-
gen, PCR amplified to introduce EcoRI and 
XhoI sites, and subcloned in the same sites 
of pTTE, pcDNA-TTE, and LZRSn-TAG-LAGE3. 
Full-length TP53RK/PRPK and TPRKB 
were amplified by PCR from cDNA of K562 
cells and subcloned as EcoRI and XhoI frag-
ments to generate all constructs used.
Mutagenesis to generate OSGEP and 
LAGE3 mutants was performed using the 
QuikChange II XL site-directed mutagenesis 
kit (Stratagene) according to the manufac-
turer’s instructions. 
All constructs were checked by se-
quencing.
Purification of protein complexes and 
mass spectrometry analysis
Protein complex purifications and 
mass spectrometry were performed from 
nuclear extracts (unless otherwise indi-
cated) essentially as described (Costessi 
et al, 2011). For HeLaS3 cells the protein 
extraction protocol was performed with a 
tighter douncer (pestle B). The quality of 
cytoplasmic and nuclear extractions were 
tested by immunoblotting of equiva-
lent volume fractions for alpha tubulin 
(cytoplasmic marker) and HDAC2 (nuclear 
marker). 
For TAG-PRAME purifications with MYC 
antibody, about 10 ml of protein extracts 
(~100 mg) were incubated with 50µl (MYC1 
experiment) or 600µl (MYC2 experiment) 
of crosslinked MYC beads and peptide elu-
tion was performed. For protein complex 
purifications with HA antibody, about 5-6 
ml of protein extracts were incubated with 
600µl HA-12CA5 crosslinked beads and 
acidic glycine (pH 2.9) was used for elution.
The data analysis steps of pep-
tide-to-protein remapping and emPAI cal-
culation were automated with a PERL script 
to generate output tables of unique protein 
IDs with peptide frequencies and emPAI 
values for each samples (see Supporting 
Information Protocol S1 and Analysis Script 
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S1). The protein list was manually filtered 
to discard proteins identified in the control 
samples (false positives).
Expression of recombinant proteins in 
Sf21 insect cells 
cDNAs encoding wild type or mutant 
PRAME, OSGEP, LAGE3, TP53RK and TPRKB 
were subcloned into pBAcPAK 8 and recom-
binant baculoviruses were generated. SF21 
cells were cultured at 27°C in SF-900 me-
dium supplemented with 10% fetal bovine 
serum. SF21 cells were co-infected with 
the recombinant baculoviruses indicated in 
the figures. 50 hours after infection, cells 
were collected, lysed, and processed as 
described (Mahrour et al, 2008).
ChIP and qPCR
Chromatin harvests, ChIPs and qPCR 
analyses were performed as previously 
described (Costessi et al, 2011). The BB2 
antibody recognizing the TY1 epitope 
(Diagenode) was used to ChIP TTE-tagged 
proteins from K562 stable cell lines.
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Supplementary figure 1
Detailed expression 
profiles of MAG, TBP, 
CUL2, and PRAME 
from the GeneSapiens 
database.
Normalized relative 
gene expression levels 
in healthy (green) and 
cancer (red) tissues are 
plotted as boxplots. 
MAG and TBP are shown 
as references: MAG is a 
known neuronal marker 
gene and shows an 
expression profile that 
is highly specific for the 
central nervous system. 
On the contrary, TBP is a 
ubiquitously expressed 
gene. Similary to 
TBP, the expression 
profile of CUL2 indicates 
ubiquitous expression in 
both healthy and cancer 
tissues. On the contrary, 
PRAME is expressed 
mainly in the healthy 
testis, and is upregu-
lated in a number of 
cancers.
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Supplementary figure 1
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Detailed expres-
sion profiles of 
EKC subunits from 
the GeneSapiens 
database.
Normalized relative 
gene expression 
levels in healthy 
(green) and cancer 
(red) tissues are plot-
ted as boxplots. The 
expression profiles of 
LAGE3, OSGEP, TPRKB, 
and TP53RK indicate 
expression in all or 
most healthy and 
cancer tissues.
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Renal cancer, n=209 , r= 0.4247, p=1.5e 10
Prostate adenocarcinoma, n=349 , r= 0.2414, p=5.1e 06
Colorectal carcinoma, n=400 , r= 0.2205, p=8.5e 06
Lung, carcinoid tumor, n=27 , r= 0.7131, p=3e 05
Breast carcinoma, NOS, n=553 , r= 0.1499, p=0.00040
Neuroblastoma, n=123 , r= 0.3094, p=5e 04
Lung adenocarcinoma, n=311 , r= 0.1689, p=0.0028
Lung, squamous cell carcinoma, n=83 , r= 0.3186, p=0.0033
Ovarian tumor, others, n=10 , r= 0.7910, p=0.0064
Bladder cancer, n=174 , r= 0.1839, p=0.015
B ALL, n=793 , r= 0.0854, p=0.016
T cell lymphoma, n=43 , r= 0.3538, p=0.02
Breast cancer, others, n=15 , r= 0.5807, p=0.023
Ovarian, mucinous carcinoma, n=19 , r= 0.5116, p=0.025
Adrenal tumors, n=11 , r= 0.6496, p=0.031
AML, n=322 , r= 0.1131, p=0.043
Breast ductal cancer, n=327 , r= 0.0956, p=0.084
Gastric adenocarcinoma, n=21 , r= 0.3739, p=0.095
Breast medullary cancer, n=12 , r= 0.4923, p=0.10
Parotid gland, carcinoma, n=5 , r= 0.7905
Melanoma, n=8 , r= 0.5966, p=0.12
Esophagus adenocarcinoma, n=13 , r= 0.4536, p=0.12
Peritoneum adenocarcinoma, n=13 , r= 0.4490, p=0.12
Lung, small cell cancer, n=6 , r= 0.6912, p=0.13
Lung, large cell cancer, n=8 , r= 0.5820, p=0.13
Plasma cell leukemia, n=6 , r= 0.6797, p=0.14
Skin, squamous cell carcinoma, n=4 , r= 0.8580
Sarcoma, NOS, n=9 , r= 0.5043, p=0.17
Uterine, Mullerian tumor, n=15 , r= 0.3756, p=0.17
Rhabdomyosarcoma, n=37 , r= 0.2102, p=0.21
Nephroblastoma, n=33 , r= 0.2219, p=0.21
Mesothelioma, n=35 , r= 0.2085, p=0.23
Uterine adenocarcinoma, n=140 , r= 0.0988, p=0.25
Burkitts lymphoma, n=36 , r= 0.1800, p=0.29
Ovarian, serous carcinoma, n=141 , r= 0.0887, p=0.30
Renal oncocytoma, n=5 , r= 0.5872
Cervical squamous cell carcinoma, n=57 , r= 0.1385, p=0.30
Ovarian adenocarcinoma, NOS, n=59 , r= 0.1264, p=0.34
Ovarian, endometrioid carcinoma, n=37 , r= 0.1571, p=0.35
Uterine sarcoma, n=14 , r= 0.2589, p=0.37
B CLL, n=101 , r= 0.0887, p=0.38
Breast lobular cancer, n=46 , r= 0.1271, p=0.4
Myeloma, n=102 , r= 0.0795, p=0.43
Ewings sarcoma, n=18 , r= 0.1930, p=0.44
MPNST, n=5 , r= 0.4344
B cell lymphoma, n=198 , r= 0.0515, p=0.47
Chondrosarcoma, n=15 , r= 0.2002, p=0.47
Osteosarcoma, n=11 , r= 0.2259, p=0.5
Laryngopharynx squamous cell carcinoma, n=9 , r= 0.2534, p=0.51
Thyroid carcinoma, n=58 , r= 0.0843, p=0.53
Liver cancer, n=7 , r= 0.2762, p=0.55
Glioma, n=275 , r= 0.0356, p=0.56
Testis, non seminoma, n=90 , r= 0.0607, p=0.57
Cervical adenocarcinoma, n=8 , r= 0.2181, p=0.6
Testis, seminoma, n=15 , r= 0.1417, p=0.61
GIST, n=6 , r= 0.2360, p=0.65
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respiratory system, n=625 , r= 0.286, p=3.3e 13
kidney, n=322 , r= 0.324, p=2.6e 09
heart, n=234 , r= 0.361, p=1.2e 08
prostate, n=496 , r= 0.221, p=6.6e 07
colorectal, n=405 , r= 0.217, p=1.0e 05
whole blood, n=214 , r= 0.293, p=1.3e 05
adipose tissue, n=38 , r= 0.558, p=0.00027
breast, n=978 , r= 0.116, p=0.00029
nervous system, n=123 , r= 0.309, p=5e 04
liver, n=22 , r= 0.640, p=0.0013
bone marrow lymphoid cell, n=852 , r= 0.101, p=0.0032
uterus, n=246 , r= 0.184, p=0.0037
bladder, n=190 , r= 0.189, p=0.0091
endocrine system, n=140 , r= 0.219, p=0.0094
skin, n=15 , r= 0.639, p=0.010
blood myeloid cell, n=156 , r= 0.196, p=0.014
eye, n=14 , r= 0.604, p=0.022
blood lymphoid cell, n=580 , r= 0.082, p=0.049
bone marrow myeloid cell, n=332 , r= 0.107, p=0.052
other urogenital system, n=34 , r= 0.304, p=0.081
blood vessel, n=37 , r= 0.280, p=0.094
mesenchymal stem cell, n=10 , r= 0.550, p=0.1
testis, n=128 , r= 0.137, p=0.12
lymphatic system, n=148 , r= 0.127, p=0.12
gum, n=4 , r= 0.875
mesothelium, n=54 , r= 0.208, p=0.13
salivary gland, n=14 , r= 0.413, p=0.14
bone, n=34 , r= 0.228, p=0.19
blood unspecified leukocyte, n=35 , r= 0.200, p=0.25
hair follicle, n=16 , r= 0.285, p=0.28
ovary, n=298 , r= 0.061, p=0.29
other GI system, n=89 , r= 0.098, p=0.36
central nervous system, n=780 , r= 0.029, p=0.42
tongue, n=19 , r= 0.183, p=0.45
liver and biliary system, n=11 , r= 0.219, p=0.52
cervix, n=59 , r= 0.084, p=0.53
placenta, n=48 , r= 0.084, p=0.57
muscle, n=211 , r= 0.034, p=0.62
musculoskeletal system, n=17 , r= 0.096, p=0.71
pancreas, n=46 , r= 0.052, p=0.73
adult stem cell, n=10 , r= 0.120, p=0.74
circulating reticulocyte, n=30 , r= 0.044, p=0.82
peripheral nervous system, n=28 , r= 0.043, p=0.83
hematopoietic stem cell, n=26 , r= 0.036, p=0.86
bone marrow, n=8 , r= 0.043, p=0.92
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Prostate adenocarcinoma, n=66 , r= 0.3303, p=0.0068
Ovarian, mucinous carcinoma, n=10 , r= 0.7316, p=0.016
Ovarian tumor, others, n=10 , r= 0.6984, p=0.025
Sarcoma, NOS, n=6 , r= 0.8666, p=0.026
Ovarian, serous carcinoma, n=124 , r= 0.1729, p=0.055
Uterine squamous cell carcinoma, n=5 , r= 0.8245
T cell lymphoma, n=43 , r= 0.2470, p=0.11
Leiomyosarcoma, n=4 , r= 0.8883
Renal cancer, n=190 , r= 0.1124, p=0.12
Ovarian, endometrioid carcinoma, n=28 , r= 0.2867, p=0.14
Lung, carcinoid tumor, n=6 , r= 0.6496, p=0.16
Vagina/Vulva carcinoma, n=9 , r= 0.4646, p=0.21
B cell lymphoma, n=13 , r= 0.3465, p=0.25
Breast carcinoma, NOS, n=4 , r= 0.7200
Breast ductal cancer, n=252 , r= 0.0648, p=0.31
Uterine, Mullerian tumor, n=15 , r= 0.2816, p=0.31
Ovarian adenocarcinoma, NOS, n=56 , r= 0.1357, p=0.32
Cervical adenocarcinoma, n=8 , r= 0.3739, p=0.36
GIST, n=6 , r= 0.4378, p=0.39
Liposarcoma, n=6 , r= 0.4250, p=0.4
Uterine adenocarcinoma, n=140 , r= 0.0677, p=0.43
Ovarian, germ cell tumor, n=4 , r= 0.5605
Liver cancer, n=7 , r= 0.3388, p=0.46
Colorectal carcinoma, n=320 , r= 0.0409, p=0.47
Lung, squamous cell carcinoma, n=26 , r= 0.1460, p=0.48
Skin, squamous cell carcinoma, n=4 , r= 0.5155
Breast cancer, others, n=15 , r= 0.1929, p=0.49
Thyroid carcinoma, n=38 , r= 0.1132, p=0.5
Bladder cancer, n=30 , r= 0.1253, p=0.51
Ovarian, clear cell carcinoma, n=13 , r= 0.1979, p=0.52
Esophagus adenocarcinoma, n=5 , r= 0.3611
Lung, large cell cancer, n=6 , r= 0.2966, p=0.57
Parotid gland, carcinoma, n=5 , r= 0.3261
Small intestine, adenocarcinoma, n=6 , r= 0.2402, p=0.65
Breast lobular cancer, n=33 , r= 0.0715, p=0.69
Renal oncocytoma, n=5 , r= 0.1836
Cervical squamous cell carcinoma, n=57 , r= 0.0332, p=0.8
Chondrosarcoma, n=5 , r= 0.1393
Gastric adenocarcinoma, n=21 , r= 0.0414, p=0.86
Uterine sarcoma, n=14 , r= 0.0386, p=0.9
Melanoma, n=8 , r= 0.0532, p=0.9
Peritoneum adenocarcinoma, n=13 , r= 0.0366, p=0.9
Pancreatic cancer, n=15 , r= 0.0292, p=0.92
Lung adenocarcinoma, n=58 , r= 0.0069, p=0.96
Oral squamous cell carcinoma, n=3 
Laryngopharynx squamous cell carcinoma, n=2 
Ewings sarcoma, n=3 
Synovial sarcoma, n=2 
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central nervous system, n=209 , r= 0.242, p=0.00042
muscle, n=13 , r= 0.715, p=0.006
uterus, n=196 , r= 0.192, p=0.0071
ovary, n=247 , r= 0.163, p=0.010
heart, n=95 , r= 0.250, p=0.014
prostate, n=75 , r= 0.264, p=0.022
kidney, n=233 , r= 0.148, p=0.024
lymphatic system, n=88 , r= 0.196, p=0.067
mesothelium, n=19 , r= 0.361, p=0.13
gum, n=4 , r= 0.869
other GI system, n=63 , r= 0.187, p=0.14
breast, n=316 , r= 0.077, p=0.17
skin, n=11 , r= 0.369, p=0.26
bladder, n=26 , r= 0.225, p=0.27
adipose tissue, n=6 , r= 0.521, p=0.29
salivary gland, n=9 , r= 0.364, p=0.34
liver, n=8 , r= 0.359, p=0.38
peripheral nervous system, n=8 , r= 0.347, p=0.4
colorectal, n=322 , r= 0.043, p=0.44
whole blood, n=56 , r= 0.099, p=0.47
bone marrow, n=5 , r= 0.429
blood unspecified leukocyte, n=13 , r= 0.196, p=0.52
respiratory system, n=107 , r= 0.060, p=0.54
liver and biliary system, n=5 , r= 0.357
blood vessel, n=6 , r= 0.236, p=0.65
tongue, n=10 , r= 0.162, p=0.66
endocrine system, n=60 , r= 0.053, p=0.69
hematopoietic stem cell, n=4 , r= 0.264
blood myeloid cell, n=67 , r= 0.033, p=0.8
pancreas, n=15 , r= 0.074, p=0.8
cervix, n=59 , r= 0.034, p=0.8
testis, n=8 , r= 0.061, p=0.89
blood lymphoid cell, n=23 , r= 0.022, p=0.92
other urogenital system, n=34 , r= 0.007, p=0.97
bone marrow lymphoid cell, n=1 
bone, n=2 
eye, n=1 
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adipose tissue, n=38 , r= 0.9000, p=1.5e 14
uterus, n=244 , r= 0.4520, p=1.1e 13
respiratory system, n=331 , r= 0.3153, p=4.5e 09
blood myeloid cell, n=156 , r= 0.4065, p=1.4e 07
testis, n=126 , r= 0.3219, p=0.00024
peripheral nervous system, n=26 , r= 0.6155, p=0.00082
liver, n=20 , r= 0.6602, p=0.0015
central nervous system, n=577 , r= 0.1215, p=0.0035
breast, n=769 , r= 0.1000, p=0.0055
other GI system, n=89 , r= 0.2653, p=0.012
mesothelium, n=19 , r= 0.5526, p=0.014
whole blood, n=182 , r= 0.1669, p=0.024
prostate, n=98 , r= 0.2234, p=0.027
blood lymphoid cell, n=469 , r= 0.1011, p=0.029
circulating reticulocyte, n=30 , r= 0.3537, p=0.055
other urogenital system, n=34 , r= 0.3258, p=0.06
musculoskeletal system, n=17 , r= 0.4559, p=0.066
hematopoietic stem cell, n=26 , r= 0.3548, p=0.075
hair follicle, n=16 , r= 0.4447, p=0.084
salivary gland, n=12 , r= 0.4893, p=0.11
endocrine system, n=97 , r= 0.1466, p=0.15
lymphatic system, n=142 , r= 0.1148, p=0.17
bone marrow, n=8 , r= 0.5160, p=0.19
pancreas, n=43 , r= 0.1934, p=0.21
adult stem cell, n=10 , r= 0.4255, p=0.22
eye, n=13 , r= 0.3596, p=0.23
colorectal, n=405 , r= 0.0589, p=0.24
tongue, n=19 , r= 0.2804, p=0.24
heart, n=173 , r= 0.0814, p=0.29
bone marrow myeloid cell, n=304 , r= 0.0478, p=0.41
bladder, n=87 , r= 0.0896, p=0.41
kidney, n=280 , r= 0.0484, p=0.42
muscle, n=169 , r= 0.0603, p=0.44
blood unspecified leukocyte, n=35 , r= 0.1117, p=0.52
nervous system, n=22 , r= 0.1343, p=0.55
mesenchymal stem cell, n=10 , r= 0.1913, p=0.6
skin, n=15 , r= 0.1454, p=0.6
liver and biliary system, n=9 , r= 0.1812, p=0.64
bone, n=20 , r= 0.1077, p=0.65
placenta, n=41 , r= 0.0681, p=0.67
gum, n=4 , r= 0.3110
blood vessel, n=29 , r= 0.0686, p=0.72
cervix, n=59 , r= 0.0400, p=0.76
bone marrow lymphoid cell, n=449 , r= 0.0087, p=0.85
ovary, n=248 , r= 0.0085, p=0.9
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Lip sarcoma, n=16 , r= 0.8616, p=1.8e 05
Myeloma, n=102 , r= 0.2747, p=0. 52
Lung, squamous cell carcinoma, n=44 , r= 0.3915, p=0.0086
Burkitts ly phoma, n=36 , r= 0. 292, p=0.009
Thyroid carcinoma, n=50 , r= 0.3606, p=0.01
Uterine adenocarcinoma, n=140 , r= 0.2051, p=0.015
Breast carcinoma, NOS, n=456 , r= 0.1037, p=0.027
Prostate adenocarcinoma, n=86 , r= 0.2383, p=0.027
Renal cancer, n=209 , r= 0.1527, p=0.027
T cell lymphoma, n=43 , r= 0.2945, p=0.055
Lung adenocarcinoma, n=107 , r= 0.1592, p=0.10
Ewings sarcoma, n=8 , r= 0.5639, p=0.15
Leiomyosarcoma, n=12 , r= 0.4406, p=0.15
Ovarian, germ cell tumor, n=4 , r= 0.8113
Glioma, n=210 , r= 0.0899, p=0.19
Ovarian, clear cell carcinoma, n=13 , r= 0.3762, p=0.21
Lung, large cell cancer, n=6 , r= 0.5666, p=0.24
Uterine squamous cell carcinoma, n=5 , r= 0.6397
Testis, non seminoma, n=90 , r= 0.1236, p=0.25
Parotid gland, carcinoma, n=5 , r= 0.6274
Peritoneum adenocarcinoma, n=13 , r= 0.3353, p=0.26
Gastric adenocarcinoma, n=21 , r= 0.2533, p=0.27
Breast lobular cancer, n=33 , r= 0.1967, p=0.27
Oral squamous cell carcinoma, n=19 , r= 0.2479, p=0.31
Ovarian, mucinous carcinoma, n=10 , r= 0.3595, p=0.31
Colorectal carcinoma, n=400 , r= 0.0502, p=0.32
Plasma cell leukemia, n=6 , r= 0.4552, p=0.36
Uterine, Mullerian tumor, n=15 , r= 0.2493, p=0.37
Sarcoma, NOS, n=9 , r= 0.3382, p=0.37
AML, n=294 , r= 0.0500, p=0.39
Liver cancer, n=7 , r= 0.3850, p=0.39
Ovarian adenocarcinoma, NOS, n=56 , r= 0.1155, p=0.4
Ovarian tumor, others, n=10 , r= 0.2867, p=0.42
Small intestine, adenocarcinoma, n=6 , r= 0.3717, p=0.47
T ALL, n=5 , r= 0.4260
Pancreatic cancer, n=29 , r= 0.1367, p=0.48
Uterine sarcoma, n=14 , r= 0.2018, p=0.49
B ALL, n=453 , r= 0.0289, p=0.54
Neuroblastoma, n=22 , r= 0.1343, p=0.55
Osteosarcoma, n=11 , r= 0.1821, p=0.59
Breast ductal cancer, n=252 , r= 0.0331, p=0.6
Chordoma, n=4 , r= 0.3925
Bladder cancer, n=81 , r= 0.0467, p=0.68
Lung, carcinoid tumor, n=6 , r= 0.2120, p=0.69
MPNST, n=5 , r= 0.2222
Cervical squamous cell carcinoma, n=57 , r= 0.0475, p=0.73
Cervical adenocarcinoma, n=8 , r= 0.1427, p=0.74
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Ewings sarcoma, n=18 , r= 0.72643, p=0.00064
Lung, small cell cancer, n=6 , r= 0.97425, p=0.00099
Neuroblastoma, n=123 , r= 0.27252, p=0.0023
Thyroid carcinoma, n=58 , r= 0.35222, p=0.0067
Chordoma, n=4 , r= 0.98774
Testis, non seminoma, n=90 , r= 0.21710, p=0.04
Parotid gland, carcinoma, n=5 , r= 0.88521
B ALL, n=793 , r= 0.06490, p=0.068
Bladder cancer, n=174 , r= 0.11568, p=0.13
Oral squamous cell carcinoma, n=34 , r= 0.26016, p=0.14
Sarcoma, NOS, n=9 , r= 0.53335, p=0.14
Chondrosarcoma, n=15 , r= 0.39849, p=0.14
Peritoneum adenocarcinoma, n=13 , r= 0.42279, p=0.15
Pancreatic cancer, n=29 , r= 0.25307, p=0.19
Uterine squamous cell carcinoma, n=5 , r= 0.69531
B cell lymphoma, n=198 , r= 0.09279, p=0.19
Ovarian, mucinous carcinoma, n=19 , r= 0.30584, p=0.20
Renal cancer, n=209 , r= 0.08755, p=0.21
Uterine adenocarcinoma, n=140 , r= 0.10647, p=0.21
Lung, carcinoid tumor, n=27 , r= 0.23708, p=0.23
Synovial sarcoma, n=12 , r= 0.36810, p=0.24
Cervical squamous cell carcinoma, n=57 , r= 0.14263, p=0.29
Ovarian, germ cell tumor, n=4 , r= 0.67105
T cell lymphoma, n=43 , r= 0.14750, p=0.35
Testis, seminoma, n=15 , r= 0.25367, p=0.36
Adrenal tumors, n=11 , r= 0.29246, p=0.38
Ovarian, clear cell carcinoma, n=20 , r= 0.19619, p=0.41
Lung adenocarcinoma, n=311 , r= 0.04543, p=0.42
Cervical adenocarcinoma, n=8 , r= 0.32486, p=0.43
B CLL, n=101 , r= 0.07827, p=0.44
Small intestine, adenocarcinoma, n=6 , r= 0.39532, p=0.44
Melanoma, n=8 , r= 0.30561, p=0.46
Leiomyosarcoma, n=12 , r= 0.22406, p=0.48
T ALL, n=68 , r= 0.08273, p=0.5
Colorectal carcinoma, n=400 , r= 0.03343, p=0.5
GIST, n=6 , r= 0.34291, p=0.51
Ovarian, endometrioid carcinoma, n=37 , r= 0.10756, p=0.53
Plasma cell leukemia, n=6 , r= 0.32355, p=0.53
Skin, squamous cell carcinoma, n=4 , r= 0.46281
Breast carcinoma, NOS, n=553 , r= 0.02578, p=0.55
Liposarcoma, n=16 , r= 0.15705, p=0.56
Vagina/Vulva carcinoma, n=9 , r= 0.22246, p=0.57
Laryngopharynx squamous cell carcinoma, n=9 , r= 0.21723, p=0.57
Myeloma, n=102 , r= 0.05596, p=0.58
Uterine sarcoma, n=14 , r= 0.15213, p=0.6
Mesothelioma, n=35 , r= 0.08724, p=0.62
Breast medullary cancer, n=12 , r= 0.15069, p=0.64
Ovarian tumor, others, n=10 , r= 0.16703, p=0.64
Esophagus adenocarcinoma, n=13 , r= 0.13798, p=0.65
AML, n=322 , r= 0.02321, p=0.68
Ovarian, serous carcinoma, n=141 , r= 0.03308, p=0.7
Breast cancer, others, n=15 , r= 0.10375, p=0.71
Uterine, Mullerian tumor, n=15 , r= 0.10103, p=0.72
Gastric adenocarcinoma, n=21 , r= 0.08210, p=0.72
Lung, squamous cell carcinoma, n=83 , r= 0.03630, p=0.74
Nephroblastoma, n=33 , r= 0.05591, p=0.76
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blood myeloid cell, n=156 , r= 0.37874, p=1.1e 06
whole blood, n=214 , r= 0.27902, p=3.5e 05
blood lymphoid cell, n=580 , r= 0.14729, p=0.00037
salivary gland, n=14 , r= 0.76704, p=0.0014
nervous system, n=123 , r= 0.27252, p=0.0023
adipose tissue, n=38 , r= 0.42483, p=0.0078
other GI system, n=89 , r= 0.27642, p=0.0087
mesothelium, n=54 , r= 0.33003, p=0.015
musculoskeletal system, n=17 , r= 0.47367, p=0.055
kidney, n=322 , r= 0.10312, p=0.065
hair follicle, n=16 , r= 0.45526, p=0.076
bladder, n=190 , r= 0.12150, p=0.095
testis, n=128 , r= 0.14746, p=0.097
prostate, n=496 , r= 0.06831, p=0.13
eye, n=14 , r= 0.41949, p=0.14
muscle, n=211 , r= 0.10026, p=0.15
other urogenital system, n=34 , r= 0.25187, p=0.15
lymphatic system, n=148 , r= 0.10777, p=0.19
blood unspecified leukocyte, n=35 , r= 0.19366, p=0.26
peripheral nervous system, n=28 , r= 0.19891, p=0.31
mesenchymal stem cell, n=10 , r= 0.33973, p=0.34
placenta, n=48 , r= 0.13969, p=0.34
circulating reticulocyte, n=30 , r= 0.17092, p=0.37
uterus, n=246 , r= 0.05645, p=0.38
blood vessel, n=37 , r= 0.12877, p=0.45
colorectal, n=405 , r= 0.03676, p=0.46
breast, n=978 , r= 0.02117, p=0.51
tongue, n=19 , r= 0.15867, p=0.52
hematopoietic stem cell, n=26 , r= 0.12892, p=0.53
liver and biliary system, n=11 , r= 0.20095, p=0.55
ovary, n=298 , r= 0.03086, p=0.6
liver, n=22 , r= 0.11592, p=0.61
skin, n=15 , r= 0.13766, p=0.62
bone marrow, n=8 , r= 0.20242, p=0.63
heart, n=234 , r= 0.03153, p=0.63
bone marrow myeloid cell, n=332 , r= 0.01905, p=0.73
adult stem cell, n=10 , r= 0.10227, p=0.78
respiratory system, n=625 , r= 0.01111, p=0.78
endocrine system, n=140 , r= 0.02074, p=0.8
central nervous system, n=780 , r= 0.00857, p=0.81
pancreas, n=46 , r= 0.03065, p=0.84
gum, n=4 , r= 0.11350
bone, n=34 , r= 0.00996, p=0.96
cervix, n=59 , r= 0.00645, p=0.96
bone marrow lymphoid cell, n=852 , r= 0.00016, p=1
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Renal cancer, n=209 , r= 0.4247, p=1.5e 10
Prostate adenocarcinoma, n=349 , r= 0.2414, p=5.1e 06
Colorectal carcinoma, n=400 , r= 0.2205, p=8.5e 06
Lung, carcinoid tumor, n=27 , r= 0.7131, p=3e 05
Breast carcinoma, NOS, n=553 , r= 0.1499, p=0.00040
Neuroblastoma, n=123 , r= 0.3094, p=5e 04
Lung adenocarcinoma, n=311 , r= 0.1689, p=0.0028
Lung, squamous cell carcinoma, n=83 , r= 0.3186, p=0.0033
Ovarian tumor, others, n=10 , r= 0.7910, p=0.0064
Bladder cancer, n=174 , r= 0.1839, p=0.015
B ALL, n=793 , r= 0.0854, p=0.016
T cell lymphoma, n=43 , r= 0.3538, p=0.02
Breast cancer, others, n=15 , r= 0.5807, p=0.023
Ovarian, mucinous carcinoma, n=19 , r= 0.5116, p=0.025
Adrenal tumors, n=11 , r= 0.6496, p=0.031
AML, n=322 , r= 0.1131, p=0.043
Breast ductal cancer, n=327 , r= 0.0956, p=0.084
Gastric adenocarcinoma, n=21 , r= 0.3739, p=0.095
Breast medullary cancer, n=12 , r= 0.4923, p=0.10
Parotid gland, carcinoma, n=5 , r= 0.7905
Melanoma, n=8 , r= 0.5966, p=0.12
Esophagus adenocarcinoma, n=13 , r= 0.4536, p=0.12
Peritoneum adenocarcinoma, n=13 , r= 0.4490, p=0.12
Lung, small cell cancer, n=6 , r= 0.6912, p=0.13
Lung, large cell cancer, n=8 , r= 0.5820, p=0.13
Plasma cell leukemia, n=6 , r= 0.6797, p=0.14
Skin, squamous cell carcinoma, n=4 , r= 0.8580
Sarcoma, NOS, n=9 , r= 0.5043, p=0.17
Uterine, Mullerian tumor, n=15 , r= 0.3756, p=0.17
Rhabdomyosarcoma, n=37 , r= 0.2102, p=0.21
Nephroblastoma, n=33 , r= 0.2219, p=0.21
Mesothelioma, n=35 , r= 0.2085, p=0.23
Uterine adenocarcinoma, n=140 , r= 0.0988, p=0.25
Burkitts lymphoma, n=36 , r= 0.1800, p=0.29
Ovarian, serous carcinoma, n=141 , r= 0.0887, p=0.30
Renal oncocytoma, n=5 , r= 0.5872
Cervical squamous cell carcinoma, n=57 , r= 0.1385, p=0.30
Ovarian adenocarcinoma, NOS, n=59 , r= 0.1264, p=0.34
Ovarian, endometrioid carcinoma, n=37 , r= 0.1571, p=0.35
Uterine sarcoma, n=14 , r= 0.2589, p=0.37
B CLL, n=101 , r= 0.0887, p=0.38
Breast lobular cancer, n=46 , r= 0.1271, p=0.4
Myeloma, n=102 , r= 0.0795, p=0.43
Ewings sarcoma, n=18 , r= 0.1930, p=0.44
MPNST, n=5 , r= 0.4344
B cell lymphoma, n=198 , r= 0.0515, p=0.47
Chondrosarcoma, n=15 , r= 0.2002, p=0.47
Osteosarcoma, n=11 , r= 0.2259, p=0.5
Laryngopharynx squamous cell carcinoma, n=9 , r= 0.2534, p=0.51
Thyroid carcinoma, n=58 , r= 0.0843, p=0.53
Liver cancer, n=7 , r= 0.2762, p=0.55
Glioma, n=275 , r= 0.0356, p=0.56
Testis, non seminoma, n=90 , r= 0.0607, p=0.57
Cervical adenocarcinoma, n=8 , r= 0.2181, p=0.6
Testis, seminoma, n=15 , r= 0.1417, p=0.61
GIST, n=6 , r= 0.2360, p=0.65
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respiratory system, n=625 , r= 0.286, p=3.3e 13
kidney, n=322 , r= 0.324, p=2.6e 09
heart, n=234 , r= 0.361, p=1.2e 08
prostate, n=496 , r= 0.221, p=6.6e 07
colorectal, n=405 , r= 0.217, p=1.0e 05
whole blood, n=214 , r= 0.293, p=1.3e 05
adipose tissue, n=38 , r= 0.558, p=0.00027
breast, n=978 , r= 0.116, p=0.00029
nervous system, n=123 , r= 0.309, p=5e 04
liver, n=22 , r= 0.640, p=0.0013
bone marrow lymphoid cell, n=852 , r= 0.101, p=0.0032
uterus, n=246 , r= 0.184, p=0.0037
bladder, n=190 , r= 0.189, p=0.0091
endocrine system, n=140 , r= 0.219, p=0.0094
skin, n=15 , r= 0.639, p=0.010
blood myeloid cell, n=156 , r= 0.196, p=0.014
eye, n=14 , r= 0.604, p=0.022
blood lymphoid cell, n=580 , r= 0.082, p=0.049
bone marrow myeloid cell, n=332 , r= 0.107, p=0.052
other urogenital system, n=34 , r= 0.304, p=0.081
blood vessel, n=37 , r= 0.280, p=0.094
mesenchymal stem cell, n=10 , r= 0.550, p=0.1
testis, n=128 , r= 0.137, p=0.12
lymphatic system, n=148 , r= 0.127, p=0.12
gum, n=4 , r= 0.875
mesothelium, n=54 , r= 0.208, p=0.13
salivary gland, n=14 , r= 0.413, p=0.14
bone, n=34 , r= 0.228, p=0.19
blood unspecified leukocyte, n=35 , r= 0.200, p=0.25
hair follicle, n=16 , r= 0.285, p=0.28
ovary, n=298 , r= 0.061, p=0.29
other GI system, n=89 , r= 0.098, p=0.36
central nervous system, n=780 , r= 0.029, p=0.42
tongue, n=19 , r= 0.183, p=0.45
liver and biliary system, n=11 , r= 0.219, p=0.52
cervix, n=59 , r= 0.084, p=0.53
placenta, n=48 , r= 0.084, p=0.57
muscle, n=211 , r= 0.034, p=0.62
musculoskeletal system, n=17 , r= 0.096, p=0.71
pancreas, n=46 , r= 0.052, p=0.73
adult stem cell, n=10 , r= 0.120, p=0.74
circulating reticulocyte, n=30 , r= 0.044, p=0.82
peripheral nervous system, n=28 , r= 0.043, p=0.83
hematopoietic stem cell, n=26 , r= 0.036, p=0.86
bone marrow, n=8 , r= 0.043, p=0.92
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Prostate adenocarcinoma, n=66 , r= 0.3303, p=0.0068
Ovarian, mucinous carcinoma, n=10 , r= 0.7316, p=0.016
Ovarian tumor, oth rs, n=10 , r= 0.6984, p=0.025
Sarcoma, NOS, n=6 , r= 0.8666, p=0.026
Ovarian, serous carcinoma, n=124 , r= 0.1729, p=0.055
Uterine squamous cell carcinoma, n=5 , r= 0.8245
T cell lymphoma, n=43 , r= 0.2470, p=0.11
Leiomyosarcoma, n=4 , r= 0.8883
Renal cancer, n=190 , r= 0.1124, p=0.12
Ovarian, endometrioid carcinoma, n=28 , r= 0.2867, p=0.14
Lung, carcinoid tumor, n=6 , r= 0.6496, p=0.16
Vagina/Vulva carcinoma, n=9 , r= 0.4646, p=0.21
B cell lymphoma, n=13 , r= 0.3465, p=0.25
Breast carcinoma, NOS, n=4 , r= 0.7200
Breast ductal cancer, n=252 , r= 0.0648, p=0.31
Uterine, Mullerian tumor, n=15 , r= 0.2816, p=0.31
Ovarian adenocarcinoma, NOS, n=56 , r= 0.1357, p=0.32
Cervical adenocarcinoma, n=8 , r= 0.3739, p=0.36
GIST, n=6 , r= 0.4378, p=0.39
Liposarcoma, n=6 , r= 0.4250, p=0.4
Uterine adenocarcinoma, n=140 , r= 0.0677, p=0.43
Ovarian, germ cell tumor, n=4 , r= 0.5605
Liver cancer, n=7 , r= 0.3388, p=0.46
Colorectal carcinoma, n=320 , r= 0.0409, p=0.47
Lung, squamous cell carcinoma, n=26 , r= 0.1460, p=0.48
Skin, squamous cell carcinoma, n=4 , r= 0.5155
Breast cancer, others, n=15 , r= 0.1929, p=0.49
Thyroid carcinoma, n=38 , r= 0.1132, p=0.5
Bladder cancer, n=30 , r= 0.1253, p=0.51
Ovarian, clear cell carcinoma, n=13 , r= 0.1979, p=0.52
Esophagus adenocarcinoma, n=5 , r= 0.3611
Lung, large cell cancer, n=6 , r= 0.2966, p=0.57
Parotid gland, carcinoma, n=5 , r= 0.3261
Small intestine, adenocarcinoma, n=6 , r= 0.2402, p=0.65
Breast lobular cancer, n=33 , r= 0.0715, p=0.69
Renal oncocytoma, n=5 , r= 0.1836
Cervical squamous cell carcinoma, n=57 , r= 0.0332, p=0.8
Chondrosarcoma, n=5 , r= 0.1393
Gastric adenocarcinoma, n=21 , r= 0.0414, p=0.86
Uterine sarcoma, n=14 , r= 0.0386, p=0.9
Melanoma, n=8 , r= 0.0532, p=0.9
Peritoneum adenocarcinoma, n=13 , r= 0.0366, p=0.9
Pancreatic cancer, n=15 , r= 0.0292, p=0.92
Lung adenocarcinoma, n=58 , r= 0.0069, p=0.96
Oral squamous cell carcinoma, n=3 
Laryngopharynx squamous cell carcinoma, n=2 
Ewings sarcoma, n=3 
Synovial sarcoma, n=2 
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central nervous system, n=209 , r= 0.242, p=0.00042
muscle, n=13 , r= 0.715, p=0.006
uterus, n=196 , r= 0.192, p=0.0071
ovary, n=247 , r= 0.163, p=0.010
heart, n=95 , r= 0.250, p=0.014
prostate, n=75 , r= 0.264, p=0.022
kidney, n=233 , r= 0.148, p=0.024
lymphatic system, n=88 , r= 0.196, p=0.067
mesothelium, n=19 , r= 0.361, p=0.13
gum, n=4 , r= 0.869
other GI system, n=63 , r= 0.187, p=0.14
breast, n=316 , r= 0.077, p=0.17
skin, n=11 , r= 0.369, p=0.26
bladder, n=26 , r= 0.225, p=0.27
adipose tissue, n=6 , r= 0.521, p=0.29
salivary gland, n=9 , r= 0.364, p=0.34
liver, n=8 , r= 0.359, p=0.38
peripheral nervous system, n=8 , r= 0.347, p=0.4
colorectal, n=322 , r= 0.043, p=0.44
whole blood, n=56 , r= 0.099, p=0.47
bone marrow, n=5 , r= 0.429
blood unspecified leukocyte, n=13 , r= 0.196, p=0.52
respiratory system, n=107 , r= 0.060, p=0.54
liver and biliary system, n=5 , r= 0.357
blood vessel, n=6 , r= 0.236, p=0.65
tongue, n=10 , r= 0.162, p=0.66
endocrine system, n=60 , r= 0.053, p=0.69
hematopoietic stem cell, n=4 , r= 0.264
blood myeloid cell, n=67 , r= 0.033, p=0.8
pancreas, n=15 , r= 0.074, p=0.8
cervix, n=59 , r= 0.034, p=0.8
testis, n=8 , r= 0.061, p=0.89
blood lymphoid cell, n=23 , r= 0.022, p=0.92
other urogenital system, n=34 , r= 0.007, p=0.97
bone marrow lymphoid cell, n=1 
bone, n=2 
eye, n=1 
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adipose tissue, n=38 , r= 0.9000, p=1.5e 14
uterus, n=244 , r= 0.4520, p=1.1e 13
respiratory system, n=331 , r= 0.3153, p=4.5e 09
blood myeloid cell, n=156 , r= 0.4065, p=1.4e 07
testis, n=126 , r= 0.3219, p=0.00024
peripheral nervous system, n=26 , r= 0.6155, p=0.00082
liver, n=20 , r= 0.6602, p=0.0015
central nervous system, n=577 , r= 0.1215, p=0.0035
breast, n=769 , r= 0.1000, p=0.0055
other GI system, n=89 , r= 0.2653, p=0.012
mesothelium, n=19 , r= 0.5526, p=0.014
whole blood, n=182 , r= 0.1669, p=0.024
prostate, n=98 , r= 0.2234, p=0.027
blood lymphoid cell, n=469 , r= 0.1011, p=0.029
circulating reticulocyte, n=30 , r= 0.3537, p=0.055
other urogenital system, n=34 , r= 0.3258, p=0.06
musculoskeletal system, n=17 , r= 0.4559, p=0.066
hematopoietic stem cell, n=26 , r= 0.3548, p=0.075
hair follicle, n=16 , r= 0.4447, p=0.084
salivary gland, n=12 , r= 0.4893, p=0.11
endocrine system, n=97 , r= 0.1466, p=0.15
lymphatic system, n=142 , r= 0.1148, p=0.17
bone marrow, n=8 , r= 0.5160, p=0.19
pancreas, n=43 , r= 0.1934, p=0.21
adult stem cell, n=10 , r= 0.4255, p=0.22
eye, n=13 , r= 0.3596, p=0.23
colorectal, n=405 , r= 0.0589, p=0.24
tongue, n=19 , r= 0.2804, p=0.24
heart, n=173 , r= 0.0814, p=0.29
bone marrow myeloid cell, n=304 , r= 0.0478, p=0.41
bladder, n=87 , r= 0.0896, p=0.41
kidney, n=280 , r= 0.0484, p=0.42
muscle, n=169 , r= 0.0603, p=0.44
blood unspecified leukocyte, n=35 , r= 0.1117, p=0.52
nervous system, n=22 , r= 0.1343, p=0.55
mesenchymal stem cell, n=10 , r= 0.1913, p=0.6
skin, n=15 , r= 0.1454, p=0.6
liver and biliary system, n=9 , r= 0.1812, p=0.64
bone, n=20 , r= 0.1077, p=0.65
placenta, n=41 , r= 0.0681, p=0.67
gum, n=4 , r= 0.3110
blood vessel, n=29 , r= 0.0686, p=0.72
cervix, n=59 , r= 0.0400, p=0.76
bone marrow lymphoid cell, n=449 , r= 0.0087, p=0.85
ovary, n=248 , r= 0.0085, p=0.9
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Lip sarcoma, n=16 , r= 0.8616, p=1.8e 05
Myeloma, n=102 , r= 0.2747, p=0. 52
Lung, squamous cell carcinoma, n=44 , r= 0.3915, p=0.0086
Burkitts ly phoma, n=36 , r= 0. 292, p=0.009
Thyroid carcinoma, n=50 , r= 0.3606, p=0.01
Uterine adenocarcinoma, n=140 , r= 0.2051, p=0.015
Breast carcinoma, NOS, n=456 , r= 0.1037, p=0.027
Prostate adenocarcinoma, n=86 , r= 0.2383, p=0.027
Renal cancer, n=209 , r= 0.1527, p=0.027
T cell lymphoma, n=43 , r= 0.2945, p=0.055
Lung adenocarcinoma, n=107 , r= 0.1592, p=0.10
Ewings sarcoma, n=8 , r= 0.5639, p=0.15
Leiomyosarcoma, n=12 , r= 0.4406, p=0.15
Ovarian, germ cell tumor, n=4 , r= 0.8113
Glioma, n=210 , r= 0.0899, p=0.19
Ovarian, clear cell carcinoma, n=13 , r= 0.3762, p=0.21
Lung, large cell cancer, n=6 , r= 0.5666, p=0.24
Uterine squamous cell carcinoma, n=5 , r= 0.6397
Testis, non seminoma, n=90 , r= 0.1236, p=0.25
Parotid gland, carcinoma, n=5 , r= 0.6274
Peritoneum adenocarcinoma, n=13 , r= 0.3353, p=0.26
Gastric adenocarcinoma, n=21 , r= 0.2533, p=0.27
Breast lobular cancer, n=33 , r= 0.1967, p=0.27
Oral squamous cell carcinoma, n=19 , r= 0.2479, p=0.31
Ovarian, mucinous carcinoma, n=10 , r= 0.3595, p=0.31
Colorectal carcinoma, n=400 , r= 0.0502, p=0.32
Plasma cell leukemia, n=6 , r= 0.4552, p=0.36
Uterine, Mullerian tumor, n=15 , r= 0.2493, p=0.37
Sarcoma, NOS, n=9 , r= 0.3382, p=0.37
AML, n=294 , r= 0.0500, p=0.39
Liver cancer, n=7 , r= 0.3850, p=0.39
Ovarian adenocarcinoma, NOS, n=56 , r= 0.1155, p=0.4
Ovarian tumor, others, n=10 , r= 0.2867, p=0.42
Small intestine, adenocarcinoma, n=6 , r= 0.3717, p=0.47
T ALL, n=5 , r= 0.4260
Pancreatic cancer, n=29 , r= 0.1367, p=0.48
Uterine sarcoma, n=14 , r= 0.2018, p=0.49
B ALL, n=453 , r= 0.0289, p=0.54
Neuroblastoma, n=22 , r= 0.1343, p=0.55
Osteosarcoma, n=11 , r= 0.1821, p=0.59
Breast ductal cancer, n=252 , r= 0.0331, p=0.6
Chordoma, n=4 , r= 0.3925
Bladder cancer, n=81 , r= 0.0467, p=0.68
Lung, carcinoid tumor, n=6 , r= 0.2120, p=0.69
MPNST, n=5 , r= 0.2222
Cervical squamous cell carcinoma, n=57 , r= 0.0475, p=0.73
Cervical adenocarcinoma, n=8 , r= 0.1427, p=0.74
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Ewings sarcoma, n=18 , r= 0.72643, p=0.00064
Lung, small cell cancer, n=6 , r= 0.97425, p=0.00099
Neuroblastoma, n=123 , r= 0.27252, p=0.0023
Thyroid carcinoma, n=58 , r= 0.35222, p=0.0067
Chordoma, n=4 , r= 0.98774
Testis, non seminoma, n=90 , r= 0.21710, p=0.04
Parotid gland, carcinoma, n=5 , r= 0.88521
B ALL, n=793 , r= 0.06490, p=0.068
Bladder cancer, n=174 , r= 0.11568, p=0.13
Oral squamous cell carcinoma, n=34 , r= 0.26016, p=0.14
Sarcoma, NOS, n=9 , r= 0.53335, p=0.14
Chondrosarcoma, n=15 , r= 0.39849, p=0.14
Peritoneum adenocarcinoma, n=13 , r= 0.42279, p=0.15
Pancreatic cancer, n=29 , r= 0.25307, p=0.19
Uterine squamous cell carcinoma, n=5 , r= 0.69531
B cell lymphoma, n=198 , r= 0.09279, p=0.19
Ovarian, mucinous carcinoma, n=19 , r= 0.30584, p=0.20
Renal cancer, n=209 , r= 0.08755, p=0.21
Uterine adenocarcinoma, n=140 , r= 0.10647, p=0.21
Lung, carcinoid tumor, n=27 , r= 0.23708, p=0.23
Synovial sarcoma, n=12 , r= 0.36810, p=0.24
Cervical squamous cell carcinoma, n=57 , r= 0.14263, p=0.29
Ovarian, germ cell tumor, n=4 , r= 0.67105
T cell lymphoma, n=43 , r= 0.14750, p=0.35
Testis, seminoma, n=15 , r= 0.25367, p=0.36
Adrenal tumors, n=11 , r= 0.29246, p=0.38
Ovarian, clear cell carcinoma, n=20 , r= 0.19619, p=0.41
Lung adenocarcinoma, n=311 , r= 0.04543, p=0.42
Cervical adenocarcinoma, n=8 , r= 0.32486, p=0.43
B CLL, n=101 , r= 0.07827, p=0.44
Small intestine, adenocarcinoma, n=6 , r= 0.39532, p=0.44
Melanoma, n=8 , r= 0.30561, p=0.46
Leiomyosarcoma, n=12 , r= 0.22406, p=0.48
T ALL, n=68 , r= 0.08273, p=0.5
Colorectal carcinoma, n=400 , r= 0.03343, p=0.5
GIST, n=6 , r= 0.34291, p=0.51
Ovarian, endometrioid carcinoma, n=37 , r= 0.10756, p=0.53
Plasma cell leukemia, n=6 , r= 0.32355, p=0.53
Skin, squamous cell carcinoma, n=4 , r= 0.46281
Breast carcinoma, NOS, n=553 , r= 0.02578, p=0.55
Liposarcoma, n=16 , r= 0.15705, p=0.56
Vagina/Vulva carcinoma, n=9 , r= 0.22246, p=0.57
Laryngopharynx squamous cell carcinoma, n=9 , r= 0.21723, p=0.57
Myeloma, n=102 , r= 0.05596, p=0.58
Uterine sarcoma, n=14 , r= 0.15213, p=0.6
Mesothelioma, n=35 , r= 0.08724, p=0.62
Breast medullary cancer, n=12 , r= 0.15069, p=0.64
Ovarian tumor, others, n=10 , r= 0.16703, p=0.64
Esophagus adenocarcinoma, n=13 , r= 0.13798, p=0.65
AML, n=322 , r= 0.02321, p=0.68
Ovarian, serous carcinoma, n=141 , r= 0.03308, p=0.7
Breast cancer, others, n=15 , r= 0.10375, p=0.71
Uterine, Mullerian tumor, n=15 , r= 0.10103, p=0.72
Gastric adenocarcinoma, n=21 , r= 0.08210, p=0.72
Lung, squamous cell carcinoma, n=83 , r= 0.03630, p=0.74
Nephroblastoma, n=33 , r= 0.05591, p=0.76
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blood myeloid cell, n=156 , r= 0.37874, p=1.1e 06
whole blood, n=214 , r= 0.27902, p=3.5e 05
blood lymphoid cell, n=580 , r= 0.14729, p=0.00037
salivary gland, n=14 , r= 0.76704, p=0.0014
nervous system, n=123 , r= 0.27252, p=0.0023
adipose tissue, n=38 , r= 0.42483, p=0.0078
other GI system, n=89 , r= 0.27642, p=0.0087
mesothelium, n=54 , r= 0.33003, p=0.015
musculoskeletal system, n=17 , r= 0.47367, p=0.055
kidney, n=322 , r= 0.10312, p=0.065
hair follicle, n=16 , r= 0.45526, p=0.076
bladder, n=190 , r= 0.12150, p=0.095
testis, n=128 , r= .14746, p=0.097
prostate, n=496 , r= 0.06831, p=0.13
eye, n=14 , r= 0.41949, p=0.14
muscle, n=211 , r= 0.10026, p=0.15
other urogenital system, n=34 , r= 0.25187, p=0.15
lymphatic system, n=148 , r= 0.10777, p=0.19
blood unspecified leukocyte, n=35 , r= 0.19366, p=0.26
peripheral nervous system, n=28 , r= 0.19891, p=0.31
mesenchymal stem cell, n=10 , r= 0.33973, p=0.34
placenta, n=48 , r= 0.13969, p=0.34
circulating reticulocyte, n=30 , r= 0.17092, p=0.37
uterus, n=246 , r= 0.05645, p=0.38
blood vessel, n=37 , r= 0.12877, p=0.45
colorectal, n=405 , r= 0.03676, p=0.46
breast, n=978 , r= 0.02117, p=0.51
tongue, n=19 , r= 0.15867, p=0.52
hematopoietic stem cell, n=26 , r= 0.12892, p=0.53
liver and biliary system, n=11 , r= 0.20095, p=0.55
ovary, n=298 , r= 0.03086, p=0.6
liver, n=22 , r= 0.11592, p=0.61
skin, n=15 , r= 0.13766, p=0.62
bone marrow, n=8 , r= 0.20242, p=0.63
heart, n=234 , r= 0.03153, p=0.63
bone marrow myeloid cell, n=332 , r= 0.01905, p=0.73
adult stem cell, n=10 , r= 0.10227, p=0.78
respiratory system, n=625 , r= 0.01111, p=0.78
endocrine system, n=140 , r= 0.02074, p=0.8
central nervous system, n=780 , r= 0.00857, p=0.81
pancreas, n=46 , r= 0.03065, p=0.84
gum, n=4 , r= 0.11350
bone, n=34 , r= 0.00996, p=0.96
cervix, n=59 , r= 0.00645, p=0.96
bone marrow lymphoid cell, n=852 , r= 0.00016, p=1
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Supplementary figure 3
Figure S3. Gene expression cor-
relation plots between PRAME and 
subunits of Cul2 ligases or the EKC 
complex.
Co-expression plots were generated 
from the GeneSapiens database for 
PRAME and CUL2 or each of the EKC 
subunits. Correlations plots are shown 
for healthy tissues (A), and cancer 
tissues (B).
The plots indicate that the expression 
of the genes tested do not correlate 
linearly. In particular, a large number 
of samples are characterized by low or 
no PRAME expression, while CUL2 and 
EKC subunits are expressed at higher 
levels.
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Supplementary figure 4
Figure S4. Gene expression cor-
relation plots between subunits 
of Cul2 ligases and subunits of the 
EKC complex.
Co-expression plots were generated 
from the GeneSapiens database for 
CUL2 and TCEB1, and couples of EKC 
subunits. Correlations plots are shown 
for healthy tissues (A), and cancer 
tissues (B).
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CHAPTER 5
DEVELOP-
MENT OF 
REAGENTS 
AND TOOLS
for the study of the 
human oncoprotein 
PRAME
Adalberto Costessi, Rieka Stunnenberg, Esther Tijchon, Hendrik G. Stunnen-
berg
Department of Molecular Biology, Nijmegen Centre for Molecular Life Scienc-
es, Radboud University, Nijmegen, The Netherlands
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ABSTRACT
Expression of the human oncoprotein PRAME has been investigated in 
several tumours and numerous cohorts of cancer patients. However, studies 
of PRAME function at the molecular and cellular level are scarce and are also 
hindered by the lack of validated antibodies. In this chapter, we report the 
development and validation of PRAME antibodies raised against five differ-
ent peptides. We successfully raised sera and affinity-purified antibodies for 
use in western blot, immunoprecipitation and ChIP-seq with high sensitivity 
and specificity. We established that PRAME is a chromatin-associated protein 
and we generated the first genome-wide ChIP-seq binding profiles of epi-
tope-tagged as well as endogenous PRAME in K562 cells. Finally, we inves-
tigated the reported interplay between PRAME and retinoic acid signaling 
in the A375 melanoma cell line using two independent silencing constructs 
and complementation with a knockdown-resistant PRAME. In contrast to 
published reports, our data suggest that the growth phenotype identified 
in PRAME knockdown cells treated with retinoic acid is likely caused by 
“off-target” knockdown of a gene unrelated to PRAME by one of the silencing 
constructs used. 
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INTRODUCTION
The human PRAME gene was first identified in 1998 as the gene cod-
ing for the antigen responsible for the anti-tumour immune response in a 
melanoma patient (Ikeda et al, 1997). Since then, numerous studies have 
investigated the transcript expression levels of PRAME in patients affected by 
different types of cancers, establishing that this gene is often overexpressed 
in a wide range of malignancies. Investigation of the molecular and cellular 
functions of PRAME, however, has been hindered by the lack of validated 
reagents for use in experimental research. For instance, several assays rely 
on antibodies with high specificity for the protein of interest, and it takes sig-
nificant efforts to develop and test antibodies when these are not available 
from commercial suppliers. Therefore, we invested on the development of a 
toolbox of reagents, including antibodies, expression plasmids, and suitable 
epitope tags. 
In this chapter, we report the development of a number of rabbit poly-
clonal antibodies against human PRAME and their validation for western blot, 
immunoprecipitation, and ChIP assays. We further discuss strategies that 
can be undertaken to generate genome-wide ChIP-seq binding profiles of 
proteins of interest, and we present an epitope-tagged approach based on 
a double TY1 epitope that we successfully applied for ChIP-seq profiling of 
PRAME in K562 cells. A recent study reported that downregulation of PRAME 
sensitized A375 melanoma cells to retinoic acid-induced growth arrest, sug-
gesting a repressive function for PRAME on retinoic acid signaling (Epping et 
al, 2005). Here, we report data generated with two independent knockdown 
constructs, which do not support the published model and rather suggest 
that the phenotype observed is likely caused by an “off-target” effect of the 
knockdown vector used in the literature.
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RESULTS AND DISCUSSION
Development of anti-PRAME peptide antibodies
At the beginning of our study, antibodies for human PRAME were not 
commercially available. Therefore, we performed an immunization protocol 
in rabbits to raise anti-PRAME peptide antibodies (see Table 1 and Figure 1). 
Peptides 2, 3, 4, and 5 were designed in regions of PRAME that showed low 
sequence homology with other PRAME-like proteins, in order to reduce the 
chance of cross-reactivity; peptide 7 was previously described (Ikeda et al, 
1997). Each peptide was administered to two rabbits in parallel, and crude 
sera were collected every three weeks for a maximum of ten harvests (S1 to 
S10). 
Sera were first tested in dot blot assays to assess if the sera contained 
antibodies directed against the peptides administered. The results showed 
that all rabbits mounted an efficient immune response against the corre-
sponding peptide (data not shown).
Next, we tested the sera in western blot assays using protein extracts 
from 293T cells transiently transfected with pcDNA5-TAG-PRAME (StrepII-TEV-
MYC-3xHA-PRAME, 73 kDa) and control untransfected cells. Importantly, 293T 
cells do not express significant levels of endogenous PRAME. Figure 2 shows 
the results obtained with sera from bleed S5 (panel A) and bleed S8 (panel 
       1  MERRRLWGSI QSRYISMSVW TSPRRLVELA GQSLLKDEAL AIAALELLPR ELFPPLFMAA
 
      61  FDGRHSQTLK AMVQAWPFTC LPLGVLMKGQ HLHLETFKAV LDGLDVLLAQ EVRPRRWKLQ 
     
     121  VLDLRKNSHQ DFWTVWSGNR ASLYSFPEPE AAQPMTKKRK VDGLSTEAEQ PFIPVEVLVD 
     181  LFLKEGACDE LFSYLIEKVK RKKNVLRLCC KKLKIFAMPM QDIKMILKMV QLDSIEDLEV 
     241  TCTWKLPTLA KFSPYLGQMI NLRRLLLSHI HASSYISPEK EEQYIAQFTS QFLSLQCLQA 
     301  LYVDSLFFLR GRLDQLLRHV MNPLETLSIT NCRLSEGDVM HLSQSPSVSQ LSVLSLSGVM 
     361  LTDVSPEPLQ ALLERASATL QDLVFDECGI TDDQLLALLP SLSHCSQLTT LSFYGNSISI 
     421  SALQSLLQHL IGLSNLTHVL YPVPLESYED IHGTLHLERL AYLHARLREL LCELGRPSMV 
     481  WLSANPCPHC GDRTFYDPEP ILCPCFMPN
Peptide 7
Peptide 2 Peptide 3
Peptide 4
Peptide 5
Figure 1Figure 1 Peptides used for the generation of PRAME antibodies. The locations of the peptides used in the 
immunization protocol are highlighted on the complete amino acid sequence of human PRAME.
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B). Sera V19, V20, V22, V27 and V28 successfully detected TAG-PRAME, while 
the other sera did not work efficiently in these assays.
The V19 and V20 sera recognized also an additional band of about 50-55 
kDa. Notably, this band was not detected by antibodies raised against other 
peptides, nor by the pre-immune serum from rabbit V19 (Fig. 2C), suggesting 
that reactivity against this band was mediated by antibodies raised by the 
immunization protocol against peptide 2. Consistent with this hypothesis, a 
Figure 2
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Validation of crude sera in 
western blot assays.
(A-B) Western blot experiments 
with PRAME crude sera using 
extracts from HEK293T cells 
(indicated as C, control) and from 
HEK293T transiently transfect-
ed with pcDNA5-TAG-PRAME 
(indicated as PR). Results are 
shown for sera obtain with bleed 
5 (A) and bleed 8 (B). About 
20 micrograms of whole cell 
protein extracts were loaded for 
the control cell line, and about 
40 micrograms for TAG-PRAME 
transfected cells. Sera were used 
at 1:1000 dilution in 5% skimmed 
milk and PBS/T, and secondary 
antibody conjugated to HRP. The 
two main bands recognized for 
TAG-PRAME are indicated with 
arrows. Sera recognizing TAG-
PRAME are underlined.
(C) Peptide competition assay 
with serum V19. Whole cell 
extracts from the cell lines indi-
cated were probed with 1:1000 
dilutions of: preimmune serum 
from rabbit V19 (Preimm V19), 
V19/S5 serum, or V19/S5 serum 
(7 μl) after a 2 hours incubation 
at 37°C with 50 μg peptide 2 and 
100 μl PBS.
(D) Peptide competition with 
serum V28, as in (C). Asterisk 
indicates unrelated bands. 
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peptide competition experiment revealed that the band was not recognized 
when the V19 serum was pre-incubated with peptide 2 (Fig. 2C). Therefore, we 
conclude that the V19 and V20 sera cross-react with a 50-55 kDa protein unre-
lated to PRAME, but containing an epitope similar or identical to peptide 2.
Remarkably, V28 (but not V27) sera recognized two additional bands with 
an apparent molecular weight of 40-45 kDa (Fig. 2A-B). These bands were 
specifically recognized in 293T cells transiently transfected with pcDNA5-TAG-
PRAME or K562 cells transduced with LZRS-TAG-PRAME, but not in the control 
untransfected cells (Fig. 2D). The preimmune serum from rabbit V28 detect-
ed the same bands (Fig. 2D), indicating that the antibodies against these 
proteins were already present in the serum of rabbit V28 before the immu-
nization protocol, and were not raised by the immunization with peptide 7. 
This was confirmed by a peptide competition experiment in which V28 serum 
was pre-incubated with peptide 7 before western blot detection: as expect-
ed, detection of PRAME was inhibited, but the two lower “aspecific” bands 
were still efficiently detected (Fig. 2D).
Table 1.        Peptides used to generate PRAME antibodies and corresponding sera.
Peptide ID Peptide sequence Peptide position Rabbits ID Affinity-purified Ab
Peptide 2 NRASLYSFPEPEA 139-151 V19, V20 P1 (V19/S5)
Peptide 3 FIPVEVLVDLFL 172-183 V21, V22 P2 (V22/S5)
Peptide 4 LLLSHIHASSYIS 265-277 V23, V24 -
Peptide 5 RASATLQDLVFDE 375-387 V25, V26 -
Peptide 7 FPEPEAAQPMTKKRKVDG 146-163 V27, V28 P3 (V27/S6)
P4 (V28/S5)
Purification of anti-PRAME antibodies
The best performing sera V19/S5, V22/S5, V27/S6 and V28/S5 were 
further subjected to two different purification protocols. The first protocol 
consisted of tandem precipitations with caprilic acid and ammonium sulphate 
to deplete abundant serum proteins and enrich in immunoglobulins. Caprilic 
acid in mildly acidic conditions precipitates most serum proteins, with the 
exception of IgG molecules. The soluble antibodies are then precipitated with 
ammonium sulphate and resuspended in PBS. These IgG-enriched fractions 
were referred to as “clean sera”: V19cl, V20cl, V22cl, V27cl, V28cl. 
The second protocol was a peptide affinity purification that specifically 
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selects the antibodies that have affinity for the peptide used in the rabbit 
immunization. The peptide is first crosslinked to an insoluble agarose matrix 
to generate an affinity column, through which the serum is flowed. Antibod-
ies that recognize the peptide bind to the insoluble matrix, while unrelated 
antibodies and serum proteins flow-through. Eventually, the immobilized 
antibodies are eluted from the column with acidic glycine, which destabilizes 
the antibody-peptide interactions. The antibodies purified with this approach 
were labelled “purified antibodies”: P1 to P4 (Table 1). 
The crude sera, the flow-through fractions from the affinity column and 
the purified antibodies (P1-P4) were tested in ELISA to assess the efficiency 
of the protocol (data not shown). The results confirmed that P1 (derived from 
V19/S5 serum) and P2 (from V22/S5) were enriched in specific antibodies, 
while the flow-through fractions had little reactivity against the peptides, 
as expected for an efficient affinity purification. The purified antibodies P3 
(from V27/S6) and P4 (from V28/S5) showed also a good reactivity against 
the peptides; however, also the flow-through fractions displayed reactivity 
against peptide 7, indicating that a fraction of PRAME antibodies did not bind 
efficiently the affinity column and were still present in the flow-through. 
Cleaned sera and affinity purified antibodies were tested in western blot 
assays in the same conditions used previously for the crude sera (Figure 3). 
Taken together, our experiments established that antibodies raised 
against peptide 2 (V19, V19cl, V20, V20cl and P1) efficiently recognized TAG-
PRAME but also an unrelated protein with an apparent molecular weight 
similar to PRAME (Figures 2 and 3). Therefore, these antibodies are not 
suitable for detection of the endogenous PRAME protein, but can be used for 
detection of epitope-tagged PRAME.
Similarly, sera V22 and V22cl reproducibly detected TAG-PRAME and an 
additional band of about 40-45 kDa. This band was less prominent in western 
blots with the purified antibody P2, where an aspecific band running just 
above TAG-PRAME was identified (Figure 3B). 
Sera V23, V24, V25, V26 performed poorly in all experiments and did not 
react against TAG-PRAME in western blots (Figure 2). 
All antibodies raised against peptide 7 (V27, V27cl, V28, V28cl, P3 and 
P4) displayed a very strong reactivity against PRAME (Figures 2 and 3). A 
band of 55 kDa was detected with lower intensity as compared to TAG-
PRAME in transfected 293T cells but not in untransfected cells: this bands 
most likely represents untagged PRAME expressed from the transiently 
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Figure 3
Validation of cleaned sera 
and affinity-purified antibod-
ies in western blot assays.
(A) Western blot with cleaned 
sera on whole cell extracts from 
HEK293T cells (C) and HEK293T 
cells transiently transfected with 
pcDNA5-TAG-PRAME (PR).
(B) Western blot with affini-
ty-purified antibodies P1 and P2 
on whole cell protein extracts 
from the cell lines indicated.
(C) Western blot with affini-
ty-purified antibodies P3 and P4 
on whole cell protein xtracts 
from the cell lines indicated. 
Epitope-tagged a d endogenous 
PRAME are indicated.
(D) Western blot on nuclear 
protein extracts separated on a 
4-12% Novex gradient gel. An 
unrelated protein detected by 
P4 antibody is indicated with an 
asterisk. 
(E) Nuclear and cytoplasmic ex-
tracts from K562 cells show that 
the unrelated band detected by 
the P4 antibody is mainly pres-
ent in the nuclear fraction. 
(F-G) Whole cell protein extracts 
were probed with V27/S6 serum 
or Abcam PRAME antibody in 
parallel. The asterisk indicates 
an unrelated protein detected by 
Abcam antibody.
137
transfected plasmid, since the starting ATG codon of PRAME was still present 
in the pcDNA5-TAG-PRAME construct. 
The P3 and P4 purified antibodies performed very well with whole cell 
extracts of several cell lines: a single band at the expected molecular weight 
of PRAME was identified in K562 and FM6 melanoma cells, which express 
endogenous gene, while no band was detected in the PRAME-negative 293T 
cells (Figure 3C). Subsequent experiments, however, revealed that the P4 
antibody recognized also an unrelated protein with the same apparent mo-
lecular weight of TAG-PRAME in nuclear extracts of K562 cells. This unrelated 
protein was less evident in whole cell extracts (Fig. 3C), cytoplasmic extracts 
(Fig. 3E), and chromatin fraction (Fig. 7B).
During the course of our study, a commercial antibody became available 
against human PRAME (ab32185, Abcam). Western blot experiments revealed 
that this antibody could recognize epitope-tagged PRAME (Figure 3F-G). 
However, this antibody displayed a significant cross-reactivity with a protein 
of similar molecular weight as PRAME in all cell lines tested. Therefore, an-
tibody ab32185 (Abcam) could not be used for detection of the endogenous 
PRAME protein, although this antibody has been used in recent publications 
(De Carvalho et al, 2011; Partheen et al, 2009; Quintarelli et al, 2008; Parth-
een et al, 2008; Passeron et al, 2009).
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Figure 4
Validation of P4 antibody spec-
ificity with PRAME knockdown 
cells.
(A) The target sites of knockdown 
constructs pRS-P1 and pRS-P2 are 
indicated on the coding sequence of 
human PRAME.
(B) Western blot on the cell lines 
indicated. HeLaS3-TAG-PRAME cl.3 
and K562-TAG-PRAME cl.12 lines were 
transduced with the pRS knockdown 
constructs indicated.
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PRAME knockdown
The specificity of the affinity purified P4 antibody was further tested 
upon knockdown of PRAME. For this purpose, stable cell lines were made 
using two independent retroviral pRetroSuper constructs targeting PRAME: 
pRS-PRAME1 and pRS-PRAME2 (further indicated as pRS-P1 and pRS-P2; Fig-
ure 4). Double-stable cell lines were made by transduction of zeocin-resistant 
K562-TAG-PRAME cl.12 and HeLaS3-TAG-PRAME cl.3 with pRS-P1 or pRS-P2 
retroviral particles and selection of polyclonal cell populations with puromy-
cin. Western blot analysis with HA antibody established that both knockdown 
constructs efficiently silenced TAG-PRAME (Figure 4). As expected, the 55 kDa 
band recognized by P4 antibody was also downregulated, demonstrating that 
this band corresponds to the endogenous PRAME protein. The same experi-
ment showed that PRAME is not detectable in HeLaS3 wild type cells in these 
conditions, which is consistent with cDNA gene expression analyses (Chapter 
2, Figure 2D).
PRAME antibodies in immunoprecipitation assays
Finally, PRAME antibodies were tested in immunoprecipitation assays us-
ing nuclear extracts of K562-TAG-PRAME cells (Figure 5). Immunoprecipitation 
without antibodies, or with rabbit HA antibodies (Abcam) were performed 
as negative and positive controls, respectively. Supernatant and IP fractions 
were analyzed by western blotting with mouse HA.Y11 antibody. The results 
s/nInput
1 2 3 4 5 6 7 8 9 10 11 12 13 14
No Ab HA P2 P4 V19cl V27cl
IP s/n IP s/nInput IP s/n IP s/n IP s/n IP
WB: HA / mouse k-specific
WB: P4 / rabbit k-specific (after HA)
TAG-PRAME
PRAME / Ab heavy chains
TAG-PRAME / unrelated protein
Figure 5
Figure 5
Validation of PRAME antibodies 
in immunoprecipitation assays.
Immunoprecipitation experiments 
on nuclear extracts from K562-TAG-
PRAME cl.12 cells. The following 
antibodies were used: HA Abcam 
(1 μl), P2 (8 μl), P4 (5 μl), V19cl 
(5 μl), V27cl (5 μl). Equivalent 
amounts (18%) of nuclear extract 
(input), supernatant after IP, and 
IP fractions (beads boiled after IP) 
were separated by SDS-PAGE and 
probed with HA.Y11 antibody and 
secondary antibody specific for 
mouse k chains. Next, the same 
membranes were probed with 
P4 antibody using a secondary 
antibody specific for rabbit k chains.
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show that P4, V19cl and V27cl antibodies successfully immunoprecipitated 
TAG-PRAME, while P2 purified antibody did not work in this assay. Moreover, 
also the endogenous PRAME protein was efficiently immunoprecipitated by 
V27cl, since it was depleted from the supernatant (Figure 5, lane 13). Nota-
bly, the immunoprecipitated endogenous PRAME protein is difficult to visu-
alize in the IP fractions, since it runs at the same height as the heavy chains 
of the antibodies that are highly abundant in such fractions. Taken together, 
our results established that PRAME antibodies raised against peptide 2 and 7 
performed efficiently also in immunoprecipitation assays.
PRAME association to chromatin
PRAME was recently reported to associate with the retinoic acid receptor 
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- Antibody concentration
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- …
-
-
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Confirm specificity:
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Figure 6
Experimental strategy 
to generate ChIP-seq 
binding profiles for a 
factor of interest.
The scheme presents a 
general strategy to obtain 
a genome-wide binding 
profile and the validation 
experiments required 
(modified from Brinkman & 
Stunnenberg, 2009).
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alpha (RARA) and the polycomb protein EZH2, and to mediate repression of 
transcription of RARA target genes (Epping et al, 2005). However, PRAME 
binding to chromatin was reported only for the RARB promoter in the reti-
noic-acid responsive A375 melanoma cell line (Epping et al, 2005). Notably, 
the K562 cell line was reported to be unresponsive to retinoic acid treatment 
because of low endogenous expression of retinoic acid receptors (Robertson 
et al, 1991). Evidence for the association of PRAME with chromatin can be 
obtained using ChIP and ChIP-seq, though a major hurdle is the absence of 
validated ChIP-grade antibodies against PRAME.
A general approach to obtain a genome-wide binding profile for a factor 
of interest is illustrated by the decision tree of Figure 6 (Brinkman & Stunnen-
berg, 2009). First of all, an appropriate cell system needs to be selected, which 
involves testing expression of the factor of interest and establishing its asso-
ciation with chromatin. If antibodies and (putative) target sites are available, 
these can be tested in ChIP-qPCR assays. If a signal is obtained by ChIP-qPCR, 
this can be further improved by optimizing the antibody concentration, the 
buffers used, crosslinking and sonication conditions. Subsequently, the specific-
ity of the signals can be validated by using antibodies raised against different 
epitopes of the protein, knock-out or knockdown systems, or epitope-tagged 
versions of the protein of interest. When these steps are completed, it is possi-
ble to proceed with a genome-wide profiling experiment.
If no signal is obtained in an exploratory ChIP-qPCR assay, either the 
antibody used is not ChIP-grade, or the presumed genomic sites investigat-
ed are not bound by the protein of interest. The ChIP-grade properties of 
the antibody can be tested performing an immunoprecipitation assay on 
crosslinked chromatin followed by western blot, or preferably on crosslinked 
chromatin purified by caesium chloride density centrifugation, which sepa-
rates free soluble proteins and nucleic acids from the sample, and enriches in 
chromatin-associated proteins. If the target protein can be IP’ed, the antibody 
is likely ChIP-grade and a “blind” ChIP-seq experiment can be performed. If 
putative binding sites are discovered, these can be used in ChIP-qPCR exper-
iments to optimize the assay conditions before performing a new profiling 
experiment.
If the antibody does not IP the protein of interest, the antibody is not 
ChIP-grade and alternative approaches can be undertaken, i.e. raising new 
(ChIP-grade) antibodies, or applying epitope tagging in stable cells lines with 
retroviral expression systems or BAC transgenics.
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In our study, we first investigated the association of PRAME to chromatin 
in the K562 cell line. We prepared formaldehyde-crosslinked chromatin from 
K562 wild type and K562-TAG-PRAME cells and fractionated it on a CsCl
2
 den-
sity gradient by ultracentrifugation. This technique separates the free soluble 
proteins from the chromatin-associated proteins based on their different 
densities. Five different fractions were collected as indicated in Figure 7A 
and analyzed by agarose gel electrophoresis and western blot. Agarose gel 
electrophoresis confirmed that chromatin was enriched in fractions 3 and 4, 
as indicated by the intense staining present in the wells, which represents 
crosslinked chromatin that cannot enter the gel matrix (Fig. 7A). As expect-
ed, western blotting showed that the core histone H3 was also enriched in 
these fractions (Fig. 7B). TAG-PRAME and endogenous PRAME were present 
in the free-protein fraction (fraction 1), but they were also detected in the 
chromatin fractions, consistent with their association with chromatin in vivo 
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Figure 7
PRAME associates to chroma-
tin in vivo.
(A) Left, photograph under UV 
light of crosslinked chromatin 
from K562 cells after CsCl
2
 gra-
dient centrifugation in the pres-
ence of EtBr. Right, the fractions 
collected (1-5) for K562 wild 
type and K562-TAG-PRAME cl.12 
were analyzed by electrophore-
sis on 1% agarose gel to assess 
their nucleic acid content.
(B) Western blot analysis of the 
CsCl
2
 fractions analyzed in (A).
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(Fig. 10B). Consistent with previous western blot results, a protein unrelated 
to PRAME with a higher apparent molecular size was recognized by the P4 
antibody in the nuclear extracts. Importantly, this protein was not detected 
in the input or fractionated chromatin fractions, suggesting that the use of 
V27/P4 antibodies for ChIP assays should not result in cross-reactivity with 
proteins other than PRAME (Costessi et al, 2011).
In the absence of validated binding sites for PRAME in the K562 cell line, 
we setup an epitope-tagging approach to identify PRAME binding sites in 
an unbiased way. For this purpose, we established K562 stable cell lines ex-
pressing PRAME fused to a composite N-terminal TTE tag, including two TY1 
epitopes and one ERalpha epitope, against which efficient ChIP-grade mono-
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Figure 8
The TTE (TY1-TY1-ER) 
epitope tag.
(A) Map of the pTTE plas-
mid, and coding sequence 
of the TY1 and ER epitope 
tags in orange and blue, 
respectively.
(B) Western blot on K562 
stable cell lines carrying 
the pTTE empty vector 
(negative control) or the 
pTTE-PRAME expression 
vector.
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clonal antibodies are available: BB2 and F3A6, respectively (Fig. 8A). Ex-
pression of TTE-PRAME was tested by western blot in the polyclonal cell line 
K562-TTE-PRAME and the control cell line K562-TTE carrying the empty vector 
(Fig. 8B). Next, we performed an exploratory ChIP-seq experiment using the 
BB2 antibody (against the TY1 tag) and chromatin from K562-TTE control and 
K562-TTE-PRAME cells. Sequencing was performed on a Solexa GAIIx with a 
single-read protocol for 36 cycles and generated 4 059 488 reads for the TTE 
control and 3 615 534 reads for TTE-PRAME after alignment to the human 
hg18 reference genome. Reads numbers were normalized to the lowest 
number and average profiles were visualized in the UCSC genome browser. 
Manual inspection of these profiles revealed a number of loci with specific 
enrichment of sequence tags for TTE-PRAME (Figure 9). ChIP-qPCR assays 
were performed with primer sets targeting these putative binding sites, and 
the assay conditions were optimized to improve the signal-over-background 
ratio. The results confirmed that the sites tested are bona fide binding sites 
for TTE-PRAME (see chapter 3).
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Figure 9
Genome-wide profiling of 
TTE-PRAME and endogenous 
PRAME association with 
chromatin.
UCSC genome browser views of 
ChIP-seq profiles generated with 
preimmune serum (negative con-
trol), PRAME V27 serum on K562 
wild type cells, BB2 antibodies 
on K562-TTE control cells (TTE) 
and K562-TTE-PRAME cells (TTE-
PRAME). Specific peaks identified 
at the promoters of the MED15, 
EIF2AK3, DSTYK (previously 
known as RIPK5), and TRIM63 
genes are shown.
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We then performed ChIP-qPCR experiments using our PRAME antibodies 
and chromatin from K562 wild type cells. As shown in chapter 3 (Supple-
mentary Figure 1), the V27cl serum gave good recoveries, indicating that it is 
ChIP-grade and establishing that also the endogenous PRAME protein binds 
to the genomic loci tested.
Based on these results, we performed a ChIP-seq profiling on K562 wild 
type cells using the PRAME antibody V27, or the preimmune serum from the 
same rabbit as negative control. We obtained 3 101 777 sequence reads for 
PRAME and 2 815 020 sequence reads for the preimmune serum. Screen-
shots in Figure 9 show genomic regions bound by both TTE-PRAME as well as 
endogenous PRAME.
Next, we used the MACS algorithm (Zhang et al, 2008) to identify bind-
ing sites for TTE-PRAME and PRAME using their corresponding control tracks 
as negative controls. We iterated the peak calling with different stringency 
settings: the “e-value” was set to 5, 6, or 7, where 5 corresponds to relaxed 
settings (that can result in a higher false-positives rate), while an e-value 
of 7 corresponds to more stringent settings. Table 2 shows that significantly 
more peaks were called for the endogenous PRAME than for TTE-PRAME. 
Table 2.          Number and overlap of binding sites identified for TTE-PRAME and endogenous PRAME.
e-value
TTE-PRAME 
peaks
PRAME 
peaks
Overlap TTE-PRAME 
with PRAME peaks
e-5 (m16) 7517 24611 41% (3084)
e-6 (m16) 2467 14153 56% (1380)
e-7 (m16) 1142 9228 63% (579)
This is consistent with the lower recoveries obtained for TTE-PRAME in 
ChIP-qPCR experiments and a higher signal-to-noise ratio for the PRAME serum 
than the BB2 antibody. We next calculated the overlap between binding sites 
identified for TTE-PRAME and endogenous PRAME. Notably, the percentage 
of overlapping peaks was dependent on the stringency applied to the peak 
calling: the overlap was 41% for e5 peaks, 56% for e6 peaks, and 63% for e7 
peaks. This suggests that low e-values (low stringency) result in larger pools of 
putative binding sites, likely containing a higher percentage of false positives, 
while higher e-values (high stringency) result in the identification of smaller 
numbers of high-confidence peaks, although binding sites might be missed.
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Take together, our data demonstrate that the oncoprotein PRAME is 
a chromatin-associated factor, we validated an epitope-tagging approach 
as well as a PRAME antibody for ChIP-seq analyses and generated the first 
genome-wide profile of PRAME association to chromatin.
PRAME and retinoic acid signaling
Recent work indicated that overexpression of PRAME prevents the 
growth arrest and apoptosis induced by histone deacetylase inhibitors (HDACIs) 
(Epping et al, 2007). The authors proposed a model in which HDACI-induced 
growth arrest requires an active retinoic acid signaling pathway, which 
PRAME would repress via direct protein-protein interactions with the retinoic 
acid receptor alpha (RARalpha), recruitment of the EZH2 polycomb protein 
and eventual transcriptional repression of RARalpha target genes (Epping et 
al, 2005). 
In support of their model, the authors reported that knockdown of 
PRAME in A375 melanoma cells caused downregulation of the retinoic acid 
receptor alpha (RARa) at the protein level (Epping et al, 2005, Figure 6F), 
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Figure 10
Cell proliferation assays upon 
PRAME knock-down.
(A) Growth curve of A375 cell 
lines upon treatment with 
1μM atRA or vehicle (ethanol). 
A375-pRS-P1 and A375-pRS-P2 
cells were kept under puromycin 
selection.
(B) Cumulative cell numbers at the 
end of the growth assay (day 19). 
(C) Gene expression analysis of 
PRAME in A375 cell lines used 
for the growth assay (wild type, 
pRS-P1and pRS-P2), two single 
cell clones derived from the A375-
pRS-P1 polyclonal population, 
and double-stable for pRS-P1 and 
LZRS control vector. Expression 
was measured in triplicate and 
normalized to a pool of 3 control 
genes (AU, arbitrary units).
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which was interpreted as a sign of derepression of retinoic acid signaling. 
Remarkably, the same experiment presented in a follow-up publication 
showed no difference in RARalpha levels upon PRAME knockdown (Epping et 
al, 2007, Figure 4E). Although the authors did not comment on this differ-
ence, this discrepancy raises doubts about the reproducibility of the reported 
RARalpha-PRAME interplay. 
Further, the authors reported that knockdown of PRAME sensitized A375 
cells to the growth inhibiting effects of retinoic acid treatment (Epping et al, 
2005). Importantly, complementation of the cells with a knockdown-resistant 
version of PRAME was shown to re-establish a normal growth curve, indi-
cating that expression of PRAME confers resistance to retinoic acid-induced 
growth arrest. 
We have recently characterized PRAME as a component of Cullin2-based 
E3 ubiquitin ligases (see chapter 3 and Costessi et al, 2011). In order to 
confirm whether PRAME can act as a repressor of the retinoic acid signaling 
as reported, we performed growth assays upon downregulation of PRAME in 
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Figure 11
Cell proliferation assays and 
knockdown-resistant PRAME.
(A) Growth curve of A375-pRS-P1 
polyclonal cells further trans-
duced with LZRS control vector, 
LZRS-TAG-PRAME_WT_KDR, or 
LZRS-TAG-PRAME_M2_KDR. Cells 
were treated with 1μM atRA or 
vehicle (ethanol), and data are 
averages of two independent 
plates.
(B) Cumulative cell numbers at 
the end of the growth assay 
(day 15). 
(C) Gene expression analysis of 
PRAME in A375 double-stable cell 
lines. Expression was measured 
in triplicate and normalized to 
a pool of 3 control genes (AU, 
arbitrary units).
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the presence or absence of retinoic acid.
First, we generated A375 stable knockdown cell lines by retroviral 
transduction using two different silencing constructs, pRS-P1 and pRS-P2 
and compared them to wild type untransduced cells. Construct pRS-P1 
was the one used in the publication of Epping et al. (Epping et al, 2005), 
while pRS-P2 is an independent construct targeting a region of the PRAME 
transcript partially overlapping with the region targeted by pRS-P1 (Figure 
4). Cells were treated with a final concentration of 1 µM all-trans retinoic 
acid (atRA) or the equal volume of vehicle (ethanol), and knockdown cells 
were kept under puromycin selection during the course of the experiment. 
Cumulative cell numbers reported in Figure 10A-B reflect a growth inhibition 
on A375-pRS-P1 cells upon retinoic acid treatment. On the contrary, A375-
pRS-P2 cells were only slightly affected as compared to the wild type control 
cells, even though PRAME was downregulated to similar levels by both 
silencing constructs (Figure 10C).
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Figure 12
Cell proliferation assays 
upon PRAME knock-
down and control 
vectors.
(A) Growth curve of A375 
stable cell lines upon 
treatment with 1μM atRA 
or vehicle (ethanol).
(B) Cumulative cell 
numbers at the end of the 
growth assay (day 21). 
(C) Gene expression anal-
ysis of PRAME in A375 cell 
lines used for the growth 
assay. Expression was 
measured in triplicate and 
normalized to a pool of 3 
control genes (AU, arbitrary 
units).
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Next, we generated wild type and BC-box mutant versions of PRAME 
that are resistant to knockdown (KDR) in order to test if ectopic re-expres-
sion of PRAME could rescue the growth phenotype, as previously reported 
(Epping et al, 2005, Supplementary Figure 3). For this purpose, we used the 
LZRS retroviral system to express either wild type or the M2 BC-box mutant 
TAG-PRAME in A375-pRS-P1, and the empty LZRS vector was used as nega-
tive control. Unexpectedly, a growth assay on these cell lines revealed that 
complementation of A375-pRS-P1 cells with wild type PRAME did not rescue 
their growth phenotype, in disagreement with the published data (Figure 
11A-B). Expression of TAG-PRAME_KDR was confirmed by cDNA expression 
analysis (Figure 11C).
Given this discrepancy, we setup an independent knockdown experiment 
in which two control lines were also included using the empty pRS vector and 
the pRS-GFP vector expressing a silencing hairpin against GFP. New PRAME 
knockdown cell lines were generated at the same time with pRS-P1 and 
pRS-P2 vectors. Growth curves of these lines are reported in Figure 12A-B. 
First, cells carrying the empty vector grew better than the cells ex-
pressing the GFP control hairpin. This result is consistent with reports that 
overexpression of silencing hairpins can overload the silencing machinery 
and therefore lead to growth defects and cell mortality in vitro and in vivo, 
independent from the downregulation of specific target genes (Grimm et 
al, 2006). This result further underscores the critical importance of proper 
controls for knockdown experiments.
Second, no significant difference was found between A375-pRS-GFP 
control and A375-pRS-P2 knockdown cells, while A375-pRS-P1 cells were 
clearly affected: almost no A375-pRS-P1 cells survived after three weeks of 
treatment with retinoic acid, consistent with the first experiment. Untreated 
A375-pRS-P1 cells displayed a slower growth rate than other cell lines and 
this might be caused by an increased sensitivity to the low levels of retinoic 
acid present in the medium used. 
In order to investigate the lack of phenotype in A375-pRS-P2 lines, we 
measured PRAME expression levels during the course of the experiment (day 
17). The results displayed in Figure 12C established that both pRS-P1 and 
pRS-P2 vectors lead to a significant and similar downregulation of PRAME. 
Therefore, the lack of phenotype for A375-pRS-P2 cells could not be ex-
plained by inefficient knockdown of PRAME by this vector as compared to 
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pRS-P1; atRA-treated A375-pRS-P1 cells could not be tested because too few 
cells were present in the plates.
Taken together, independent experiments with polyclonal cell popula-
tions consistently showed that vector pRS-P1 caused a severe growth phe-
notype in A375 melanoma cells exposed to 1 µM retinoic acid. However, the 
pRS-P2 vector did not affect cell growth compared to the pRS-GFP control, 
even though it silenced PRAME expression with equal efficiency as pRS-P1 
(~80%). 
Moreover, complementation of A375-pRS-P1 cells with knockdown-re-
sistant TAG-PRAME did not alleviate the growth phenotype. Formally, we 
cannot exclude that overexpression of TAG-PRAME_KDR and the epitope tag 
used might have prevented an efficient rescue of the growth phenotype. 
However, this epitope tag has been successfully used for the purification of 
native PRAME-containing protein complexes, showing that this tag does not 
alter the protein structure of PRAME or its ability to establish protein-protein 
interactions. 
In contrast to the report of Epping et al., our data suggest that the growth 
phenotype induced by the pRS-P1 silencing vector is highly unlikely caused 
by down-regulation of PRAME, but rather by down-regulation of an unrelated 
gene which is specifically targeted by construct pRS-P1, but not by pRS-P2.
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CONCLUSIONS
In this chapter, we described the development of antibodies against 
the human oncoprotein PRAME, we tested the reported interplay between 
PRAME and the retinoic acid signaling using knockdown systems, we es-
tablished the in vivo chromatin association of PRAME and reported the first 
genome-wide ChIP profiling of PRAME.
We immunized a total of ten rabbits against five different peptides 
designed in regions of human PRAME with low sequence similarity to other 
annotated or predicted PRAME-like proteins (Figure 1 and Table 1). Sera and 
affinity-purified antibodies were extensively tested in dot blot, western blot, 
immunoprecipitation and ChIP assays and a number of them were character-
ized by high sensitivity and specificity (Figures 2-5). Taken together, our data 
indicate that antibodies raised against peptide 2 (V19, V20, P1) and peptide 
3 (V22, P2) can be efficiently used to detect epitope-tagged versions of 
PRAME by western blot, but are not suited for endogenous PRAME because 
of cross-reactivity with other proteins of similar size. On the contrary, anti-
bodies raised against peptide 7 (V27, V28, P3, P4) are suitable for detection 
of both epitope-tagged as well as endogenous PRAME. Furthermore, V19, 
V27, P4 (Figure 5) and V28 (not shown) antibodies performed successfully in 
immunoprecipitations assays. Notably, our antibodies performed better than 
a commercially available PRAME antibody, which had been used in a number 
of recent publications. Our results underscore the importance of extensive 
testing of both specificity and sensitivity of antibodies.
We further discussed a general experimental strategy to generate ChIP-
seq binding profiles of a factor of interest (Figure 6), which we applied to our 
study of the PRAME oncoprotein. We established that PRAME is present in 
the crosslinked-chromatin fraction in caesium chloride gradient experiments 
(Figure 7) and we successfully applied an epitope-tagging approach with a 
double TY1 epitope to discover genomic binding sites for TTE-PRAME with 
a “blind” ChIP-seq profiling (Figure 8 and 12). Moreover, we validated the 
ChIP-profiling properties of one of our PRAME antibodies, and we generated 
the first profiles for the endogenous PRAME protein in K562 cells (Figure 9).
We investigated the reported function of PRAME as dominant repres-
sor of retinoic acid signaling. In particular, we aimed to investigate if the 
interaction of PRAME with Cullin2-based ubiquitin ligases plays in role in the 
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reported repression. We performed cell proliferation assays in the presence 
of all trans retinoic acid (atRA) on A375 melanoma cells, similarly to recent 
studies from the Bernards lab (Epping et al, 2005). While published work in-
cluded only one silencing vector, we used two different knockdown plasmids 
in our experiments (pRS-P1 and pRS-P2). Notably, the regions of the PRAME 
transcript which are targeted by the two silencing plasmids showed a signifi-
cant overlap (Figure 4) and both constructs resulted in ~80% downregulation 
of PRAME transcript (Figures 4B, 6-8). 
Unexpectedly, several independent experiments reproduced the report-
ed growth phenotype only in A375-pRS-P1 cells, but not in A375-pRS-P2 cells 
(Figure 10 and 12). Moreover, complementation with a knockdown-resistant 
PRAME did not rescue the growth phenotype of A375-pRS-P1 cells in our 
assays (Figure 11), although a rescue was previously reported (Epping et 
al, 2005). Since wild type PRAME did not rescue the growth phenotype, we 
could not investigate the potential role of a BC-box mutant PRAME in this 
assay. Taken together, our data suggest that the growth phenotype induced 
by the pRS-P1 silencing vector might not be caused by down-regulation of 
PRAME, but rather by down-regulation of an unrelated transcript which is 
specifically targeted by construct pRS-P1, but not by pRS-P2. A genome-wide 
mRNA-seq profiling experiment on these cell lines could potentially identify 
this gene and shed light on the reported growth phenotype.
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MATERIALS AND METHODS
Antigen preparation and rabbit immu-
nization
PRAME peptides with a leading ATA 
group were synthesized at the Dept. 
Organic Chemistry (Radboud University) 
and checked by mass spectrometry. The 
peptides were first conjugated to KLH (Im-
ject Mariculture Keyhole Limpet Hemocy-
anin, Pierce, product #77600) according to 
standard protocols.
A total of ten rabbits (two rabbits for 
each peptide) were subjected to a first im-
munization by lymphnode injection of 200 
µg of KLH-peptide and Freund adjuvant. Ev-
ery three weeks, an immunization booster 
was performed by subcutaneous injection 
of 400 µg of KLH-peptide and Freund adju-
vant. Blood was harvested two weeks ev-
ery each immunization booster. Rabbit V21 
died prematurely during the experiment 
before the fifth serum harvest. The rabbits 
were subjected to 8 cycles of booster 
immunization and blood collection, except 
rabbits V19, V22, V27, and V28 which were 
subjected to a total of 10 cycles.
Antibody purification with caprilic acid/
ammonium sulphate precipitation
4 ml of rabbit sera were mixed with 2 
volumes (8 ml) of 60 mM sodium acetate 
buffer pH 4.0 (for 250 ml of buffer: 1,23 
g/l sodium acetate trihydrate, 3,06 g/l 
acetic acid). The pH was adjusted to 4,8, 
if necessary, and 300 µl caprilic acid were 
added drop-wise. The solution was incu-
bated for 30 minutes on a rotating wheel 
at room temperature, and centrifuged for 
20 minutes at 5000 g, 10 °C. This step pre-
cipitates abundant serum proteins, while 
IgG molecules remain soluble. The top 
lipid layer and pellet were discarded, the 
supernatant carefully decanted (~11-12 ml) 
and 150-200 µl Tris 2M (pH 11) was added 
to neutralize the acidic pH. A half volume 
(5,5-6 ml) of saturate ammonium sulphate 
pH 7,0-7,2 (132 g in 250 ml water) was 
added slowly to the supernatant, and the 
solution was incubated for 4 h in rotation 
at 4 °C. This pre-precipitation step removes 
large protein aggregates and any proteins 
that may precipitate with low concentra-
tions of ammonium sulphate. After 30 
minutes centrifugation at 3000 g at 4 °C, 
the supernatant was carefully transferred 
to a new tube, and enough ammonium 
sulphate (5,5-6 ml) was added slowly to 
obtain a 50% ammonium sulphate satura-
tion. This step precipitates IgG molecules. 
The solution was incubated in rotation 
overnight at 4 °C, and centrifuged for 30 
minutes, 3000 g, 4 °C. The pellet contain-
ing IgG was resuspended with 0,8-1 ml PBS 
and dialyzed versus three changes of PBS 
overnight. On average, the final antibody 
solution doubles its volume after dialysis. 
Dialysis tubing was prepared by boiling 
twice for 5 min in 5 mM EDTA, 200 mM 
sodium bicarbonate, and eventually rinsed 
in sterile water.
Peptide affinity purification of antibod-
ies
An affinity column was prepared by 
covalent binding of the peptides used in 
the immunization protocol to the agarose 
matrix SulfoLink (#2040, Pierce). Crude sera 
were then passed through the columns, 
so that peptide-binding IgG bind to the 
matrix. After several washes, the IgG were 
eluted with100 mM glycine pH 2,7. Next, 
a gel filtration step (G25, Hightrap, Acta, 
GE Healthcare) was performed to remove 
glycine from the eluates and exchange the 
buffer for PBS (NaCl 0,14 M, KCl 0,0027 M, 
KH
2
PO
4
 0,001 M, Na
2
HPO
4
 0,01 M) pH 7,4 
containing NaN
3
 0,05% w/v and ProClin300 
0,05% w/v. The crude sera, flow-through 
from the affinity column (unbound antibod-
ies) and the purified antibodies were tested 
by ELISA (see Supplementary Materials). 
Western blot
Proteins were separated by conven-
tional SDS-PAGE or NuPAGE 4-12% BisTris 
gels (Invitrogen) run with MES buffer. After 
blotting, protein transfer was checked by 
staining of the membranes with Ponceau 
S. The PRAME sera were diluted 1:1000 in 
standard PBS/T with 5% skimmed milk, 
and incubated for 1 hour at room tempera-
ture. Western blots were visualized by ECL 
(GE Healthcare).
Cell culture, stable cell lines and growth 
assays
Stable cell lines were generated as de-
scribed (Costessi et al, 2011). The pRetroSu-
per plasmid carries a Puromycin resistance 
gene, while LZRS carries zeocin resistance. 
For cell proliferation assays, between 
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300 000 and 900 000 A375 cells were 
seeded in 9 cm tissue culture dishes. Cells 
were passages every 2-3 days, when at 
least one plate reached ~70% confluence 
and cell densities measured (Beckman 
Coulter). Cells were detached with 1 ml 
0,5% Trypsin-EDTA (GIBCO), incubated 5 
min at 37°C and 3 ml medium were added 
(10% FCS, 1% PenStrep cocktail, DMEM 
1640 with GlutaMAX-I, GIBCO). All plates 
were diluted with the same factor, so that 
the fastest growing cells would be con-
fluent after 2-3 days. Either 1 µM atRA or 
the same volume of ethanol 96% (vehicle) 
was added to the medium when cells were 
split. Stable cell lines carrying pRS vectors 
were kept on puromycin selection (2 µg 
puromycin/ml medium).
Chromatin isolation CsCl
2
 gradient
Chromatin was isolated from 150 
million K562 and K562-TAG-PRAME cl.12 
cells essentially as described (Costessi et 
al, 2011) with the following modifications: 
cells were crosslinked for 30 min in 40 ml 
volume and sonicated in 2 ml buffer D 
without SDS (1mM EDTA, 0,5 mM EGTA, 20 
mM HEPES and protease inhibitors) for 15 
min, because SDS is not compatible with 
caesium chloride gradient sedimentation. 
Next, 2 ml of chromatin were mixed with 
1,25 g CsCl
2
 (final concentration 568 mg 
CsCl
2
/ml), 70 µl sarcosyl 15% and 1-2 µl 
EtBr, and centrifuged at 260 000 g for 48 
h or overweekend. Samples from different 
layers were collected and dialysed o/n 
against buffer D with 5% glycerol. 
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CHAPTER 6
DISCUS-
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In this thesis, we explored the molecular function(s) of the human 
oncoprotein PRAME using an innovative combination of biochemical pro-
tein-complex purification techniques and next-generation sequencing. 
We dissected the protein-protein interaction network of PRAME applying 
epitope-tagging and retroviral transduction in cell lines (chapter 2). Mass 
spectrometry analysis provided the first unbiased list of PRAME interactors, 
including all subunits of Cullin2-based ubiquitin ligases (chapter 2). These 
interactions were further characterised in chapter 3, where we identified 
PRAME as a BC-box protein and substrate receptor component of Cul-
lin2-based ubiquitin ligases. This data associated for the first time a defined 
biochemical activity to the PRAME oncoprotein. Furthermore, we used 
specific antibodies and ChIP-sequencing techniques to generate the first 
genome-wide profiling of PRAME interactions with chromatin. We discovered 
that PRAME is specifically recruited to transcriptionally and epigenetically 
active promoter regions bound by NFY and nearby enhancers, implicating 
PRAME in the NFY signaling pathway. Optimisation of the protein affinity 
purification protocols and a complex walking approach allowed us to identify 
and characterise the human EKC/KEOPS complex and its interactions with 
Cul2-PRAME ligases (chapter 4). In chapter 5, we described the development 
and validation of PRAME antibodies that have been a crucial tool for our 
study, and we discussed in detail the strategy we undertook to generate the 
genome-wide ChIP-seq profiles presented in chapter 3. Finally, we reported 
the results of cell proliferation assays that do not support the previously 
reported function of PRAME as dominant repressor of retinoic acid signaling 
(chapter 5). 
 The results presented in this thesis are discussed in more detail in 
this chapter together with an outlook on the future perspectives of this field 
of research.
Epitope-tagging technology and dissection of protein 
complexes
During the past two decades, epitope tagging has become an indispens-
able technology in many fields of research, including biochemistry, cellular 
and molecular biology, and biotechnology. Affinity fusion tags have been 
used as research tools for detection, purification, and immobilisation of 
recombinant proteins expressed in bacteria, yeast, insect cells, plants, and 
mammalian cells (Nilsson et al, 1997). We applied this technology to purify 
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PRAME-containing protein complexes and identify its protein interactors by 
mass spectrometry analysis. In chapter 2, we described our approach based 
on the LZRS retroviral expression system and the StrepII-TEV-MYC-3xHA com-
posite epitope tag that we used throughout our study. We setup a single-step 
immunoprecipitation protocol to purify PRAME-containing protein complexes 
using crosslinked MYC antibodies and peptide elution (chapters 2 and 3). The 
yield of the protein-complex purifications were further increased by the use 
of crosslinked HA antibodies and acidic glycine elution (chapter 4). Nota-
bly, this improvement of the protocol allowed us to significantly reduce the 
amount of cells and protein extracts needed for one purification experiment, 
and we could scale down from about 10 liters of cell culture (~10^10 cells) to 
about 3 liters (~3x10^9 cells) for each purification experiment.
Taken together, our mass spectrometry data combined with biochemical 
experiments characterized PRAME as a BC-box protein and component of 
Cullin2-based E3 ubiquitin ligases. The interactions between PRAME and the 
Cullin complex are mediated by conserved amino acid motifs (the so-called 
“BC-box” and “Cul2-box”) at the N-terminus of PRAME. In vitro experiments 
with purified recombinant proteins further established that a reconstituted 
Cullin2–PRAME complex is a catalytically active ubiquitin ligase. Moreover, 
we discovered that PRAME bridges Cul2 ligases to EKC via direct interactions 
between PRAME and the OSGEP and LAGE3 subunits, supporting a functional 
link between these complexes (chapter 4).
Cullin-based ubiquitin ligases
Cullin complexes (also referred to as cullin-RING ligases, CRL) are 
multi-subunit enzymes and constitute the largest known class of ubiquitin 
ligases (Petroski & Deshaies, 2005; Lipkowitz & Weissman, 2011; Okumura et 
al, 2012). Owing to the different cullin proteins expressed in human cells and 
the great diversity of their substrate-receptor subunits, hundreds of distinct 
cullin-based E3 ubiquitin ligases are thought to exist, which establishes these 
enzymes as key mediators of post-translational protein regulation (Petroski 
& Deshaies, 2005). CRLs have been implicated in a wide range of cellular 
processes, including cell cycle regulation, DNA replication, gene transcription, 
and development. Moreover, substrate receptor subunits of these ligases are 
targeted by viral and bacterial pathogens to subvert normal cellular pro-
cesses. Although most target proteins that bind to CRL substrate receptors 
are ubiquitinated as a prelude to degradation, proteolysis is not the only 
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outcome, and ubiquitination can also lead to post-translational regulation 
without alteration of protein levels (Petroski & Deshaies, 2005).
All CRLs share a similar modular architecture with a central cullin protein 
of elongated shape. The cullin N-terminus binds the substrate-selector 
module, while the C-terminus interacts with a RING box protein (Petroski & 
Deshaies, 2005). The N-terminal domain of Cullin2 interacts with the het-
erodimer ElonginB-ElonginC to bind a BC-box protein, which in turn recruits 
the ubiquitination substrate to the ligase (Okumura et al, 2012). The Von 
Hippel-Lindau tumour suppressor (VHL) is one of the most well-studied BC-
box proteins and mutations in its coding sequence lead to renal carcinomas 
because of deregulation of the hypoxia-inducible factor-1α (HIF1α) transcrip-
tion factor (Okumura et al, 2012). In standard normoxic conditions HIF1α is 
hydroxylated, which creates a binding site for VHL and subsequent ubiquiti-
nation by a Cul2-VHL ubiquitin ligase and degradation by the proteasome. 
In hypoxic conditions, however, HIF1α is not hydroxylated and cannot be 
recognised by the Cul2-VHL ligase, resulting in increased protein levels and 
upregulation of genes mediating adaptation to low oxygen tension, includ-
ing factors stimulating the formation of new blood vessels. Loss-of-function 
mutations of VHL result in constitutive higher levels of HIF1α and aberrant 
activation of its target genes, contributing to angiogenesis and tumour de-
velopment (Okumura et al, 2012).
Identification of the substrate(s) of Cul2-PRAME ubiquitin ligases consti-
tutes a crucial step in elucidating the detailed molecular mechanisms and 
pathways of this so-far elusive oncoprotein and should be the priority of fol-
low-up studies. Our mass spectrometry data indicated that the EKC complex 
is the most abundant and stable interactor of Cul2-PRAME ligases in several 
cell lines and EKC subunits are therefore potential substrates of PRAME-me-
diated ubiquitination. As expected for BC-box proteins, PRAME was itself 
ubiquitinated in our experiments, but we could not detect a PRAME-medi-
ated ubiquitination of EKC components. However, we cannot exclude that 
our negative results were caused by technical limitations of the assays used. 
Therefore, we believe that more and probably different assays should be 
developed to assess whether EKC subunits can be substrates of PRAME-medi-
ated ubiquitination.
Importantly, our present knowledge of CRLs indicates that interactions 
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between ligases and substrates are often dependent on post-translation 
modifications of the substrates like proline hydroxylation, phosphorylation, 
or glycosylation (Verma et al, 1997; Yoshida et al, 2002; Ivan et al, 2001). It is 
therefore likely that PRAME substrates are not (or at very low level) amongst 
the stable interactors identified in our mass spectrometry data, which were 
generated from cell lines cultured in standard conditions. Specific signaling 
events might be necessary to trigger the interaction between PRAME and 
its substrate(s). Moreover, it appears likely that substrates of PRAME are 
expressed in a tissue-specific manner, and this would potentially account 
for the reported tissue-specific effects of PRAME upregulation. The apparent 
discrepancies of PRAME being associated to good as well as to bad prognosis 
cancers might be explained by differential expression of PRAME targets in 
different tumour types.
Intriguingly, we found a complete conservation of the BC-box and Cul2-
box at the N-terminus of all the annotated PRAME-like proteins. This suggests 
that all members of the large PRAME protein family are likely to function 
as substrate recognition subunits of cullin-based ubiquitin ligases, possibly 
displaying different degrees of specificity and/or redundancy in substrate 
selection. It is tempting to speculate that the reported roles of PRAME-like 
genes in early development and stemness might be mediated by functional 
interactions with CRLs and ubiquitination of proteins involved in these path-
ways.
PRAME and the retinoic acid signaling
 A function of PRAME as dominant repressor of the retinoic acid 
signaling was reported by the Bernards lab (Epping et al, 2005). Using a 
genetic screen, the authors found that ectopic expression of the retinoic acid 
receptor alpha (RARA) or PRAME prevented the growth arrest and apopto-
sis induced by histone deacetylase inhibitors (HDACIs) (Epping et al, 2007). 
They provided evidence supporting a model in which HDACI-induced growth 
arrest requires an active retinoic acid signaling pathway, which PRAME would 
repress via direct protein-protein interactions with the retinoic acid receptor 
alpha and the EZH2 polycomb protein, resulting in transcriptional repression 
of retinoic acid target genes like RARB and CDKN1A (also known as p21) (Ep-
ping et al, 2005; 2007). However, the suggested mechanisms do not seem to 
play a general role, since higher PRAME levels were found to correlate with 
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lower RARA levels in breast cancer patients (Epping et al, 2008). Moreover, 
the retinoic acid target genes RARB and CDKN1A were not repressed in acute 
myeloid leukemia patients with high PRAME levels (Steinbach et al, 2007).
 Epping et al. reported that the C-terminus of PRAME (aa. 416-509) 
interacts directly with the ligand-binding domain (LBD) of RARalpha in GST 
pull downs and a mammalian two-hybrid system (Epping et al, 2005). The 
authors further showed that the C-terminal amino acid motif LRELL in PRAME 
was required for the interaction with the LBD of RARa; reciprocal mutations 
of the LBD of RARa were not included in the study. Using the full-length 
PRAME protein, however, Wadelin et al could not detect any interaction with 
the LBD of RARa using similar GST pull down or yeast two-hybrid assays 
(Wadelin et al, 2010). In agreement with the findings of Wadelin et al, we 
did not succeed in reproducing the interaction between RARa and PRAME in 
coimmunoprecipitations assays upon transient transfections in 293T cells, or 
upon immunoprecipitation of TAG-PRAME from stable cell lines in the pres-
ence or absence of ligand. 
 Epping et al further described that knockdown of PRAME in A375 
human melanoma cells resulted in a higher sensitivity to the administration 
of retinoic acid (Epping et al, 2005) and HDACI (Epping et al, 2007). Notably, 
knockdown of PRAME in these cells was shown to cause downregulation 
of the retinoic acid receptor alpha (RARA) at the protein level (Epping et al, 
2005, Figure 6F) and this was interpreted as a derepression of the retino-
ic acid signaling pathway. However, the same experiment presented in a 
follow-up publication showed no difference in RARA levels upon PRAME 
knockdown (Epping et al, 2007, Figure 4E), casting doubts about the reported 
effects. As described in chapter 5, we successfully reproduced the retinoic 
acid phenotype upon PRAME knockdown in A375 cells. However, this effect 
was limited to one of the two knockdown constructs used, despite a similar 
down-regulation of PRAME expression, and we could not rescue the pheno-
type by ectopic expression of knockdown-resistant version of PRAME. Our 
data are consistent with an “off-target” effect of the pRS-P1 knockdown con-
struct. In other words, the phenotype observed is likely caused by down-reg-
ulation of a transcript unrelated to PRAME, which is specifically targeted by 
the published construct pRS-P1, but not by pRS-P2. A genome-wide mRNA-seq 
profiling experiment on these cell lines could potentially identify this gene 
and shed light on the cause of the growth phenotype observed.
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 Our protein-complex purifications clearly established that Cullin2 
ligases and EKC subunits are the most abundant interactors of PRAME in a 
number of human cell lines kept in standard culture conditions, while we did 
not detect RARa or EZH2. However, we cannot exclude that PRAME might 
establish interactions with RARa and EZH2 upon activation of particular 
signaling pathways. Notably, Epping et al performed their genetic screen in 
p53-deficient mouse embryonic fibroblasts stably expressing an oncogenic 
RasV12 gene (RasV12 MEFs) (Epping et al, 2007). It is therefore possible that 
the activation of Ras pathways plays an unforeseen role in PRAME pathways. 
 In order to disentangle the conflicting result, purifications of 
PRAME-containing protein complexes from RasV12 MEFs should be performed 
to identify the most abundant PRAME interactors in this cell system in the 
presence and absence of retinoic acid. Moreover, the effect of PRAME BC-box 
mutations on the sensitivity to HDACI should also be tested in the same cells.
The enigmatic EKC/KEOPS complex
Our biochemical experiments demonstrate that the EKC complex is con-
served and expressed also in human cells. Several crystal structures of yeast 
and archaeal EKC subunits were reported and supported a model in which 
the complex dimerises around the Pcc1/LAGE3 subunit assuming a V shape. 
Our experimental data together with preliminary structural modelling of the 
human subunits are consistent with a similar dimeric model for the human 
EKC. Furthermore, we detected specific interactions between the conserved 
EKC orthologues and an uncharacterised protein of small size, C14orf142, 
suggesting that this might be a novel EKC subunit or interactor.
The EKC or KEOPS complex has been first identified in yeast by two inde-
pendent laboratories that described a role for the complex in either transcrip-
tion regulation (Kisseleva-Romanova et al, 2006) or telomere maintenance 
(Downey et al, 2006). More recently, the complex has been involved in the 
biosynthesis of a chemical modification of tRNAs that is critical for efficient 
protein synthesis (Daugeron et al, 2011; Yacoubi et al, 2011; Srinivasan et al, 
2011).
Human EKC comprises four evolutionarily conserved subunits (yeast 
and human names are given): Pcc1p/LAGE3, Kae1p/OSGEP, Bud32p/TP53RK, 
Cgi121p/TPRKB. Additionally, the yeast complex comprises a fifth subunit 
called Gon7p or Pcc2p, which seems to be fungi-specific. While PCC1/LAGE3, 
BUD32/TP53RK and CGI121/TPRKB are present in archaea and eukarya, but 
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not in bacteria, orthologues of KAE1/OSGEP are present in all three domains 
of life (although often annotated with different names). In fact, a study from 
2004 found that KAE1/OSGEP was one of the about 60 genes present in all 
genomes sequenced until then, with the only exceptions of the reduced 
genomes of the endosymbiotic bacteria Carsonella ruddii and Sulcia muelleri 
(Galperin & Koonin, 2004; Galperin, 2008). Moreover, KAE1/OSGEP is repre-
sented in bacteria by two different homologues that were shown to establish 
protein-protein interactions: YeaZ (specific to bacteria) and YgjD (orthologue 
of Kae1/OSGEP) (Handford et al, 2009).
 Phylogenetic analysis of 767 Kae1 homologues grouped these proteins 
in four distinct clusters (Hecker et al, 2007):
1. archaeal Kae1;
2. eukaryotic orthologues of yeast Kae1p and human OSGEP;
3. bacterial orthologues of E. coli YgjD and eukaryotic orthologues of 
Qri7p/OSGEPL1;
4. bacterial orthologues of E. coli YeaZ. 
Interestingly, the eukaryotic orthologues of Kae1p/OSGEP and the ar-
chaeal Kae1 proteins appeared significantly more similar to one another than 
to the two bacteria-specific subfamilies (Hecker et al, 2007). Yeast Qri7p and 
human OSGEPL1 are nuclear-encoded paralogues that localize to mitochon-
dria, itself a bacterial symbiont (Oberto et al, 2009). The clustering of Qri7p/
OSGEPL1 within the bacterial orthologues of YgjD supports the bacterial ori-
gin of these genes. Unlike the YgjD/KAE1/OSGEP gene family, PRAME genes 
seem to have appeared significantly later in evolution and to have under-
gone several rounds of gene duplication events in the rodent and hominin 
lineages (Birtle et al, 2005; Rhesus Macaque Genome Sequencing and Anal-
ysis Consortium et al, 2007). The peculiar evolutionary history of these gene 
families suggests that PRAME might function as a modulator of EKC.
The function of YgjD/KAE1/OSGEP proteins has been uncertain for many 
years and is still unclear, and functions have been ascribed to these proteins 
that later appeared to be incorrect. First, the Gcp protein was cloned from 
Pasteurella haemolytica and suggested to be an O-sialoglycoprotein endo-
peptidase, hence the names OSGEP and KAE1 (kinase-associated endopep-
tidase) (Abdullah et al, 1991; Abdullah et al, 1992). However, a peptidase 
activity was never confirmed by independent studies (Hecker et al, 2007). 
Second, a study of the archaeal orthologue of Kae1 from Pyrococcus abyssii 
detected apurinic-endonuclease activity in vitro (Hecker et al, 2007). 
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Although Srinivasan et al detected this enzymatic activity for yeast Kae1p 
expressed and purified from E. coli, they reported that the endonuclease ac-
tivity was caused by a low level contamination from the highly active E. coli 
enzyme Fpg that copurified with Kae1p (Srinivasan et al, 2011).
Two independent laboratories identified the yeast EKC/KEOPS complex 
starting from genetic clues. The laboratory of Domenico Libri isolated Pcc1, 
a protein of small size with no predicted functional domains in a search for 
suppressors of a splicing defect and demonstrated that its function is not 
related to splicing (Kisseleva-Romanova et al, 2006). Their genetic and bio-
chemical experiments led to the description of the five-subunit EKC complex, 
the integrity of which was required for normal induction of pheromone- and 
galactose-responsive genes.
A parallel genome-wide screen in yeast identified the cgi121 null mutant 
as a suppressor of the telomere-capping defect of cdc13-1 cells (Downey et 
al, 2006). Deletion of CGI121 or other EKC/KEOPS subunits resulted in short 
telomeres in an otherwise wild-type context.
Since kae1, pcc1, and pcc2/gon7 temperature-sensitive strains stop 
dividing at the non-permissive temperature already after a few divisions, 
Kisseleva et al. suggested that telomere maintenance is unlikely to be the 
primary function of the complex. The authors did not exclude that the telo-
mere phenotype might result from an altered transcriptional regulation, or 
that the complex might be involved in some general chromatin remodelling 
that would eventually affect both gene loci and their transcription as well as 
the telomeres (Kisseleva-Romanova et al, 2006).
Most recently, the group of Crécy-Lagarde used in silico comparative 
genomics approaches to identify a critical function for Kae1 in the universal 
t6A biosynthesis pathway (Yacoubi et al, 2011). This pathway mediates the 
chemical modification of position 37 of all tRNAs that pair with ANN codons 
(thus, including the first ATG of protein-coding genes), with the only excep-
tion of prokaryotic fMet tRNA. The modification consists of a carbonyl group 
and a threonine attached to the amino group of adenine at nucleotide 37 
immediately 3’ of the anticodon, and is necessary to prevent mispairing 
between the first base of the codon and the third base of the anticodon 
(Yacoubi et al, 2011).
Work from three independent laboratories established that the t6A 
modification activity was dependent on Pcc1p, the ATPase activity of Kae1p, 
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and the kinase activity of Bud32p, but not on Cgi121p (Srinivasan et al, 2011; 
Yacoubi et al, 2011; Daugeron et al, 2011). Moreover, Qri7p was found to 
mediate modification of mitochondrial tRNAs (Yacoubi et al, 2011).
Although the most recent data show that the EKC/KEOPS complex is 
required for t6A synthesis, this might not be its only role and its function in 
telomere maintenance might be unrelated to t6A modification of tRNAs. More 
specifically, it was hypothesised that the predicted chaperone activity of this 
complex might contribute to several processes, t6A formation being just one 
of them (Srinivasan et al, 2011).
Outlook on the interplay between PRAME, EKC and NFY
Studying the relationships between PRAME, Cul2 ligases and EKC, we 
discovered that PRAME recruited Cullin2-based ligases to EKC via direct in-
teractions with OSGEP and LAGE3. In fact, we consistently found that PRAME 
established stable interactions with OSGEP and LAGE3, but not with TP53RK 
or TPRKB. These results might represent a PRAME-mediated disruption of an 
otherwise complete EKC complex, or association of PRAME to an already ex-
isting EKC subassembly. Characterisation of the amino acid residues involved 
in these interactions should be prioritised in follow-up studies in order to 
shed light on the precise stoichiometry of the complexes. In particular, it 
is not known whether PRAME influences the conformation of OSGEP and 
LAGE3 and whether PRAME might cause steric hindrance and thus inhibit the 
formation of a complete dimeric EKC. Ideally, resolution of crystal structures 
containing PRAME, OSGEP and LAGE3 could provide ultimate clues on the 
three-dimensional relationships of these proteins. 
No data is available yet on EKC function(s) in human cells and the 
absence of efficient knockdown or knock-out models have severely hin-
dered functional analyses of EKC in higher eukaryotes so far. Considering the 
extreme conservation of EKC subunits, however, it is reasonable to expect 
that at least some of the functions and pathways identified for this complex 
in yeast could be conserved in human cells. However, the complex seems 
to have acquired also additional functions during evolution, like phosphor-
ylation of the proto-oncogene p53 by TP53RK. Future studies will have to 
address the connections between apparently different functions ascribed to 
this complex, like phosphorylation of the p53 oncogene, chemical modifica-
tion of tRNAs, roles in telomere maintenance and physical association with 
promoter regions. 
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Kae1p and Pcc1p were found to associate with active chromatin and to 
regulate expression of some of the yeast promoters to which they are re-
cruited (Kisseleva-Romanova et al, 2006). In a yeast strain deficient for Pcc1p 
the activator Gal4p was still found on chromatin, but recruitment of Gal1p, 
the SAGA histone acetyltransferase and Mediator were inhibited, suggesting 
a role for EKC in gene transcription. We found that epitope-tagged EKC sub-
units in human cells can specifically associate with chromatin at active pro-
moter regions bound by PRAME and NFY. Unfortunately, stable knockdown 
strategies did not detect a clear function of EKC or PRAME on transcriptional 
regulation of those loci. As we elaborated in chapter 4, likely different cell 
systems and assays are needed to investigate the functional role(s) of PRAME 
and EKC on chromatin. As soon as an assay will become available to evidence 
EKC functions in human cells, the role of PRAME on such functions should be 
tested. For example, EKC function could be measured in a PRAME-negative 
cell line before and after ectopic expression of PRAME.
Our genome-wide ChIP-seq analyses revealed that PRAME is strongly 
enriched at promoters bound by the transcription factor NFY, and binding 
of PRAME predicts a permissive epigenetic landscape and transcriptional 
activity at these regions. Moreover, we found that PRAME is also significantly 
enriched at adjacent enhancer regions, suggesting that it could participate in 
promoter-enhancer interactions. Although our genome-wide ChIP-seq pro-
files are consistent with a role for PRAME in active transcription, more efforts 
are required to provide a definitive answer to the burning question if PRAME 
can function as a transcriptional modulator. 
Since neither PRAME nor EKC proteins possess known DNA-binding do-
mains, it is not clear whether they can bind DNA directly and if the transcrip-
tion factor NFY might play a direct or indirect role in the targeting of a Cul2-
PRAME-EKC complex to chromatin. However, we did not find NFY subunits 
in our mass spectrometry interaction data of PRAME or EKC. Future studies 
should investigate the molecular determinants of the association of PRAME 
and EKC to chromatin and the role of NFY, and whether there is a hierarchy in 
their binding. 
Analyses of gene expression levels in human samples indicate that most 
normal adult tissues express NFY, EKC and Cul2, but not PRAME; therefore, 
it is expected that all (or a vast majority) of PRAME-expressing cells also 
express NFY, EKC and Cul2. Taking into consideration these expression pat-
terns and the ancient nature of EKC as compared to the later appearance of 
168
PRAME, we speculate that EKC could fulfil housekeeping (PRAME-indepen-
dent) functions also in human cells and that it could interact with chromatin 
in a PRAME-independent manner. PRAME expression would then lead to the 
recruitment of a Cul2-based ubiquitin ligase to EKC genomic loci by virtue of 
direct protein-protein interactions, resulting in ubiquitination of proteins pres-
ent at these sites, potentially affecting EKC pathways and/or NFY signaling. 
This hypothesis could be tested by comparing the chromatin-binding profiles 
of EKC subunits in PRAME-negative and PRAME-expressing cells, and devel-
opment of ChIP-grade antibodies against EKC proteins will be critical tools for 
such studies. 
Intriguingly, several studies suggested important roles for NFY in stem 
cell biology (Grskovic et al, 2007) and mouse PRAME-like genes were found 
to be involved in embryonic development and embryonic stem cells (Bortvin 
et al, 2003). It should therefore be studied if PRAME-like proteins can also 
play roles in EKC and NFY pathways in a redundant manner with PRAME, or if 
they rather display specificities of their own. We foresee that the dissection 
of the protein-protein interaction networks of PRAME-like proteins will defi-
nitely provide stimulating and exciting new leads for the field. 
Overall, the experimental work outlined in this thesis establishes a 
biochemical and molecular function for the PRAME gene family and provides 
a new twist to both PRAME and EKC biology. Our results provide an important 
contribution to understanding the molecular mechanisms in which these 
proteins are active, both in healthy and tumour cells.
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Scientific research projects usually span several years during comple-
mentary research lines and technical approaches are combined in order to 
dissect and understand the molecular mechanisms, proteins or genes of 
interest. A typical scientific project can be described as a collection of ex-
perimental tasks performed at different points in time and often in parallel, 
whose results are eventually bundled together in a scientific report (i.e. an 
article in scientific journals, a presentation at a conference, a PhD thesis). 
Scientific reports are generally structured in a logical and/or chronological 
order: an initial finding is extended with follow-up experiments, and then 
a final conclusion or model is presented. Notably, articles in peer-reviewed 
journals focus on the results obtained, while the time and resources re-
quired to obtain them are traditionally not discussed. The efforts required to 
raise an antibody, to setup a novel technique or negative results are rather 
discussed at meetings and conferences, or at informal gatherings among 
researchers. On the other hand, the timeline and the financial and human 
resources needed for a research project have become standard requirements 
of increasing importance when submitting project proposals to agencies 
responsible for research funds.
The aim of this appendix is to provide an overview of our PRAME re-
search project in a chronological context and describe how the different lines 
of research developed over time, and often in parallel. The main activities 
and milestones are presented in schemes called Gantt chart, a project man-
agement tool that represents the start, duration and end of each activity.
Overall, the research presented in this thesis can be divided in four main 
lines or tasks (Figure 1):
i. the development of PRAME antibodies, 
ii. the identification and characterisation of the protein interactors of 
PRAME,
iii. the identification and characterisation of PRAME interactions with the 
EKC complex,
iv. the investigation of PRAME association to chromatin.
As depicted in Figure 2, the project started in the fall of 2005 with a 
focus on the first two tasks: PRAME antibody development and protein com-
plex purification. The peptides needed to raise the antibodies were designed 
and synthesised, the immunisation scheme started in March 2006 and lasted 
about eight months until the last serum was harvested. The antibody charac-
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terisation and testing started as soon as the first sera became available (May 
2006) and continued through the second half of 2006, when conditions were 
setup for use of sera and affinity-purified antibodies in western blot and 
immunoprecipitation assays (chapter 5).
In parallel, we attempted PRAME protein-complex purifications using 
FM6 stable cell lines that were already available in the lab. As described in 
chapter 2, this strategy was not successful because of a too low efficien-
cy and we therefore moved to a different epitope tag (StrepII-Myc-3xHA) 
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combined with the use of suspension cell lines. In the first half of 2006 we 
generated the retroviral expression plasmids required and we setup the sta-
ble transfection protocol. In the second half of 2006 we generated single-cell 
clones stably expressing epitope-tagged PRAME and established that PRAME 
is part of high molecular weight complexes by size-exclusion chromatog-
raphy (K562 Sup6 in Fig. 2). In parallel, we setup the nuclear/cytoplasmic 
protein extraction protocol and the immunoprecipitation strategy for protein 
complex purifications (TAP-TAG). These resulted in the first mass spectrom-
etry data of PRAME interactors in July 2007 using a single MYC IP strategy 
(chapter 3). TAG-PRAME purification experiments were repeated several 
times later in the project, also in combination with optimisation of sin-
gle-step HA IP strategy (chapter 4). In total, almost 2 years of experimental 
work were required to identify the first protein-protein interactors of PRAME. 
Based on these results, we started in September 2007 a close collaboration 
with the Conaway lab (Stowers Institute, USA).
Early in 2007 we started to study the association of PRAME to chromatin 
(Figure 3). As reported in chapter 5, we performed first caesium chloride 
gradient experiments and then setup the TTE epitope tag approach for ChIP 
assays. During the course of 2007, we developed the retroviral pTTE vector, 
cell lines stably expressing TTE-PRAME and towards the end of the year we 
performed the first genome-wide ChIP-sequencing experiments for TTE-
PRAME (ChIP-seq #1). Analysis of the data identified the first putative binding 
sites which have been instrumental to setup and optimise ChIP assays for the 
endogenous PRAME protein in wild type K562 cells (ChIP-seq #2). Bioinfor-
matical analysis revealed a link to the NFY transcription factor (chapter 3), 
whose binding sites were mapped in ChIP-seq experiments in early 2010 
(ChIP-seq #3). 
In the second half of the project we also characterised the discovered in-
teractions of PRAME with Cullin2-based E3 ubiquitin ligases and with the hu-
man EKC complex (Figure 3). These experiments started with the generation 
of expression plasmids for all four human EKC subunits (Q3 2007), establish-
ment of stable cell lines, ChIP assays and protein complex purifications and 
mass spectrometry (Figure 3). Between the end of 2008 and the beginning 
of 2010, mass spectrometry data for all four subunits were collected and 
analyzed, while biochemical experiments were performed in parallel.
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Our results were first presented at the CSHL Eukaryotic transcription 
meeting in August 2009 and at the EMBL transcription meeting in August 
2010 (Figure 1). After submissions of our work to Nature Cell Biology (NSB) 
and Nature Structural and Molecular Biology (NSMB), we published chapter 
3 of this thesis in EMBO Journal (Q2 of 2010), and chapter 4 in PlosOne (Q3 of 
2012).
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SUMMARY
The genome present in the nucleus of each human somatic cell is made 
of about 2 meters of DNA organized in 23 chromosome pairs with a total of 
6 billion basepairs. About 5% of the human genome contains protein-coding 
genes that can be activated to produce proteins under strict regulation. The 
proteins present in a cell (also called the “proteome”) are not lonely islands, 
but they rather interact with each other in dynamic networks and multipro-
tein complexes. Importantly, deregulation of gene expression programs and 
protein interaction networks can lead to disease and cancer.
The focus of this PhD thesis is to unravel the molecular function of the 
human oncoprotein PRAME (preferentially expressed antigen of melanoma) 
using cell line model systems and a powerful combination of proteomic and 
genomic techniques. At the beginning of this study, PRAME was known to be 
frequently overexpressed in tumours and high expression levels were found to 
correlate with poor clinical outcome in melanoma, neuroblastoma, and breast 
cancer patients. Moreover, evidence that expression of PRAME is restricted 
mainly to tumour cells has designated it as a promising therapeutic target. 
However, efforts to develop strategies to interfere with the oncogenic activity 
of PRAME are hindered by a lack of information about its molecular function(s). 
Notably, analysis of the human genome revealed that a large family of more 
than twenty PRAME-like genes exists, whose functions are also unclear. 
In order to identify the molecular functions of PRAME, we developed in-
novative high-throughput biochemical approaches to dissect the protein-pro-
tein interaction network of PRAME (chapter 2). By applying epitope-tagging 
in human cell lines and mass spectrometry analysis of purified protein com-
plexes, we discovered that PRAME is a stable component of Cullin2-based E3 
ubiquitin ligases (chapter 3). Ubiquitin ligases mediate the addition of the 
small protein ubiquitin to target proteins, altering their function and often 
leading to their degradation. Our results established a first strong functional 
link between PRAME and a defined biochemical pathway. Using the same 
epitope-tagging strategy we discovered interactions between Cullin2-PRAME 
ligases and subunits of the conserved EKC/KEOPS complex that we charac-
terised in chapter 4. In particular, knock-down experiments revealed that 
PRAME functions as a bridge between Cullin2 ligases and the EKC complex. 
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In parallel to the proteomic techniques, we set up chromatin immuno-
precipitation assays coupled to next-generation sequencing technologies 
(ChIP-seq). For this purpose, we raised specific PRAME antibodies in rabbits 
to investigate the binding profile of PRAME to the human genome (chapter 3 
and 5). The data analysis showed that PRAME (chapter 2) as well as EKC sub-
units (chapter 4) are specifically enriched at transcriptionally and epigeneti-
cally active promoter regions that are also bound by the transcription factor 
NF-Y, and at enhancer elements. These results suggest that PRAME might 
play a role in the NF-Y signaling pathway.
Overall, the experimental work outlined in this thesis establishes a 
biochemical and molecular function for the PRAME gene family and provides 
a new twist to both PRAME and EKC biology. Our results provide an important 
contribution to understand the molecular mechanisms in which these pro-
teins are active, both in healthy and tumour cells, and thus lay a foundation 
for novel therapeutic strategies against cancer.
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SAMENVATTING
Het genoom in de kern van elke menselijke somatische cel bestaat uit 
ongeveer 2 meters DNA en is ingedeeld in 23 chromosoom paren die in 
totaal 6 miljard basenparen bevatten. Ongeveer 5% van het menselijke ge-
noom bevat coderende genen die eiwitten kunnen produceren, wat gebeurt 
onder strikte regulatie. De eiwitten die aanwezig zijn in een cel (ook wel 
“proteoom” genoemd) zijn niet geïsoleerde eilanden, maar zijn betrokken 
bij dynamische netwerken en maken deel uit van multi-eiwit complexen. 
Ontregeling van genexpressie en eiwit interacties kan leiden tot verschillen-
de ziektes, waaronder kanker.
Het onderwerp van dit proefschrift betreft een uitgebreide studie naar 
de moleculaire functie van het kanker-gerelateerde eiwit PRAME (preferenti-
ally expressed antigen of melanoma) met behulp van cellijn modelsystemen 
en een krachtige combinatie van proteomische en genomische technieken. 
Aan het begin van deze studie was bekend dat PRAME vaak actief aanwezig 
is in kankercellen en dat een hoge expressie van PRAME geassocieerd is met 
een slechte klinische prognose voor melanoom-, neuroblastoom- en borst-
kankerpatiënten. 
PRAME vervult de rol van een veelbelovend therapeutisch doelwit 
aangezien expressie van dit eiwit voornamelijk beperkt is tot kankercellen. 
Echter, het ontwikkelen van strategieën om de activiteit van PRAME te beïn-
vloeden wordt gehinderd door een gebrek aan informatie over de moleculai-
re functie(s) van PRAME. Verder heeft de analyse van het menselijk genoom 
een grote familie van meer dan twintig PRAME-achtige genen aan het licht 
gebracht, waarvan de functies nog onduidelijk zijn.
Om de moleculaire functies van PRAME te onderzoeken, hebben wij 
innovatieve high-throughput biochemische technieken ontwikkeld om het 
eiwit-eiwit interactienetwerk van PRAME te ontrafelen (hoofdstuk 2). Door 
toepassing van epitoop-tagging in menselijke cellijnen en massaspectrome-
trie van gezuiverde eiwitcomplexen, hebben wij ontdekt dat PRAME een sta-
biele component is van Cullin2 E3 ubiquitine ligases (hoofdstuk 3). Ubiquitine 
ligases koppelen het kleine eiwit ubiquitine aan doeleiwitten en veranderen 
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zodoende hun functie of markeren ze om afgebroken te worden. Onze resul-
taten hebben voor het eerst een sterke relatie gelegd tussen PRAME en een 
specifieke biochemische activiteit. Met dezelfde epitoop-tagging strategie 
hebben wij laten zien dat Cullin2-PRAME ligases een interactie aangaan met 
het EKC/KEOPS complex (hoofdstuk 4). In het bijzonder hebben knock-down 
experimenten aangetoond dat PRAME fungeert als een brug tussen Cullin2 
ligases en het EKC complex.
Naast de proteomische technieken hebben wij een techniek ontwikkeld 
waarbij chromatine-immunoprecipitaties gevolgd worden door next-gene-
ration sequencing (ChIP-seq). Wij hebben specifieke PRAME antilichamen 
in konijnen opgewekt om het bindingsprofiel van PRAME op het menselijke 
genoom te onderzoeken (hoofdstuk 3 en 5). De data analyse liet zien dat 
PRAME (hoofdstuk 2) en het EKC complex (hoofdstuk 4) specifiek verrijkt zijn 
op transcriptionele en epigenetisch actieve promotors van genen die ook 
gebonden zijn door de transcriptiefactor NF-Y, als ook op enhancer elemen-
ten. Deze resultaten suggereren dat PRAME een rol zou kunnen spelen bij de 
NF-Y signaleringsroute.
Het experimentele werk beschreven in dit proefschrift heeft een nieuwe 
biochemische en moleculaire functie voor de PRAME gen-familie vastgesteld 
en geeft een vernieuwd inzicht aan zowel PRAME en EKC biologie. Onze 
resultaten leveren een belangrijke bijdrage aan het begrijpen van de mole-
culaire mechanismen waarin deze eiwitten actief zijn, zowel in gezonde als 
in kankercellen. Hiermee wordt een basis gelegd voor het ontwikkelen van 
nieuwe therapeutische strategieën tegen kanker. 
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RIASSUNTO
Il genoma presente nel nucleo di ogni cellula somatica umana è costitu-
ito da circa 2 metri di DNA organizzato in 23 coppie di cromosomi che con-
tengono un totale di 6 miliardi di paia di basi. Circa il 5% del genoma umano 
costituisce geni codificanti proteine  che possono essere attivati sotto stretta 
regolazione. Le proteine presenti in una cellula (nel loro insieme chiamate 
anche “proteoma”) non sono isole separate ed indipendenti, ma piuttosto 
interagiscono tra di loro in reti dinamiche e fanno parte di complessi mul-
tiproteici. In particolare, la disregolazione dell’espressione genica e delle 
interazione tra proteine può portare a malattie e cancro.
L’obiettivo di questa tesi di dottorato è di rivelare la funzione molecolare 
della oncoproteina umana PRAME (preferentially expressed antigen mela-
noma, antigene preferenzialmente espresso in melanoma) utilizzando linee 
cellulari come sistema modello ed una potente combinazione di tecniche 
di proteomica e genomica. All’inizio di questo studio, PRAME era noto per 
essere frequentemente attivo in tumori e livelli elevati di espressione erano 
risultati correlati con prognosi negative in pazienti di melanoma, neurobla-
stoma e cancro al seno. Inoltre, il fatto che PRAME è espresso principalmente 
in cellule tumorali e non in cellule sane ha indicato PRAME come un obiettivo 
terapeutico promettente. Tuttavia, gli sforzi per sviluppare strategie terapeu-
tiche per interferire con l’attività oncogenica di PRAME sono ostacolati dalla 
mancanza di informazione sulle sue funzioni molecolari. Inoltre, analisi del 
genoma umano ha rivelato l’esistenza di una grande famiglia di più di venti 
geni simili a PRAME (PRAME-like genes), le cui funzioni non sono ancora 
chiare.
Al fine di identificare le funzioni di PRAME a livello molecolare, abbiamo 
sviluppato approcci biochimici innovativi e high-throughput per identificare la 
rete di interazioni proteina-proteina di PRAME (capitolo 2). Applicando un ap-
proccio di “epitope-tagging” in linee cellulari umane e analisi di spettrome-
tria di massa dei complessi proteici purificati, abbiamo scoperto che PRAME 
è un componente stabile di E3 ubiquitin ligasi basati sulla proteina Cullin2 
(capitolo 3). Le ubiquitin ligasi mediano l’aggiunta della piccola proteina ubi-
quitina a proteine bersaglio, alterando la loro funzione o spesso causandone 
la degradazione. I nostri risultati hanno quindi stabilito per la prima volta un 
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forte relazione funzionale tra PRAME ed un’attività biochimica ben definita. 
Utilizzando le stesse tecniche abbiamo scoperto interazioni tra Cullin2-PRAME 
ligasi e subunità del complesso EKC/KEOPS, che abbiamo caratterizzato nel 
capitolo 4. In particolare, esperimenti di knock-down hanno rivelato che PRA-
ME funziona come un ponte tra le Cullin2 ubiquitin ligasi ed il complesso EKC.
In parallelo alle tecniche di proteomica, abbiamo sviluppato saggi di im-
munoprecipitazione della cromatina seguiti da sequenziamento high-throu-
ghput di nuova generazione (ChIP-seq). A questo scopo, abbiamo generato 
anticorpi specifici contro PRAME in conigli allo scopo di indagare il profilo 
di legame di PRAME al genoma umano (capitolo 3 e 5). L’analisi dei dati ha 
mostrato chiaramente che PRAME (capitolo 2) e subunità di EKC (capitolo 4) 
legano specificamente elementi enhancer e promotori di geni attivi che sono 
anche legati dal fattore di trascrizione NF-Y. Questi risultati suggeriscono che 
PRAME potrebbe giocare un ruolo nella via di segnale di NF-Y.
Nel complesso, il lavoro sperimentale descritto in questa tesi stabilisce 
una funzione biochimica e molecolare per PRAME e la vasta famiglia di geni 
PRAME-simili e fornisce una nuova svolta nella biologia sia di PRAME che 
del complesso EKC. I nostri risultati forniscono un importante contributo alla 
comprensione dei meccanismi molecolari in cui queste proteine sono attive, 
sia in cellule sane che tumorali, e offrono così possibilità di sviluppare nuove 
strategie terapeutiche. 
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The human protein PRAME 
(preferentially expressed antigen 
of melanoma) is frequently 
overexpressed in tumours. 
Importantly, high expression levels 
are associated to poor clinical outcome 
in melanoma, neuroblastoma, and 
breast cancer. However, its function 
and molecular mechanisms in normal 
and cancer cells are not yet well 
understood and the cellular pathways 
affected by PRAME are still elusive. 
Although PRAME has been indicated 
as a promising potential target for 
cancer therapy and anti-tumour 
immunization protocols, efforts to 
develop strategies to interfere with 
the oncogenic activity of PRAME are 
hindered by a lack of information 
about its function.
The aim of this thesis was to 
investigate the molecular function of 
human PRAME using cell line model 
systems and a powerful combination 
of proteomic and genomic techniques. 
We developed innovative biochemical 
approaches to dissect the protein-
protein interaction network of 
PRAME, and we setup chromatin 
immunoprecipitation assays coupled 
to next-generation sequencing 
technologies to reveal binding profile 
of PRAME to the human genome in 
cancer cells.
